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ABSTRACT
Studies Toward a General Synthesis of Poly-Substituted Alpha-Hydroxytropolones
by
Christine Meck
Advisor: Prof. Ryan P. Murelli, Ph.D.

Chapter 1: This chapter gives a brief history of α-hydroxytropolones, how they were discovered and
unique properties of these substrates. Included is a background on the bioactivity of these substrates in
cellular targets such as bacteria, fungi, parasites, tumors and toxicity, as well as their ability to inhibit
various metallo-based enzymes. Structure activity relationships studies are reviewed on important
metalloenzymes HIV-Reverse Transcriptase (RT) and Inositol monophosphatase (IMPase). Finally the
chapter finishes with a synthetic overview of α-hydroxytropolones including natural product targets such
as puberulic acid, puberulonic acid, β-thujaplicinol, and α-hydroxytropolone.
Chapter 2: A brief review on β-hydroxy-γ-pyrone based oxidopyrylium cycloadditions will be presented as
well as important oxidopyrylium cycloaddition/ring opening procedures to yield natural tropolone products.
Research from the Murelli laboratory will be highlighted. This chapter will discuss a new synthetic route
toward functionalized α-hydroxytropolones. A β-hydroxy-γ-pyrone intermolecular oxidopyrylium
cycloaddition with a range of alkynes that was optimized to an efficient and high yielding process will be
discussed. Next two ring catalyzed ring openings will be discussed; one that utilizes boron trichloride that
attains α-hydroxytropolones and 7-methoxytropolones, and a triflic acid mediated sequence that yields
exclusive 7-methoyxtropolones and furans. Finally, a new reaction with the oxidopyrylium species will be
highlighted that shows the exchange of alcohols in these reactive species.
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Chapter 3: Chapter three describes the background on three specific medicinal targets: ANT (2”)-Ia, HIV
RT RNase H, and HBV RT RNaseH and preliminary structure activity relationship studies with αhydroxytropolones synthesized in this research are outlined.
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CHAPTER 1: The Biology and Synthesis of α-Hydroxytropolones1
1.1 Introduction: A Short History and Background on α-Hydroxytropolones
α-Hydroxytropolones (a.k.a, 7-hydroxytropolones, αHTs) are troponoids having a basic tropone (1) structure,

O

O

O

OH

HO

OH

where the carbonyl group is flanked by two hydroxyl groups, 3
(Figure 1.1).2

The history of tropolones date back to the

isolation of two molecules containing the α-hydroxytropolone

1
tropone

2
tropolone

3
α -hydroxytropolone

Figure 1.1. Examples of the troponoid compounds.

core structure that were extracted from Penicillium puberulum and Penicillium aurantio-virens in 1932 and
named puberulic acid, 5, and puberulonic acid, 4, respectively; at the time the structures could not be
accurately determined (Figure 1.2).3
O

O
OH

HO

HO

O

OH

HO

O

O
OH

OH

HO

HO

OH

O

HO

HO
O

CO2H
4 O
5
puberulonic acid
puberulic acid
-hydroxytropolone
amnioglycoside-2''-Oinositol monophosphotase anti-malarial
adenylyltransferase inhibitor
inhibitor
3

6
-thujaplicinol
HIV RT RNase H
inhibitor

7
manicol
HIV RT RNase H
inhibitor

Figure 1.2. Naturally derived -hydroxytropolones and their therapeutic targets.

In the case of puberulonic acid, the chemical formula was originally miss-assigned with the
chemical formula, C8H4O7, but this was later amended to the chemical formula C9H4O7.4 Due to Dewar’s
work in the 1950’s, the chemical structure of puberulic acid could be established as well as related
systems and the name came into being, tropolone, 2 (Figure 1.1).5,6 Dewar was able to explain a seven
membered ring structure with potential aromatic qualities and hydrogen bonding.7 This new seven
membered ring structure proposed by Dewar mystified scientists due to its unique aromatic properties.
Later these aromatic properties were validated and the system was deduced to have a partial positive
charge, a tropylium cation system, within the seven membered ring and a partial negative charge on the
carbonyl.8
α-Hydroxytropolones are slightly acidic, with two pKa values, one at a pKa1 of 5.6 and the second
pKa2 at 7.9 Their properties lie between that of a phenol (pKa=10) and carboxylic acid (pKa=5).10 Similar to
1

tropolones that are known to bind to metals through the carboxyl and hydroxyl group, the structure of αhydroxytropolones, which contain an extra hydroxyl group, allow them to bind to divalent metal
centers.10,11 At physiological pH, the hydroxyl groups can be deprotonated giving the oxygens a
considerable negative charge.12 This is important due to the fact that many enzymatic targets use divalent
metal ions as a critical component of their activity.13 These characteristics impart notable biological
activity and have made them important targets of this troponoid family, but have created synthetic
challenges as will be discussed in this chapter (Figure 1.2). 14,15,16,17,18
1.2 Cytotoxicity of α-Hydroxytropolones
1.2.1 Antifungal Activity
β-Thujaplicinol as well as other tropolone derivatives was isolated from the western red cedar.19
Due to the tree’s durability, it was thought that these compounds may contribute to its ability to fend off
plant diseases.20 The antifungal activity of the
O

prevalent extracts, β-thujaplicinol (6) and its

HO

O
OH

HO

tropolone counterpart γ-thujaplicin (8) were
studied for their activity against wood rot

6
8
β -thujaplicinol γ -thujaplicin

(Figure 1.3).21 It was found that both these
compounds had similar activity against brown

brown
rot

P.m ont icola

(MIC=10 µM) (MIC=10 µM)

C.puteana

(MIC=10 µM) (MIC=10 µM)

P.v er sicolor

rot fungi Poria monticola and Coniophora

white
rot

S.sanguinolent um (MIC=330 µM) (MIC=50 µM)
P .w eir ii

puteana at MIC (minimum growth inhibitory

(MIC=800 µM) (MIC=70 µM)

(MIC=100 µM) (MIC=50 µM)

Figure 1.3. Antifungal activity of β-thujaplicinol vs. γ-thujaplicin.

concentration) values of 10 µM. Activity toward

the white rot fungi Polyporus versicolor, Stereum sanguinolentum, and Phellinus weirii. With MIC
concentrations of 800 µM, 330 µM, and 100 µM, respectively, β-thujaplicinol was much less potent than γthujaplicin. γ-Thujaplicin had MIC values of 70 µM, 50 µM, and 50 µM respectively. While γ-thujaplicin
was a pure extract from the cedar, β-thujaplicinol was extracted from the copper screening after the kiln
(75-95°C) processing of the lumber, and was found to be an oxidation product.19 This may indicate the
higher potency values for γ-thujaplicin which was in extracts before the wood was processed. Another
fungal target for which β-thujaplicinol’s activity was studied was Aspergillus fumigatus, which is known to
2

cause disease in immuno-suppressed humans.22 Concentrations of 35 µM showed no growth of the
fungus after 96 hours. If reactions were run at longer time points, a higher concentration of β-thujaplicinol
was needed to impart growth inhibition.23 Studies from Bristol-Meyers researchers with αhydroxytropolone showed less potency activity against A.fumigatus strain IAM2530 at higher MIC
concentrations of 730 µM.24
1.2.2 Antibacterial Activity
In the two separate studies on antifungal activity by Sanders and by researchers at BristolMeyers, β-thujaplicinol and α-hydroxytropolone were also evaluated for their antibacterial effects.23, 24
Sanders tested the activity of β-thujaplicinol against 40 strains of bacteria, and in general found that the
gram-positive bacteria was more inclined to be inhibited than gram-negative bacteria.23 The most potent
effects were seen in the gram-positive strains, Bacillus megaterium and Sarcina lutea, with inhibition
values of 35 µM. Gram-negative strains P. aeruginosa, P. fluorescens, and P. pyocyaneus presented no
inhibition at concentration of 280 µM. Bristol-Meyers researchers found similar results in their studies with
α-hydroxytropolone.24 Gram- positive bacterial strains Staphylococcus aureus and Micrococcus luteus
displayed MIC values of 90 µM. Gram-negative strains such as P. aeruginosa and Klebsiella pneumonia
had values of 700 µM and 360 µM respectively. An outlier was the gram-negative strain Escherichia coli
NIHJ that had MIC values of 45 µM. No explanation for the selective bacterial inhibition was explained by
either group.

3

1.2.3 Antitumor Activity
In their broad review of activity,

O

O
OH

HO

OH

HO

Bristol-Meyers researchers also tested the
OH

antitumor quality of tropolones and

9

3

3,7-dihydroxytropolone

α-hydroxytropolones.24 They found that

α − hydroxytropolone

IC 50 = 250 nM
IC 50 = 2.2 µM
mouse model= 1.3 mg/kg/day
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Figure 1.4. Various α−hydroxytropolones' and 5-hydroxytropolone's activity
against B16 melanoma.

tropolone, 5-hydroxytropolone (11), was the least potent with an inhibitory concentration at 50% (IC50)
value of 13 µM. Animal studies that involved mice with B16 tumor cells revealed that at concentrations of
1.3 mg/kg/day of 3,7-dihydroxytropolone mice survived 29 days as compared to untreated mice who
survived 16 days. These results were notable as Mitomycin C, a currently used chemotherapeutic agent,
showed similar survival rates and concentrations at 1 mg/kg/day over 27 days. Alternatively, higher
concentrations of 3,7-dihydroxytropolone was found to have a negative effect where concentrations of 5
mg/kg/day were found to be toxic, and half that concentration (2.5 mg/kg/day) reduced the survival rate to
12 days.
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1.2.4 Antimalarial Activity
Shiomi, Omura, and co-workers isolated puberulic acid (5) and stipitatic acid (12) as well as other
new tropolone compounds, viticolins A (13), B (14), C (15), from the Pencillium species FK-4410 and
tested their ability to target malaria in vitro and in vivo (Figure 1.5) .16

The in vitro activity of the substrates against two chloroquine resistant Plasmodium falciparum strains, K1
and FCR3 were studied. Puberulic acid had activity against malaria to the same order of magnitude (Both
strains IC50=50 nM) as the well known antimalarial agents artesunate (16), (K1 strain IC50=10 nM, FCR3
strain IC50=2.5 nM) and artemisinin (17) (Both strains IC50=21 nM) in cell based assays (Figure 1.5).
Comparison of tropone (1) with no hydroxyl groups and, tropolone (2) with one hydroxyl group, showed
decreased inhibition with IC50 values for the K1 strain in the range of 89 µM and 100 µM respectively. αHydroxytropolone (3) which has two hydroxyl groups flanking the carbonyl had increased activity
compared to these two at an IC50 value of 6.4 µM for the K1 strain. Similarly stipitatic acid (12) (IC50=39
µM) showed reduced activity compared with puberulic acid (5). It would appear that the extra hydroxyl
group may play a role in the antimalarial activity, but viticolin B (14) had similar activity to αhydroxytropolone (3) suggesting that two free hydroxyl groups may not be necessary for activity. All the
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compounds showed low cytotoxicity, in fact puberulic acid (5) (IC50=287 µM) was comparable with both
artesunate (16) (IC50=36 µM) and artemisinin (17) (IC50=160 µM). α-Hydroxytropolone (3) was the most
cytotoxic of the compounds tested at a value of 1.7 µM, which could be due to the compound’s small size
and ability to intercept important bimetallic enzymes in healthy cells. Excitingly, an in vivo antimalarial
study in a mouse model using the rodent strain P. berghei, a chloroquine sensitive malaria strain, showed
that puberulic acid had similar antimalarial activity as chloroquine and artesunate. Puberulic acid
suppressed 69% of the parasite at 2 mg/kg, whereas artesunate and chloroquine had ED50 values at 1.7
mg/kg and 1.5 mg/kg, respectively.
1.2.5 Toxicology Studies
Animal studies by Sanders revealed preliminary toxicology information on β-thujaplicinol.23 At
concentrations of 50-100 mg kg-1 mice displayed depressant effects (such as not eating or drinking) that
lasted between 4-7 hours. Positively they maintained muscle control and no deaths were reported. At
concentrations of 150-200 mg kg-1 mice presented stimulant effects as well as occasional convulsions at
doses of 163 mg kg -1. Also mice died within 48 hours. The lethal dose was uncovered at 175 ± 4.2 mg
kg-1 for 48 hours and 155 ± 4.5 mg kg -1 at 72 hours. In combination with other drugs, β-thujaplicinol’s
toxicity was studied. When barbiturates, sodium thiopental and hexobarbital, were administered in
combination with β-thujaplicinol, sleeping periods increased while convulsive episodes decreased. The
hexobarbital combination prevented the lethal outcomes of β-thujaplicinol. The combination of βthujaplicinol with chlorpromazine showed a collective depressant outcome in the mice.
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1.3 Metalloenzyme Inhibition
1.3.1 Inositol Monophosphatase
Inositol Monophosphatase (IMPase) is an enzyme that catalyzes the cleavage of phosphate from
myo-inositol monophosphate and allows for hydrolysis of the compound by water, hence forming a fully
protonated myo-inositol (Figure 1.6).25

IMPase needs at least two Mg2+ ions for activation. Magnesium may be needed to act as an activator of
a nucleophile, stabilize or allow for cleavage of a leaving group, or stabilize the enzymes geometry, or a
combination of these events in the enzyme.26 It has been implicated as a target in bipolar disorder
therapy when it was discovered that lithium inhibits this enzyme. Lithium is the current treatment for
bipolar disorder and is involved in inhibiting this enzyme-substrate complex.26a Current lithium treatment
involves a near toxic amount of the drug, so a new drug is of a high interest.26b
Puberulonic acid, 4, a α-hydroxytropolone, was found to inhibit the enzyme in the low micromolar
range (Figure 1.7).15 Initially it was thought that the
2+M

anhydride moiety of puberulonic acid chelated to two Mg2+
molecules in the enzyme. However, modeling studies
based on crystallographic data of the inhibitor-substrate
complex suggested the carbonyl and dihydroxyl moieties

M2+
O

O

O

O

HO

O
4

O
Figure 1.7. Metal centers of enzyme binding
to puberulonic acid.

bind to the two Mg2+ ions within the enzyme, displacing a phosphate that would otherwise bind there
(Figure 1.7). They found that the distance between the two metal centers were about 3.73 Å.12
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Piettre and co-workers were intrigued by this activity, so they tested different α-hydroxytropolone
derivates for their inhibition of IMPase.15 They also investigated other bimetallic enzymes such as Alkaline
Phosphatase (APase) which contains two zinc ions and Dopamine β-monoxygenase (DBM) which
contains two copper ions. The results in relation to IMPase indicated that an additional hydroxyl group
was needed for inhibition. Substrates without
O

the extra or masked hydroxyl groups such as

O

O
OH

OH

HO

OH

HO

OH

tropolone (2) and 3,7-dihydroxytropolones
2

flanked by a methoxy and acetyl group
instead of a hydroxyl group were inactive at
concentrations less than 1 mM (Figure 1.8).

IMPase (Mg-Mg) IC50=
APase (Zn-Zn) IC 50 =
DBM (Cu-Cu) IC 50 =

>1 mM
>1 mM
2 µM

3
75 µM
15 µM
2 µM

9
8 µM
60 µM
3 µM

Figure 1.8. Activities of tropolones in relation to bimetallic enzymes
IMPase, APase, and DBM.

Puberulonic acid (4) and 3,7-dihydroxytropolone (9) revealed the best profiles at 10 µM and 8 µM
respectively. These results indicated that the placement of an extra hydroxyl at the C3 position of the
tropolone ring may play a role in increased binding ability due to secondary interactions with amino acid
residues within the enzyme. Structures without that C3 hydroxy group, such as α-hydroxytropolone (3)
showed a bit lower activity at a value of 75 µM. Further, the efficiency and rate of deprotonation was
believed to be a factor in the chelation of α-hydroxytropolones. Pyrogallol, whose structure contains three
contiguous oxygens on a benzyne ring and is super imposable with α-hydroxytropolone showed low
inhibition of >1 µM. The authors stated that α-hydroxytropolone, which is much more acidic then
pyrogallol with pKa of 6.7 versus 9.3, can be deprotonated much better at a neutral pH which increases its
anionic character and thus its binding ability.
The other enzyme targets tested, APase and DBM, revealed a bit more about the activity. APase
which has a smaller pocket then IMPase was affected by substitution on the ring. An extra hydroxyl group
at the C3 position of the 3,7-hydroxytropolone (9) lowered inhibition to 60 µM, as compared to the
unsubstituted α-hydroxytropolone (3) at 15 µM. Where the enzymes structural makeup may have had an
impact on those enzymes, DBM illustrated that chelating ability may be the main path of inhibition. Both
tropolones and α-hydroxytropolones inhibited DBM in the same range of 2-3 µM; the authors indicated
that the possible mechanism of inhibition was chelation to the metals and they believed that no other
secondary interaction were necessary to increase the binding effect.
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1.3.2 Aminoglycoside 2’’-O-adenylyltransferase [ANT(2’’)]
Aminoglycoside-2”-O-Adenylyltransferase (ANT(2”)) is part of a class of enzymes that include
acetyltransferases (AAC), and O-phosphotransferases (APH); they were developed by gram-negative
bacteria to deactivate aminoglycoside based antibiotics.27 This creates a problem as it imparts resistance
which leads to the need to discover new classes of antibiotics. Molecules that could inhibit this enzyme
and allow the aminoglycosides to regain their powerful activity are essential to preserve this class of
clinically important compounds. Allen and co-workers discovered that α-hydroxytropolones have the
ability to inhibit this enzyme;14 to test this theory they used a strain of E coli, E. coli W677/JR76.2 that
contained the enzymes 2’’-O-adenylyltransferase, and phosphotransferases: 3"-O-neomycin-kanamycin
phosphotransferase and a 3'-O-streptomycin phosphotransferase. They monitored the growth of the
strain with a series of aminoglycoside
antibiotics:

tobramycin,

gentamicin,

O
HO

O
OH

O
OH

HO

OH

HO

kanamycin A, dideoxykanamycin B
(dibekacin),

or

butirosin

and

a
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combination of an antibiotic spiked
with α-hydroxytropolone. They found
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ability alone, indicating that they were
Figure 1.9. Inhibitory concentrations of some α-hydroxytropolones against ANT(2'').

interrupting the activity of the enzyme.
Further, some aminoglycosides and α-hydroxytropolone mixtures showed greater inhibition than others;
tobramycin was the most effective while kanamycin A was the least. They postulated that another
enzyme interaction within the bacteria could be disrupting the antibiotic affect, and α-hydroxytropolone did
not inhibit that particular enzyme; For example, the group indicated that α-hydroxytropolone did not touch
the phosphotransferase enzymes.

Using the most effective aminoglycoside, tobramycin, they tested

different tropolone substrates to see if the dihydroxyl groups were necessary for inhibition. They tried
9

tropolone (2) with one hydroxyl group as well as derivates where the 7-hydroxyl group of αhydroxytropolone was replaced with a carboxyl, bromo, nitro, and amino group. The tropolone was shown
to be inactive, as well as the bromo, amino, and carboxyl derivatives. The nitro group showed very little
activity. They concluded that the extra hydroxyl group had a substantial effect on inhibition. Additionally,
they tried other diversely substituted dihydroxylated structures to see if derivation upon the seven
membered rings affected the inhibition activity. IC50 values were not recorded but percent inhibition was
presented at 100, 10, 1 µg/mL concentrations (converted to µM concentrations in figure) (Figure 1.9). βthujaplicinol (6) which contains an isopropyl group at the C4 position of the α-hydroxytropolone ring
demonstrated similar activity as α-hydroxytropolone, 76% vs. 78% at 10 µg/ml (55 µM and 73 µM),
respectively. Ring alkylation with a 4-dimethylallyl group (18) displayed reduced activity at 21% inhibition
at 10 µg/ml concentration (48 µM). This result possibly indicates that different types of substitution, such
as alkenes, may have unfavorable secondary interactions or be too bulky, hence interfering with the
binding. If an extra hydroxyl group was placed at the C4 position as in 10 versus the C3 position as in 9 of
the α-hydroxytropolone ring, this proved to have better activity, 50% vs. 0% at 10 µg/ml (65 µM),
respectively. In addition, derivatives that had enzyme inhibition activity allowed tobramycin to gain back
its activity.
Finally they concluded that α-hydroxytropolone hinders adenylation by competing with adenosine
triphosphate (ATP) for the enzyme, with a Ki value of 10 µM. α-hydroxytropolone was not competitive with
the aminoglycoside. A kinetics study showed that an increase of an antibiotic such as tobramycin did not
affect the inhibitory ability of α-hydroxytropolone, but concentration of ATP did affect the inhibition
potential of α-hydroxytropolone.
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1.3.3 HIV (Human Immunodeficiency Virus) Reverse Transcriptase [HIV RT]: The
Ribonuclease H (RNase H) Active Site
While reverse transcriptase (RT) polymerase inhibitors are well known HIV drugs on the market,
drugs that target the alternative site of the enzyme, RNase H, are not currently used. In 2005 Le Grice,
Beutler, and co-workers tested the inhibition potential of some naturally derived tropolones and two αhydroxytropolones in four types of RNase H studies: retroviral, HIV-1 RT and HIV-2 RT, bacterial, E.coli.,
and human.17 The most active
compounds against HIV-1 RT were
the

α-hydroxytropolones
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thujaplicinol (6) and manicol (7) at
values of 0.21 µM and 0.60 µM
respectively (Figure 1.10). Overall,
most of the tropolones showed no
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19
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Figure 1.10. Inhibition values of tropolone and α−hydroxytropolone based compounds
f or HIV-RT, E.coli (E.C) and Human (Hu) RNase H.

inhibition, except with respect to Human RNase H. A slight exception was α-thujaplicin (19); it had minor
inhibition in HIV-1 RT at 50 µM and HIV-2 RT at 33 µM. Manicol and β-thujaplicinol were more selective
towards HIV-1 RT than HIV-2 RT. Further, α-thujaplicin showed a better selectivity for HIV-2 RT; they
suggested this data may indicate a difference between these two domains. Importantly, β-thujaplicinol
was more selective for HIV-1 RT RNase H, at 0.21 µM than human RNase H; with a value of 5.7 µM.
Bacterial RNase H inhibition was not as strong in β-thujaplicinol or manicol, at 40 µM and 50 µM
respectively which showed evidence of selective inhibition of HIV RNase H. They also found that the
hydroxytropolones had very little binding ability to DNA polymerase. The authors concluded that the
binding ability to RNase H was not affected by an indirect effect of being bound to DNA polymerase. In
addition, they found that the hydroxytropolones did not intercalate to the DNA/RNA hybrid. Both βthujaplicinol and manicol displayed a mixed type of inhibition instead of competitive modes. The authors
suggested that the hydroxytropolones could bind to either the free enzyme or an enzyme-substrate
complex. They believed that this further signified that perhaps the hydroxytropolones could occupy a
pocket near the active site. Additionally, they combined β-thujaplicinol and a nucleoside, calanolide A, in a
HIV-1 RT model, and found that these two inhibitors targeted different sites. The nucleoside exclusively
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targeted the polymerase site, while β-thujaplicinol targeted the RNase H site, and they did this
simultaneously. The authors’ further postulated the idea of a bimetallic chelating ability of the
hydroxytropolone moiety to two metals at the RNase H active site.
In 2009, a crystal structure of β-thujaplicinol in the HIV RT RNase H active site was isolated.28 It
was revealed that β-thujaplicinol did indeed coordinate to two Mn2+ ions in the active site of RNase H, and
formed ionic or hydrogen bond interactions with the amnio acid residues Glu478 (glutamic acid), Asp498
(aspartic acid), His539 (histidine), and Asp549. They found that the divalent metals were essential for
binding. The data suggested that β-thujaplicinol and the RNA/DNA substrate can be bound at the same
time to the enzyme. Kinetics studies showed that the presence of the DNA/RNA substrate in RT is
needed for optimal binding; β-thujaplicinol had less binding ability for the free enzyme. Modeling of the
human RNase H site superimposed over the β-thujaplicinol RNase H model revealed that the metal
cations in both substrates align, and that β-thujaplicinol usurps the position of the scissile phosphate;
hence the inhibitor could interfere with phosphate binding and the ability of water to hydrolyze it.
Furthermore, β-thujaplicinol and manicol displayed HIV integrase inhibition activity. β-thujaplicinol
had IC50 values of 24.6 µM for 3’ processing, and 4.8 µM for strand transfer activity. Manicol had IC50
values 20.2 µM for 3’ processing, and 11.7 µM for strand transfer activity.29 α-Hydroxytropolones inhibited
integrase activity by binding to the DNA-integrase substrate after the 3’ processing step, hence affecting
the subsequent strand transfer step with greater inhibition. Similar to RNase H, tropolones did not inhibit
this process, which again outlines the importance of a dihydroxyl unit. Currently the limitations of these
substrates is their inability to have protective effects towards viral replication possibly due to their cellular
toxicity.16
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1.3.4 XMRV (xenotropic murine leukemia virus related virus) RNase H and Herpes Simplex
Virus (HSV)
Xenotropic murine leukemia-virus related virus (XMRV) is a laboratory derived potential human
retrovirus. It was initially thought to exist in patients with chronic fatigue syndrome and prostate cancer
but these studies were later retracted and refuted.30,31,32 It was found that XMRV was generated in the
laboratory by a recombination of two proviruses that produced XMRV with the passage of a human
prostate tumor cell line CWR22 in nude mice.33 Original human tumor cells CWR22 were not infected with
the virus. Since XMRV does show the passage into human cells lines there could be potential for this to
become a human pathogen such as the path of viruses like HIV. Interestingly, Sarafianos34 and
Wlodawer35 found that the HIV RNase H inhibitor β-thujaplicinol also inhibits RNase H of XMRV.
Wlodawer uncovered that β-thujaplicinol binds in a similar way to XMRV RT RNase H as HIV RT RNase
H and that at similar concentrations it has inhibitory activity. Sarafianos indicated competitive binding (as
concentration increases, inhibition activity does not) at an IC50 value of 1.4 µM.
The herpes simplex virus (HSV) is a serious human disease that effects 1 out of 6 people from
ages 14 to 49 in the United States.36 Worldwide estimates found that about 536 million people are living
with HSV-2, most of them being woman.37 This is a disturbing occurrence as HSV can be passed from the
mother to fetus at birth and cause death or serious brain injury in infants. Interestingly, HSV involves DNA
replication catalyzed by a protein called pUL29 (ICP8) that has a similar protein fold as the RNase H
enzyme.38 Tavis, Morrison, and co-workers believed that inhibitors of RNase H and integrase may also be
applicable to the HSV virus, so the tested inhibitors that fall in these classes against HSV.39 They tested
α-hydroxytropolones such as β-thujaplicinol and manicol and an array of tropolones for inhibitory potential
in HSV-1 and HSV-2 replication (in log10 units at 50 µM and 5 µM concentrations), viral replication in 50%
effective concentration (EC50), and cytotoxicity (CC50) in vero cells and human foreskin fibroblast (HFF)
cultures. Vero cells are laboratory primate host cells used for HSV analysis. HFF’s are a human cell type
that was infected with HSV-1 and HSV-2. It was found that α-hydroxytropolones, β-thujaplicinol (6) and
manicol (7), and tropolone, nootkatin (20) had some of the best inhibitory profiles of the 42 compounds
tested (Figure 1.11). Manicol was the strongest inhibitor at 5 µM concentration and inhibited vero cells

13

HSV-1 by 5.14 log10 (138,000 fold) units and HSV-2 by 5.95 log10 units (189,000 fold). They compared
these results with an anti-HSV drug, acyclovir (ACV), in their assays. At a similar concentration ACV saw
a value of 3.61 log10 units (4,070 fold) for
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O
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HO

HSV-1 and HSV-2 by 2.88 log10 units (758

O

HO

OH

OH

fold). Both nootkatin and β-thujaplicinol had
values around 5 log10 units at 5 µM
concentrations for both HIV-1 and HIV-2 in
vero cells. Similar values were seen in HFF
cells infected with HSV-1 and HSV-2 with
log10 values ≥5 at 5 µM concentrations.
CC50 values in both cells showed low
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103, 263

0.24 µM
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417, 182

0.74 µM
1.23 µM
135, 81
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Figure 1.11. EC 50 values and therapeutic indexes of β−thujaplicinol (6), manicol (7),
and nootkatin (20) for HSV.

toxicity at values of >100 µM. EC50 values and Therapeutic index (TI) values were determined
(TI=CC50/EC50) for both cell lines with HSV-1 and HSV-2. In vero cells manicol (7) showed EC50 values of
0.35 µM and 0.58 µM, and TI’s of 286 and 172 in HSV-1 and HSV-2, respectively (Figure 1.11).
Nootkatin (20) showed EC50 values of 0.24 µM and 0.22 µM, and TI’s of 417 and 454 in vero cells HSV-1
and HSV-2, respectively. In addition manicol (7) had EC50 values of 0.24 µM and 0.55 µM in HFF cells
lines with TI’s of 417 and 182 for HSV-1 and HSV-2 respectively. β-Thujaplicinol’s (6) TI was >100 in
these cells lines. For comparison the drug ACV had TI’s of 625 and 69 in vero cells HSV-1 and HSV-2
respectively and 833 for HSV-1 and HSV-2 in the HFF cell line. In addition, they found that β-thujaplicinol
suppressed replication in ACV resistant strains of HSV-1 and HSV-2 at 5 µM concentration.
1.3.5 HBV-Hepatitis B Virus RNase H
The Hepatitis B virus (HBV) causes an infectious disease of the liver. Despite the development of
a viable vaccine, worldwide the availability of the vaccine in underdeveloped countries is slim and the
disease is still prevalent with 780,000 deaths a year and more than 240 million chronically infected.40
Tavis and co-workers developed a low throughput screening assay for HBV RNase H inhibitors and
started with the HIV-1 RNase H inhibitor β-thujaplicinol to see if it inhibits HBV RNase H.41 They found
that HBV RNase H activity was inhibited with the substrate at IC50 values of 5.9 ± 0.7 µM for genotype D
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and 2.3 ± 1.7 for genotype H of the enzyme. β-Thujaplicinol inhibited HBV replication in human hepatoma
Huh7 cells, with an EC50 value of 5 µM and did not affect viral protein secretion. Finally, they found βthujaplicinol was cytotoxic to Huh7 cells at values of 10 ± 1.7 µM, but found that the membrane integrity
of the cells was not affected for CC50 values of > 150 µM. In addition they tested cytotoxicity in HepG2
cells, a heptaocyte line of cells that can be infected by HBV reverse transcriptase and found a CC50 value
of 16.7 ± 3.7 µM. In sum, the activity of α-hydroxytropolones with respect to RNase H in both HBV and
HIV is important with viable assays for both substrates, directed SAR studies would be the key to
discovering a potent therapeutic.
1.3.6 Phosphotidylcholine-Preferring Phospholipase C
Phospholipase C is a dimetallic zinc enzyme that cleaves phospholipids by hydrolysis. αHydroxytropolone was shown to have inhibition activity against this compound at a Ki of 16 µM.9 Martin
and co-workers designed molecules that they believed could mimic the chelating ability of αhydroxytropolone yet be easier to
O

synthesize by being more stable.9
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Figure 1.12. N,N'-dihydroxyurea mimics' and α-hydroxytropolone's pK a and Ki values
f or phospholipase C (NI=No Inhibition).

Unfortunately, of all the molecules
derived, none had to the ability to inhibit the zinc containing enzyme phosphotidylcholine-preferring
phospholipase C as well as α-hydroxytropolone. At more basic pH values the dihydroxyureas became
more active. Compound 21 showed no inhibition at a pH of 7.3, but at a pH of 9.5 had a Ki of 71 µM.
Compound 22 showed inhibition at neutral and basic pH values with Ki values of 388 µM at a 7.3 pH and
53 µM at a 9.5 pH. They believed at basic pH values the molecules would be more negatively ionized,
hence making them more active towards positive metal centers. It appeared pKa’s played a role but steric
interactions also dominated the ability of molecules to inhibit the enzyme. Molecule 23 had similar pKa
profile as α-hydroxytropolone, but showed no inhibition. The authors believed this may be due to
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unfavorable steric interaction of the ring carbonyl with an aromatic ring of the phenylalanine residue (Phe)
within the enzymatic pocket. This study showed that pH values as well as steric interactions may play an
important role in the α-hydroxytropolones ability to inhibit various enzymes with various degrees of
inhibition.
1.4 Structure Activity Relationship (SAR) Studies
1.4.1 SAR studies for IMPase Inhibitor Development
Due to the ability of 3,7-dihydroxytropolone (9) to inhibit inositol monophophatase15 Piettre and
coworkers sought out to increase potency of this substrate by constructing 37 new 3,7-dihydroxytropolone
based substrates.42 They took 3,7-dihydroxytropolone and brominated it which resulted in 57%
conversion to a 4.8:4.7

mixture of 9:24 (Scheme 1.1). Compound 24 was a mixture of the singly

brominated A to the doubly brominated B.

The

separated

compounds

were

then

protected

with

diazomethane and various substituents were installed via a Suzuki
cross coupling reaction followed by deprotection with trimethylsilyl
iodide in acetonitrile and subsequent hydrolysis. Their synthesis was
relatively successful with moderate yields, but they noted that the final

Table 1.1. IMPase Inhibitory activity
of most potent 3,7-dihydroxytropolones.
Entry

R

IC 50

25

m -CN-C6 H4

4 µM

26

OH-(CH2 )4 -

5 µM

27

o,m-(OH) 2-C6 H3

7 µM

28

2-benzofuryl

7 µM

29

m-NO2-C6 H 4

8 µM

3,7-dihydroxytropolone products were difficult to purify by any means. They developed a demethylation
process with trimethylsilyl iodide

(TMSI) in acetonitrile (MeCN) that was an important part of the

synthesis to gain access to these compounds. Of the 37 compounds only five showed activity similar to or
better than the parent compound (9) at a concentration of 10 µM (Table 1.1).
The best inhibitory activity was seen with the meta-cyano-phenyl dihydroxytropolone (25) with an
IC50 value of 4 µM, and the hydroxybutyl dihydroxytropolone (26) with and IC50 of 5 µM (Table 1.1).

16

Compounds

showed

27-29

similar

activity

to

3,7-dihydroxytropolone.

Disubstituted

3,7-

dihydroxytropolones yielded from a double Suzuki via structure B of 24 tended to have lower activity over
all the compounds constructed. Kinetics with the new derivatives indicated competitive inhibition modes
similar to the parent compound.
1.4.2 SAR studies for HIV RT RNase H and Polymerase, and HIV Integrase Inhibitor
Development
Due to 3,7-dihydroxytropolone’s ability to inhibit Inositol Monophosphatase, Piettre, Marquet, and
co-workers extended their studies to other bimetallic enzymes such as HIV RT RNase H and integrase.12
Nineteen monosubstituted and disubstituted derivatives of 3,7-hydroxytropolones were synthesized as
previously reported and their ability to inhibit HIV RT RNase H, HIV RT polymerase, and HIV integrase
activity was studied. Approximately eight of the compounds had RT polymerase activity better than the
parent 3,7-dihydroxytropolone (9) (IC50= 3.2 µM) (Figure 1.13).
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Figure 1.13. Inhibitory data on some notable 3,7-dihydroxytropolone derivatives.

The best inhibitor for RT polymerase activity was the benzaldehyde containing derivative 30 with an IC50
value of 0.57 µM. RT RNase H inhibition activity of most of the compounds tended to be around the same
value or had worse inhibition than the parent compound, except for the meta-nitro-aryl substituted 31 that
showed the best profile at an IC50 value of 1.3 µM. For integrase 3’ processing activity, compounds 30,
31, and 32 had IC50 values under 1 µM which represented an increase of 40-fold over 3,7dihydroxytropolone (IC50= 40 µM); additionally these three compounds showed good activity for integrase
strand transfer. The best integrase 3’ processing compound with an IC50 of 0.15 µM was the disubstituted
N-acyl-phenyl groups (32) and the best strand transfer inhibition activity was seen with the meta-nitrophenyl (31) at a value of 0.78 µM. Compounds were the three hydroxyl groups were masked by a methyl
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or acetyl for example, tended to show no activity in all sites. One exception was acetylated compound 33
that showed activity for polymerase (IC50= 7.6 µM). The authors felt this finding could infer a different
mechanism rather than a metal chelating one for the polymerase activity. They continued the polymerase
activity study by changing the Mg2+ concentration. Using 3,7-dihydroxytropolone and the acetylated 33,
they lowered the magnesium concentration from 6 mM to 0.3 mM. The result was that inhibition of 3,7dihydroxytropolone decreased to 19 µM and 33 showed no inhibition. This study implies that chelating
ability is a mechanism of inhibition by tropolones, but polymerase activity may not be simply described as
such. Another interaction or mechanism could be at play such as secondary interactions at the binding
pocket. Some of the compounds that were tested had antiviral properties in HIV-1 LAI/CEM-SS cells,
although no protective effects were seen in another cell assay (HIV-1 IIIB/MT-4 cells).
1.4.3 SAR studies for HIV RT RNase H Inhibitor Development
As noted earlier, β-thujaplicinol (IC50=0.21 µM) has the best inhibitory activity against HIV RT
RNase H followed by manicol (7) (IC50=0.60 µM); Unfortunately both substrates offer no viral protection
and are cytotoxic with CC50 values of 2.3 µM and 13.6 µM respectively.17,18 To improve the activity,
antiviral properties, and cytotoxicity profiles, Le Grice, Beutler, and co-workers synthesized 14 new
compounds by derivatizing the
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Scheme 1.2. Brief synthetic scheme of manicol derivation.

dihydroxylation

and

oxidation reactions (Scheme 1.2). In the second route they installed an epoxide at the alkene (35) and
opened it with various thiol and amine nucleophiles. None of the derivates tested improved inhibition of
RNase H compared to manicol and β-thujaplicinol, the best inhibitory activity (IC50 values) was found in
compounds 36 and 37 at a values of 0.24 µM and 0.38 µM, respectively (Figure 1.14).
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All the compounds tested except 36 were less cytotoxic than manicol, while over half of the newly
synthesized derivatives offered some viral protection. Compound 40 was an interesting prospect, its
inhibitory activity was in the same range as manicol and this substrate offered some antiviral protection
(EC50= 10.2 µM), and was much less cytotoxic (CC50= >50 µM). Substrates 37, 38, 39, which each
contained sulfur but appended to different groups such as an ethane, benzene and benzyl moieties
respectively, were a fascinating trio analyzed.
As the size of the appendage increased from ethane, benzene, benzyl, the inhibition decreased
and antiviral activity increased. The substrates were tested for polymerase activity on RNase H deficient
RT and wild type HIV-1 RT, but almost all compounds did not inhibit this site on either strain. The
exceptions were compound 41 and 42 which inhibited DNA polymerase activity on both strains. Finally 43
showed the lowest inhibition activity (IC50= 1.9 µM), no antiviral activity, but was less cytotoxic (CC50= >50
µM). It seems that as inhibitory activities increase/decreased the opposite effect was had on antiviral
activity and cytotoxicity, which did not offer a better alternative to the natural products.
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1.5 Syntheses of α-Hydroxytropolones
1.5.1 Total Synthesis of α-Hydroxytropolone
One of the first syntheses of the α-hydroxytropolone core structure was developed by Nozoe and
co-workers in 1953. They discovered that when 1.2 molar equivalent of potassium persulfate was added
to tropolone, 2, the resultant product contained a mixture of 15% α-hydroxytropolone (3) and 30% of 5hydroxytropolone (11) in addition to
un-reacted
(Scheme

starting

1.3).43
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Scheme 1.3. Nozoe's synthesis of α- hydroxytropolone (3) and 5-hydroxytropolone (11).

the two hydroxyls with methoxy groups with diazomethane (no yield given) and a diacetate in 80% yield
with acetic anhydride; additionally benzoylation by the Schotten-Baumann method gave a dibenzoate in
60% yield.
In 1986, Takeshita and Mori achieved the exclusive α-hydroxytropolone core structure through a
high yielding synthesis.44 They took methoxytropolone 44 and brominated it with N-bromosuccinimide
(NBS) (Scheme 1.4). The resultant 7-bromo-2-hydroxytropolone (45) was acetylated to compound 46 in
100% yield with acetic anhydride and acetyl trifluoroacetic acid under heat.

Under heat and acetic acid they were able to deacetylate 46 to afford α-hydroxytropolone in 100% yield,
with an overall yield of 89% from the starting material. This synthesis demonstrated a high yielding, low
step synthesis to the α-hydroxytropolone core structure.
In

2004,

Föhlisch

and

co-workers

explored

a

concise

synthesis

of

substituted

α-

hydroxytropolones by means of a ring opening of 8-oxabicyclo[3.2.1]oct-6-en-3-ones constructed from a
[4+3] cycloaddition that involved furans as starting components.45 They achieved substitution at two
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different places on the α-hydroxytropolone ring structure, as well as a synthesis of α-hydroxytropolone
and β-thujaplicinol. The synthesis started with substituted furans 47a-d; furan, 2-methylfuran, 2isopropylfuran, and 2-benzyloxymethylfuran (Scheme 1.5).
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thujaplicinol (6), and other -hydroxytropolones .

The furans were each reacted with a 1,1,3,3-tetrachloroacetone generated oxyallyl intermediate
in a [4+3] cycloaddition reaction that produced two diastereoisomers with 48 being the favored structure
in all compounds, with combined yields of both diastereoisomers ranging from 62%-78%. In the next step,
the mixture of these compounds were subjected to sodium methoxide then zinc powder, which added
dimethoxy groups and dehalogenated the substrates to yield

50 and 51. Strangely the opposite

regioisomer of the favored starting compounds 48 was favored, compound 50. They envisioned this may
have been due to steric constraints between R1 and the chloro groups in 48. They constructed the
mixtures of compounds 50 and 51 in combined yields ranging from 75%-97%. They were able to further
functionalize the core structure by installing a methyl or a 2-oxobutyl group alpha to the carbonyl. With
these compounds in hand, they tried various ring opening procedures until they discovered that a
methanolic potassium hydroxide solution followed by acidification produced methoxytropolones 52 in
yields ranging from 58%-88%. The compound with the 2-oxobutyl moiety at R2 needed alternative ring
opening procedures involving methanolic sodium methoxide at reflux. The potassium hydroxide
conditions, even at room temperature, produced an aldol condensation product between the ring carbonyl
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and the ketone at position R2. Even with the new conditions they got minor amounts (16% yield) of the
aldol product. Interestingly, only the products with the structure of 50 reacted, the 51 products did not but
could easily be separated from the mixtures via an alkaline aqueous phase workup. They took
methoxytropolones 52 and submitted them to demethylation procedures involving hydrogen bromide and
acetic acid (HBr/AcOH), and generated such compounds as the naturally occurring α-hydroxytropolone,
3, in 94% yield and β-thujaplicinol, 6 in 96% yield in five steps. This synthesis proved that more than one
point on the α-hydroxytropolone ring could be diversified and offered an alternative synthesis to the
precursor structures, 7-methoxytropolones in four steps. The limitations, as outlined by the authors, was
the unavailability of appropriate substituted furans, and the formation of the wrong oxabicyclic compounds
51 that did not undergo the ring opening and diminished the yields; they indicated that selectivity of the
initial [4+3] cycloaddition needed to be refined.
Balci and co-workers utilized a photooxygenation to obtain a functionalized α-hydroxytropolone
that is a derivative of stipitatic acid.46 They took 1,3-benzodioxole 55 and reacted it with ethyl
diazoacetate under rhodium acetate (Rh2(OAc)4) catalyzed conditions to yield cycloheptatriene 56 in 40%
yield (Scheme 1.6). Then a photooxygenation reaction with tetraphenylporphyrin yielded peroxide 57 in
90% yield. To obtain the
α-hydroxytropolone
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Scheme 1.6. Balci's synthesis of a functionalized α-hydroxytropolone.

compound was the di-epoxide 58 that could quickly rearrange to the α-hydroxytropolone 59 in 60% yield.
This photooxygenation seqaouence afforded a unique approach to installing the hydroxytropolone unit.
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1.5.2 Total Synthesis Puberulonic Acid
Nozoe and co-workers were leaders in the synthesis of compounds in the troponoid family of
molecules, so it was only fitting they would pursue the synthesis of the natural product, puberulonic acid
.47 In 1960, they attempted this synthesis using purpurogallin (60) as the starting material (Scheme
1.7).48,49 They oxidized this compound to the anhydride containing tropolone 61 in low yield as indicated
in the paper. The insertion of a bromine atom alpha to the carbonyl was assembled with the reaction of
bromine in acetic acid to form 62 in 86% yield. To install the hydroxyl group, they used βnaphthalenesulfonate in a basic solution with copper powder to yield 63 in 83% yield. Installing the
bromine beta to the carbonyl was not as facile, and the previous conditions of bromine in acetic acid left
only a decomposed product.

The circumvented this by adapting a new method which involved bromine in sodium hydrogen sulfate to
yield 64 in 50% yield. Again, the additional hydroxyl group was installed with the previous method to yield
puberulonic acid (4) in 35% yield. They noted that the reactivity of the bromine in 62, was stronger than in
64, due to yields gained of the hydroxylated products. The yields could also indicate a mass loss. This
could be attributed to the α-hydroxytropolone 64 chelating to the copper stronger than the tropolone 62 or
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the loss of 64 in the water extraction. They could further synthesize puberulic acid by decarboxylation of
puberulonic acid (4) under reflux with water; they obtained puberulic acid in 64% yield. This attempt
offered the first synthetic approach towards puberulonic acid, informed on the relative reactivity at various
places on the ring, as well as introduced a low step count sequence.
1.5.3 Total Synthesis of Puberulic Acid
Johnson and co-workers wanted to understand more about the structures of the first two
discovered natural α-HTs, puberulic acid and puberulonic acid. They made some interesting observations
that led to a synthetic strategy to puberulic acid.3,4 Initially, it was found that puberulonic acid could be
converted to puberulic acid by decarboxylation upon heating to reflux in sulfuric acid or water.4 Moreover,
observations about reactivity were uncovered, such as that the carbonyl group was inert to chemical
reactions, and substitution products were favored over addition products when bromine was added to the
tropolone structure.4 In addition, as most tropolones produced benzenoids upon heating with potassium
hydroxide, puberulic acid showed stability under temperatures of 320°C.4 These observations lead the
group to take a very early synthetic approach towards puberulic acid. They did this by first targeting
puberulic acid’s precursor, stipitatic acid, 12 which is similar to puberulic acid except for the absence of
an extra hydroxyl group alpha to the carbonyl (Scheme 1.8).50,51

They were able to achieve stipitatic acid through a synthetic sequence that involved utilizing a
rearrangement product derived from 1,2,4-trimethoxybenzene 65 and 2-propionyldiazenecarbaldehyde. In
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situ, the reaction was thought to generate a cyclopropyl intermediate, 66, that could immediately expand
to the cycloheptatriene ring structure 67. The ester was hydrolyzed with potassium hydroxide to install the
carboxylic acid in compound 68. Hydrogen bromide in bromine demethylated and oxidized 68 to reveal
stipitatic acid (12). To install that extra hydroxyl group alpha to the carbonyl, they brominated that position
in 69 then immediately subjected it to potassium hydroxide under heating to reveal puberulic acid 5 in
58% yield. This was the first synthetic strategy towards the natural product puberulic acid, and utilized
some notable chemistry such as cyclopropyl ring expansion to gain the seven membered tropolone ring
structure, as well as a low step count. The negative part of this synthetic approach was the low yields
obtained.
Banwell and co-workers creatively applied a dibromopropane ring opening to the synthesis of the
natural product puberulic acid.52 First, diol 70 was protected with acetone and perchloric acid to produce
acetonide 71 (Scheme 1.9).53
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The acetonide was brominated and the dibromopropane moiety was established in 72. It was then
deprotected and methylated with methyl iodide to craft compound 74 in 97% yield. The authors
mentioned that they tried to find a more direct route to the methylated 74 right from starting diol 70 but
failed to produce the required product for the dibromocarbene addition step (71-72).54 The cis-diol
product, 75, was generated in 75% yield with osmium tetraoxide. To obtain the diketone, they initially tried
modified Swern conditions, but this did not produce the require diketone 77. The required ketone was
garnered through an alternative oxidation process using 4-acetamido-TEMPO (2,2,6,6-Tetramethylpiperidin-1-yl)oxyl and p-toluenesulfonic acid. Interestingly, when the diketone was acetylated, a 5:3
mixture was obtained in 85% combined yield, the lesser ratio implicating the acetylated compound 76 as
well as starting diketone 77. They found that only the acetylated compound achieved the desired base
activated ring expanded tropolone core, 78, in 79% yield. Making use of the bromine handle, a carboxylic
acid was installed through a metal catalyzed methoxycarbonylation to obtain product 79 in 71% yield,
after hydrolysis. Finally through demethylation procedures that involved hydrobromic acid in acetic acid,
puberulic acid (5) was achieved in 90% yield. Although the step count increased from the previous
attempt at puberulic acid, yields were slightly improved.
In 2011, Omura and co-workers gathered the preliminary biological data on puberulic acid’s
activity against malaria and recently they attempted a synthesis of this natural product.16,55 First they
utilized the readily available and inexpensive carbohydrate D-(+)-Galactose (80) as their starting material
(Scheme 1.10). They protected the alcohols with acetonide groups and installed an iodide via an Appel
reaction to yield 81 in 97% yield. They installed an aldehyde at the iodide position through a Barbier
addition with zinc in tetrahydrofuran and water (THF/H2O) and then immediately added diene 82 until they
formed 83 in 96% yield in a (2.3:1) ratio of the diastereoisomers (6S:6R). This mixture was subjected to a
ring closing metathesis with the Grubbs second generation catalyst (10 mol%) to yield 84 in 97% yield.
After a deprotection with 2,3-dichloro-dicyano-1,4-benzoquinone (DDQ) that removed the paramethoxybenzyl (PMB) group to yield a hydroxyl group, the group tried various oxidation conditions to
generate the aromatic 7-membered ring scaffold.
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They found that under a multi-tandem Parikh-Doering oxidation with SO3∙pyridine in dimethyl sulfoxide
(DMSO) in triethylamine (NEt3) they successfully created compound 85. They believed the mechanism
first went through an oxidation that converted the hydroxyl groups to carbonyls. Then aromatization
followed through tautomerization of the protons within the structure. To install the carboxylic acid they
utilized a Pinnick oxidation to construct 86. The final step to form puberulic acid was the removal of the
acetonide which was accomplished with hydrogen bromide in acetic acid. They formed puberulic acid via
eight steps in 54% overall yield. This method not only offered a low step, and high yielding sequence, it
utilized a cheap and efficient starting material and only two carbon-carbon bond forming steps.

1.5.4 Total Synthesis of β-Thujaplicinol
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Martin Banwell was a forerunner in tropolone synthesis and in his progress toward achieving a
synthesis towards another natural product, β-thujaplicinol, he discovered a route to add substitution
around the tropolone core, which was previously not achieved up to this point. He did this through an
efficient five step synthesis that involved a dibromocyclopropane ring expansion. With the easily
accessible, cyclohexa-1,4-diene, 87, the dibrominated cyclopropane structure was installed to generate
88 in 72% yield (Scheme 1.11).56 Compound 88 was then oxidized to the diol 89.57 The key reaction
involved an in situ ring opening. First, through an oxidation procedure developed by the group using
dimethyl sulfoxide activated with trifluoroacetic anhydride, a diketone was generated.58 Then under basic
conditions, a ring expansion was promoted that generated the 7- methoxytropolone 90 in 85% yield, an
important intermediate towards the synthesis of α-hydroxytropolones.

The bromine at the four position of the ring on 90 offered a point to install diverse substitution,
including an isopropyl group that would lead to the generation of the natural product, β-thujaplicinol. They
completed the synthesis of β-thujaplicinol by attaching propene in place of the bromide through a Stille
cross coupling and obtained 91 in 89% yield; then with hydrogenation they were able to reduce the
propene to an isopropyl group.59 Finally an acetic acid hydrogen bromide demethylation reaction
generated β-thujaplicinol (6) in 73% yield over two steps. They were able to use 7-methoxytropolones to
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do various cross coupling reactions to switch out the R group on the ring (92). Demethylation afforded the
α-hydroxytropolone products. This synthesis was the first to achieve substitution on the core ring structure
of α-hydroxytropolones, but was limited to only one access point on the ring. Fortunately, ideal placement
of the bromine on the ring allowed for the first complete synthesis of the natural product, β-thujaplicinol.
1.5.5 Synthesis of 7-Methoxytropolones
Banwell and co-workers designed an alternative synthesis to obtain 7-methoxytropolones. As was
outlined in previous synthetic endeavors, 7-methoxytropolones are a demethylation away from αhydroxytropolone. Banwell took commercially available 2,3-dimethoxyphenol (93) and subjected it to
oxidation with Thallium (III) nitrate to produce the acetal, 94 (Scheme 1.12).60

The acetal was cyclopropanated with dimethyloxosulfonium methylide to form 95 in 35% yield. Hydrolysis
with hydrochloric acid (HCl) gave diketone 96 in 84% yield. This product expanded into the boron
difluoride methoxytropolone 97 in 55% yield (with minor amounts of the hydroxylated version) with six
equivalents of boron trifluoride etherate. 7-methoxytropolone 98 was generated in 83% yield with sulfuric
acid under reflux.
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Davies and Clark developed a rhodium catalyzed tandem cyclopropanation/Cope rearrangement
to construct substituted tropolones.61 They were able to construct methoxytropones, as well as
dimethoxytropolones using this technique. Utilizing a rhodium II catalyst with an acetate, pivalate, or
octanoate,

various vinyldiazomethanes were reacted with an electron rich diene 101 and the core

cyclohexadiene rearrangement products were gained through cis selective divinylcyclopropane
intermediate 102 (Scheme 1.13).

They constructed various methoxytropolones by installing different substrates alpha to the
carbonyl such as a methyl, phenyl, methyl ester, and benzene thiol. To construct a dimethoxytropone
they needed to use a vinyldiazomethane with an electron donating methoxy group (100). Due to the
decreased stability of this substrate attributed to the electron donating methoxy group, the chemistry was
a bit more challenging than their previous attempts with electron withdrawing groups. Under the rhodium
catalyzed reaction conditions that utilized the octanoate, they successfully obtained product 103 in 32%
yield. Under a one pot hydrolysis/oxidation with p-toluenesulfonic acid and DDQ conditions
dimethoxytropolone 104 was obtained in 58% yield. Davies and Clark offered a short route that allowed
versatility on the seven membered ring. It could be imagined that a variety of substrates could be
constructed by the introduction of variability on the vinyldiazomethane.
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1.6 Conclusion to the Biology and Synthesis of α-Hydroxytropolones
It has been shown that α-hydroxytropolones have promising biological activity, but SAR studies
are limited by the ability to easily access these molecules. Previous syntheses have shown that the αhydroxytropolone structure can have stability issues and unpredictable ring reactivity. Due to these
issues, synthesis of these molecules was circumvented with mimics, but reduced medicinal activity of
these mimics outlined the strength these powerful small molecule inhibitors have that cannot simply be
exchanged. Syntheses of diversely substituted α-hydroxytropolones for medicinal chemistry shines
through in the work of Banwell and Föhlisch who both introduced ways to insert functionality on the core
α-hydroxytropolone core structure. Additionally, the manipulation of natural products such as manicol
have shown promise, and cross coupling reactions reveal an efficient way to derivate the core such as in
the work with the dihydroxytropolone SAR studies. The elements of a medicinal chemistry driven
synthesis of α-hydroxytropolone are out there, but the pieces have yet come together for continuously
productive SAR studies.
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CHAPTER 2: Synthetic Route and Chemistry
2.1 Introduction
As discussed, α-hydroxytropolones are somewhat understudied therapeutically due to the lack of
a
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Scheme 2.1. Proposed route to α-hydroxytropolones via an oxidopyrylium cycloaddition.

have been shown in the work of Föhlisch and Banwell, they do have their limitations. For example,
Föhlisch’s multi- step synthesis allowed for diverse functional groups, but relied on early stage
introduction of those groups through a furan.45 On the other hand, Banwell was able to introduce late
stage substitution on the α-hydroxytropolone core, but the synthesis only allowed access to one place on
the α-hydroxytropolone ring.59 A process that allows for late stage introduction of poly-substitution on the
α-hydroxytropolone would be an ideal synthetic route for medicinal chemistry studies as a library of
substrates could easily be accessed. It was envisioned that this could be achieved through a late state
intermolecular oxidopyrylium dipolar cycloaddition with various alkynes (step 105-106) which could yield
an array of multi substituted 8-oxabicyclo-[3.2.1]octadienones (106) that could be induced to open under
acidic conditions to yield poly-substituted α-hydroxytropolones (107) (Scheme 2.1). The goal of this
research was to develop a synthetic route to obtain the generation of a diverse array of αhydroxytropolones through an intermolecular oxidopyrylium cycloaddition between a β-hydroxyγ-pyrone generated oxidopyrylium ylide and an external alkyne followed by a ring opening.
Oxidopyrylium cycloadditions have proven to be powerful transformations for the formation of 8oxabicyclo-[3.2.1]octadienones.62 Chemistry on these 8-oxabicyclo-[3.2.1]octadienones such as ring
openings of the epoxide ring have showed that through these simple one step addition processes,
structurally interesting products with defined stereochemistry can be synthesized.
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2.1.1 β-Hydroxy-γ-Pyrone Derived Oxidopyrylium Reactions
Volkmann and co-workers first identified the [5+2] cycloaddition reaction products of β-hydroxy-γpyrones, kojic acid and α-deoxykojic acid, with acrylonitrile. In addition they postulated a mechanism that
involved an oxidopyrylium intermediate.63 The reaction was first performed by Hurd and co-workers, but
wrong assignment of structural products led to an unclear mechanism.64 Volkmann identified one of the
reaction products as 113a, and proposed a mechanistic pathway (Scheme 2.2).

He suggested that the base catalyzed reaction was initiated by an intermolecular [5+2] cycloaddition
reaction (109a) between kojic acid 108a and acrylonitrile, which led to cycloadduct 110a. Nucleophilic
addition of another molecule of kojic acid to the carbonyl yielded 111a. Nucleophilic attack of the hydroxyl
group into the cyanide moiety yielded imidolactone 112a (which was one of the products isolated by Hurd
and co-workers), and after acidic workup compound 113a was obtained. Similar structures were identified
by the reaction of α-deoxykojic acid and acrylonitrile following a similar mechanistic reason, which yielded
product 111b. Also 111d and 111c that were derived from pyromeconic acid (108d) and
chloromethyldeoxykojic acid (108c) were correctly identified as reaction products.
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in 55% yield and 118 in 42% yield by refluxing in benzene for 12 hours and acetonitrile for 60 hours
respectively, followed by acetylation (Scheme 2.3). Next, they experimented with expanding the chain
length of the tethers. First they assembled compound 119a from kojic acid and they used that to achieve
cycloadduct 120a in 70% yield after 12 hours of reflux in benzene followed by acetylation. Following this

OH
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H

achieved through the generation of 120b in
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O
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O

heating at higher temperatures of 110°C for

OAc
O
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HOSO2CH 3
O
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H 3CO2 C

65% yield. They gained this substrate after

48 hours in benzene followed by acetylation

O

H 3CO2 C
H 3CO2 C

(Scheme 2.3). Expansion by one carbon
H

further in this substrate was not possible
121

122 (87%)

Scheme 2.4 . Kojic acid derived pyrones and their cycloaddition products.

(119c-120c), and higher temperatures just
led to decomposition. Alternatively, addition

of a benzene ring into the tether (121) and heating in methanesulfonic acid in methanol for 12 hours
provided ketal 122 in 87% yield (Scheme 2.3).
Volkmann’s and Garst’s work led to a hypothesis of how these short-lived oxidopyrylium
intermediates from pyrone starting materials were generated. Subsequent work done by Wender and
Mascareñas led to the theory that the transfer of the R group in 123 to the carbonyl activated the
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formation of the oxidopyrylium species 124 that reacts in an intramolecular fashion to generate
cycloadducts such as 125 (Scheme

OR

O
O R Group
Transfer

2.5).66,67,68 Not only can protons transfer

O
123

tertbutylsilane (TBS), acyl (Ac) are also

124

125

R =Ac, TBS, H, Bz
Scheme 2.5. Proposed group transf er mechanism.

known to undergo the tranfromation.62b,
69

O
O

O

but groups such as benzoate (Bz),

OR
O

Theoretical studies done by Domingo and co-workers based on Wender and Mascareñas experimental

data that used DFT (density functional theory) methods at a B3LYP/6-31G* level of theory supported this
mechanism.70 They found a more favorable energetic profile if the R group transfer happened before the
cycloaddition than after the cycloaddition took place, validating the above mechanism.
As was shown there was a strong basis for oxidopyrylium cycloaddition generated from βhydroxy-γ-pyrone, but mainly this reaction proceeded through an intramolecular mechanism.
Intermolecular β-hydroxy-γ-pyrone based oxidopyrylium cycloadditions are to a lesser extent known. In
fact, there are only two reactions to date where this reaction was demonstrated with an alkyne. In one, it
was demonstrated that α-deoxykojic acid (108a) could react through an oxidopyrylium cyclization with an
in

situ

formed

benzyne

(126)

to

form

OPh
O

O

cycloadduct 127 in 33% yield (Scheme 2.6).71
Due to the reactive nature of benzyne, another

OH
H 3C

equivalent added into the carbonyl. A more
general route was developed by Wender and

DME
reflux

O
108b

126

O
H3 C

127 (33%)

Scheme 2.6. Deoxykojic acid reaction with in situ generated benzyne.

Mascarenás, who showed that a triflate salt 105a generated through the reaction of α-deoxykojic acid
108a and methyl triflate could be converted, through deprotonation with N,N-dimethylaniline, to a reactive
oxidopyrylium zwitterion (128), capable of cyclizing with a range of activated alkene dipolarophiles under
mild conditions; In addition they demonstrated the reaction with a reactive alkyne dipolarophile Dimethyl
Acetylene Dicarboxylate (DMAD) to form the oxabicyclic compound 106a in 73% yield (Scheme 2.7).68
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To overcome the limitation of the intermolecular scope of reactions, Mascareñas and co-workers
developed temporary tethering strategies. Intramolecular pyrone based oxidopyrylium reactions are
inherently more reactive due to the nature of the reactants which are in closer contact with one another
than in the intermolecular sphere. Utilizing this reactivity, Mascareñas and co-workers envisioned that
they could attach a heteroatom containing tether to the pyrone species that would react in a more
favorable intramolecular fashion and
OR

accomplished

this

by

RO
O

O
X

They

O

RO
O

with a reaction that could remove the
specific heteroatom (Scheme 2.8).72

O

O

then simply break apart the tether

H

Y

X

129a: X=S; Y=CH 2
129b: X=O; Y=Si(CH3 )2

Y

130a: X=S; Y=CH 2
130b: X=O; Y=Si(CH3 )2

R1

H
R2

131a:R1 ,R2 =CH 3
131b: R 1=CH2 OH; R 2=OH

Scheme 2.8. Mascareñas's tethering approach in oxidopyrylium cycloadditions.

assembling a sulfur or silicon linker. Under heating in a sealed tube in toluene they successfully
completed the cycloaddition of 129a and 129b to cycloadducts 130a and 130b respectively (Scheme 2.8).
Removal of the sulfur with Raney nickel revealed the product 131a in 70% yield. The silyl was removed
with potassium fluoride (KF) in meta-chloroperbenzoic acid (mCPBA) to form the diol 131b.
Intermolecular pyrone based oxidopyrylium cycloadditions are difficult to access as shown with their
narrow scope, but the vibrant complexity of this simple reaction is an important synthetic tool and an
important stepping stone to natural based products such as α-hydroxytropolones.
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2.1.2 Oxidopyrylium Cycloadditions followed by Ring Openings in the Synthesis of the
Tropolone Moiety.
Oxidopyrylium cycloadditions followed by ring openings are powerful processes that serve as
synthetic stepping stones to important biological targets; one of those targets happen to be tropolones.
Baldwin and co-workers used an oxidopyrylium cycloaddition followed by a ring opening reaction to
construct a deoxy analogue of the tropolone containing natural product epolone B.73 Starting with a
commercially available furan, 3-methyl-2-furoate they obtained pyranulose 132 in 63% overall yield
(Scheme 2.9).

The oxidopyrylium reaction was initiated by heating the molecule in a sealed tube at 120°C in the
presence of the dienophile α-acetoxyacrylonitrile. The pyranulose served as the oxidopyrylium species
(structure in red) whereas the alkene of α-acetoxyacrylonitrile served as the reactive portion of the
dienophile (structure in blue). The reaction afforded a mixture of compounds 133 in 54% overall yield.
They tried to install another ketone in-place of the cyanide and acetate, which did not give their desired
product. Alternatively, they reduced the already present ketone and installed another ketone with sodium
methoxide in methanol to yield 134 in 98% yield. They attempted to ring open the either bridge directly
from ketone 134, but had no success. The alternative path involved opening the bridge via an iodide
induced elimination. After four steps from ketone 134 that involved a reduction, protection, removal of the
tertbutyl silyl (TBS) protecting group and finally installation of an iodide, compound 135 was obtained in
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84% yield (over 4 steps). The iodide was eliminated via reduction with zinc in refluxing ethanol to produce
an alkene moiety into the desired ring opened product 137 in 78% yield. From there they successfully
reached their tropolone core structure (138) after 6 steps in 37% yield from 135. While working on
tropolone based natural products, Baldwin employed another intramolecular oxidopyrylium
cycloaddition/ring opening procedure. The group employed a rhodium catalyzed oxidopyrylium reaction.
With starting compound 139 gained in 33% yield over two steps from commercially available phthalic
acid, an internal alkyne was installed as well as a diazoketone (Scheme 2.10.). 74

The oxidopyrylium species (structure in red) in 140 was generated from reaction of the diazoketone with
rhodium catalyst. This species reacted with the tethered internal alkyne (structure in blue) which served
as the dipolarophile. They successfully achieved the oxabicyclic species 141 in 74% yield and under
simple acidic conditions with hydrochloric acid (HCl) the bridged oxygen underwent a ring opening to form
tropolone 142 in 93% yield.
Schmalz utilized a similar oxidopyrylium reaction/ring opening reaction in the synthesis toward the
tropolone containing natural product colchicine.75 They employed a rhodium catalyzed oxidopyrylium
cycloaddition as the key step. They synthesized compound 143 over 5 steps in 45% overall yield
(Scheme 2.11). To 143 was added Rh2(OAc)4 in refluxing toluene. The reaction was commenced with the
formation of a rhodium carbene which was then attacked by the oxygen of the carbonyl (144) to generate
the ylide 145.76 The generated oxidopyrylium ylide (structure in red of 145) reacted with the tethered
alkyne (structure in blue) in a dipolar cycloaddition to yield key intermediate oxabicyclo compound 146 in
64% yield. With this compound in hand strategies were utilized to obtain a ring opened product.
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The use of diethylaluminum chloride did not yield the ring opened product but produced complete removal
of the ether bridge oxygen and resulted in the formation of a tropone. They believed they were losing the
bridged oxygen by dehydration which possibly took place before the ring opening. They exercised an
alternative method that involved reduction of the carbonyl to a hydroxyl group with L-selectride to
generate 147 in 82% yield. The ring opening was then completed with the Lewis acid trimethylsilyl
trifluoromethanesulfonate (TMS) in triethylamine (NEt3). It was believed that the TMS attacked the ether
bridge (intermediate 148) and activated the molecule; then the base deprotonated the ring and the
molecule opened to yield product 149 in 63% yield, after removal of the silyl groups. After a simple
modified Swern oxidation they achieved the important colchicine intermediate tropolone 150 in 52% yield.
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A more recent synthesis in the laboratory of Tang and co-workers further emphasized the value
of an oxidopyrylium cycloaddition followed by a ring opening.77 This was the key step in their synthesis of
the natural tropolone harringtonolide. The essential molecule for the cycloaddition (151) was obtained as
combination of four diastereoisomers in 18 steps with a 3% yield from the starting material (Scheme
2.12).

The intramolecular oxidopyrylium cycloaddition of 151 occurred in refluxing chloroform with the non
nucleophilic base DBU (1,8-Diazabicycloundec-7-ene) to yield cycloadduct 152 in 85% yield. The
oxidopyrylium species was formed in situ from the dihydropyran ring unit (highlighted in red) that reacted
with the internal cyclohexene ring (highlighted in blue) in structure 151. The cycloadduct was then set up
to undergo the ring opening, after three steps they formed tertiary alcohol 153 in 78% yield from the
cycloadduct. They installed the ketone moiety under a PCC oxidation to obtain 154 in 10%-40% yields.
They tried a reductive cleavage of the ether bridge of 154 with samarium iodide but that led to no reaction
or a complex mixture; they were not able to obtain anticipated tropone 156. An alternative procedure to
open the ether bridge involved a two step process. Starting again from 153, they installed a phenylthio
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group and obtained 155 in 75% yield. The proton attached to the same carbon as the phenylthiol was
selectively removed with lithium diisopropylamide (LDA) in the presence of hexamethylphosphoramide
(HMPA). This reaction promoted the ring opening to yield 157 in 90% yield which after 7 steps was
converted to harringtonolide (158) in 11% yield from 157. These reactions showed that oxidopyrylium
species in conjunction with creative ring opening procedures of the cycloadduct can serve as key reaction
in the synthesis towards naturally containing tropolones.
2.2 Synthesis and optimization of an Intermolecular Oxidopyrylium Cycloaddition78
2.2.1 Initial Findings in the Intermolecular Oxidopyrylium Cycloaddition
To gain access to the oxidopyrylium species a short and efficient synthesis was undertaken. The
first step was a simple chlorination of the commercially available kojic acid (108a) to obtain 108c in 90%
yield (Scheme 2.13). This was then reduced with Zn/HCl to gain 108b in 69% yield, followed by a
methylation to obtain the oxidopyrylium species, 105a, in 53+% yield following recrystallization.68,79

With conditions as outlined in the work of Wender and Mascareñas, the cycloaddition product
106a was attained in 74% yield.68 Quickly it was found that under similar conditions with various alkyne
dipolarophiles the reaction suffered from low yields and longer reaction times or little to no product
formation.

The oxidopyrylium cycloaddition was an important sequence in our proposed synthetic route

towards α-hydroxytropolones. For future SAR studies, the process ideally needed to take less time and
be better yielding than it currently was. To overcome these limitations, initial optimization experiments
were performed using one of the less reactive dipolarophiles, phenyl acetylene. Under Wender’s and
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Mascarañes’s conditions, 20 equivalents of alkyne and 2 equivalents of the base N,N-dimethylaniline, the
reaction took one week at room temperature with a yield of 35% of the oxabicyclic compound 106b
(Scheme 2.13). Since cycloadditions are accelerated by heat, the first technique attempted was to simply
heat up the reaction. A microwave reactor seemed to be a logical choice as it provided a sealed tube
enclosed environment, concentrated heating, and allowed for shorter reaction times. After a series of
temperature screens, it was found that after 10 minutes at 100°C, conversion to the cycloproduct was
taking place, whereas at lower temperatures such as 70°C, no conversion was seen. It was found that 45
minutes was necessary to complete the reaction with a yield improvement of the oxidopyrylium
cycloaddition product to 46%. During these studies, an impurity was evidenced in the nuclear magnetic
resonance (NMR) data and seemed to be increased with lower yields of the cycloproduct. The reaction
was thus run in the absence of the alkyne in deuterated chloroform (CDCl3), and it was quickly found that
this impurity was the deoxykojic acid salt 161 that formed under a substitution reaction between N,Ndimethylaniline 159 with the
deprotonated oxidopyrylium
salt 160 (Scheme 2.14).
The salt 161 was evidenced

CH3
Ph N
CH3

O

O
H 3C O

159

O
160

CH 3

O

O
161

CH3

+

CH 3
Ph N CH 2
CH 3
162

Scheme 2.14. Proposed mechanism of the demethylation of the oxidopyrylium salt via dimethylaniline.

on the 1H NMR by three singlet peaks at 6.30 ppm, 7.80 ppm, and 2.25 ppm, integrating to one, one, and
three protons, respectively. Also there appeared to be a singlet peak at 3.75 ppm integrating to nine
protons which was believed to correspond to the three methyl groups of the trimethylammonium species
162; further supporting the evidence that the mechanism of demethylation was taking place. It was
thought that perhaps over time the demethylated product 161 could react in such a way as the
oxidopyrylium salt; but when 20 equivalents of the alkyne was added to the reaction mixture no
cycloproduct was formed and 161 persisted; it was concluded that this was not a reversible process.
Additionally another important observation was made during these initial studies, It was
previously suggested in the work of Wender and Mascareñas that the formation of dimer 163 was the
major impurity (Scheme 2.15), and efforts to optimize the reaction had been geared toward reducing the
formation of this compound.68 However, it was found that in fact the dimer was not a sinkhole, and either
through a reversible process reverts back to the oxidopyrylium zwitterion, or perhaps serves as a
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productive intermediate. When a zero point
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Scheme 2.15. Conversion of the oxidopyrylium salt into the dimer.

revealed. It was interesting to note that no peaks
were observed by 1H NMR that was believed to be from the zwitterion. 1H NMR samples were taken after
various time points over the course of the reaction. Gradually over time, the peaks corresponding to the
dimer regressed, eventually disappearing completely, while the product peaks remained. Two vital
discoveries were made in these initial optimization studies: one was the discovery of a major impurity, the
deoxykojic acid salt. The second was the observation of a necessary intermediate, the oxidopyrylium
dimer which served as a way to monitor the progression of the reaction as optimization studies continued.
In addition, it was found that heating sped up the reaction significantly and slightly improved the yield.
2.2.2 Optimization and Substrate Scope of the Oxidopyrylium Cycloaddition
With these findings, the optimization was geared toward limiting the formation of the deoxykojic
acid salt. Assuming that the excess amount of base was causing this substitution reaction to take place,
the equivalents of N,N-dimethylaniline were lowered to one. With this change, the starting material did
not fully convert to product. In addition, the impurity still subsisted. A more sterically hindered base was
instituted to prevent this substitution reaction from taking place. 2,6-Lutidine, a pyridine based bulky base,
was tried in a series of reactions and there was no conversion to deoxykojic acid. This was promising,
but yields were inconsistent, and it was not clear where the mass loss was coming from. Thus, a less
dramatic change from N,N-dimethylaniline to N,N-diethylaniline, was pursued. With this change, the
impurity was reduced and less equivalents of base (1.2) achieved full conversion, thus fending off any of
the other unwanted potential side products. Applying this change to the substrates it was found that the
phenyl acetylene gave 106b in improved yields from 35% with N,N-dimethylaniline to an upper yield of
53% with N,N-diethylaniline, and the time of the reaction went from 1 week to 45 minutes (Table 2.1). If
ethyl propiolate was used as the alkyne the yield increased from 44% to 72% of 106c, and with the
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ketone, 3-butyn-2-one, a yield improvement from 44% to 75% of 106d was seen; both reaction times
went from days to minutes.

With these results in hand, it was envisioned that an even bulkier aniline would diminish the
impurity even further; it was found that using N,N-diisopropylaniline with microwave heating suppressed
the byproduct almost completely and yields increased drastically. The initial substrates used in the
optimization were tried with the new optimized conditions of microwave irradiation at 100oC, N,Ndiisopropylanaline, and 20 eq. of alkyne. With DMAD the yield increased from 74% to 90% of product
106a and a 17 hour reaction went to 5 minutes (Table 2.1). Reaction of the ester, ethyl propiolate, and
methyl ketone, 3-butyne-2-one with 105a showed an increase of products 106c and 106d from 44% to
88% and 95% yields, respectively. Also reaction times decreased to only a few minutes from 21 hours
and 70 hours, respectively. Further, with an internal alkyne, ethyl but-2-ynoate that was more
electronically rich therefore a less reactive dipolarophile, no product formation was observed in the initial
conditions A, but with the optimized conditions a yield of 32% was achieved of cycloproduct 106e after an
hour. The alkyne used for optimization, phenyl acetylene, showed a yield of product 106b increased from
35% to 57%, and reaction time decreased to 35 minutes from a week.
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Further optimization was sought by reducing the amount of alkyne from 20 equivalents. This was
a concern in cases if the alkyne target was expensive, if a specific alkyne needed to be synthesized, or if
there were only small quantities of an alkyne available. In addition, solvent free conditions were tried
because that would produce an even more efficient reaction. With these changes a yield of 42% of 106b
was found, which showed that these parameters could be manipulated with yield not suffering too
dramatically (Table 2.1). For example, for one of the more costly alkynes, 1-phenylprop-2-yn-1-one, it was
necessary to utilize 5 equivalents which gave a respectable yield of 85% of 106f (Scheme 2.16). In
addition, 70% of unreacted alkyne could be recovered during purification, and reused in subsequent
reactions.

Chloro and bromo halide appendages are quite desirable, because they allow for modification via
cross coupling reactions. Due to positive results with phenyl acetylene and the phenyl containing product,
4-nitrophenyl acetylene which gave a 64% yield of cycloproduct 106g, the alkyne, 1-bromo-4ethynylbenzene was used to generate a bromine appendage with product 106k in 61% yield (Scheme
2.16). This phenyl derivative showed yields somewhere between the other two phenyl alkynes tried,
which showed how the halides have an ambivalent electronic nature, both an electron withdrawing
inductive effect, yet electron donating resonance effects during the cycloaddition reaction. Additionally, for
the choro appendage a oxidopyrylium salt that contained a chloro (105b) was utilized. The more sluggish
alkyne, phenyl acetylene, successfully produced 106l in 66% yield but with longer conversion times
(Scheme 2.16). When coupled to DMAD, a highly reactive species, it took 45 minutes, but with phenyl
acetylene it took 4 hours of microwave heating (Scheme 2.17).80
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Alternative groups were incorporated at the R1 position of the oxidopyrylium species to further
add diverse functionality. The methyl appendage was replaced with a choro 105b, methoxy group 105c,
and proton 105d (Scheme 2.17). These oxidopyrylium species were reacted with DMAD to give the
cycloproducts 106h in 76% yield, 106i in 58% yield, and 106j in 61% yield. The times and temperatures
varied as compared to when the methyl oxidopyrylium species was used.

For example, when the choro and methoxy oxidopyrylium species were used it involved longer reaction
times; the thought was that the partial positive

destabilized if
R1 =CH 2Cl, H, or CH 2OMe

charge generated at the oxocarbenium carbon

O

was destabilized by the introduction of these

δ+
R1

groups (Scheme 2.18). In the case of the

R2

pyromeconic acid, the charge was even further

OCH3
δ−
O
R3

Scheme 2.18. Depiction of the partial positive charge generated
at the oxocarbenium carbon during the cycloaddition reaction.

destabilized as a proton was the least stabilizing
of the species tried. With the derived species 106j, the reaction was even more sluggish and needed
higher temperatures (150°C) to convert; no conversion was seen at 100oC, even at longer reaction times.
2.2.3 Conclusion: Limitations and Future Challenges
The optimization studies of the oxidopyrylium cycloaddition not only produced the desired bicyclic
compounds, but a few important key facts were learned about the reaction such as the formation and
elimination of an important side reaction, and the role the dimer played in the reaction as an important
intermediate. One of the drawbacks of these conditions was the inability to achieve the reaction with
inactivated dipolarophiles such as alkynes with aliphatic side chains. In the synthetic goals of this project
was the flexibility to add a broad range of functionality on the structure of α-hydroxytropolones. Since the
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oxidopyrylium cycloaddition was the key step to achieve this diversity, the ability to incorporate a wide
array of alkynes was a significant aim. Alkynes with aliphatic side chains were attempted in our current
conditions but there was no conversion to the cycloproducts. Therefore activation of these alkynes was
attempted with various organometallic reagents that are known to active alkynes such as copper
catalyzed click chemistry, gold (III) and cationic gold (I) chemistry. These reactions did not produce the
desired cycloproducts but some results that were evidenced was formation of the deoxykojic acid salt
when water or alcohol was used as the solvent, nonpolar solvents yielded no products, and cationic gold
(I) was converting to some other unidentified products. This creates a significant challenge but our initial
attempts were brief, so more chemistry and alternative synthetic routes have yet to be undertaken.
2.3 Ring Opening Methods to Access α-Hydroxytropolones
2.3.1 Formation of α-Hydroxytropolones and 7-Methoxytropolones from 8-Oxabicyclo[3.2.1] octadienones Employing Boron Trichloride (BCl3)78
Once the key oxidopyrylium cycloaddition was optimized the next important step was to find
suitable conditions for the ring opening.
X
OCH3
O
O
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R1
R2

R3

OCH 3
O
BX 2
O

OH
R1

OH
R2

R2 R 3
164
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The thought was that Lewis acids like the
O

R3
107

X=Br, Cl
Scheme 2.19. Proposed mechanstic ring opening with boron trihalides to
generate α-hydroxytropolones.
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deprotonates the methyl ether of the bicyclic compound (106) and promotes the ether bridge to open due
to its activation by being bound to boron (164)
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to form α-hydroxytropolones 107 (Scheme
2.19). As boron tribromide (BBr3) is one of the
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When
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Scheme 2.20. Conversion to methoxytropolone via BBr 3.

[3.2.1]octadienone 106a was attempted under these conditions, a complex mixture resulted out of which
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the ring opened product, 7-methoxytropolone 165a was obtained in 33% yield (Scheme 2.20). Attempts at
modifying these conditions were unable to
OCH 3
O
O

HO
BCl3 (7 eq. or (15 eq.)*)
CH2 Cl2 , 0°C
10 min

R1
H3 CO 2C

CO 2CH3

improve yield. Next, the closely related
OH
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106h, R 1= CH 2Cl
106i, R 1= CH 2 OCH3

O

reagent

boron

trichloride

(BCl3)

was

CO2 CH 3

evaluated. It was thought this would

107a, R1 = CH3 (77%)
107h, R 1= CH 2 Cl (87%)*
107i, R 1 = CH2 OCH3 (85%)

create a milder environment and lead to a

Scheme 2.21. DMAD substrates that converted to exclusive α-hydroxytropolones
under BCl3 conditions.

cleaner 7-methoxytropolone. Surprisingly,

7 equivalents of BCl3 at 0°C yielded the α-hydroxytropolone 107a in 77% yield (Scheme 2.21).
Unfortunately, all the substrates did not exhibit this selectivity towards the α-hydroxytropolone
product. It was found that the electronic properties of substitution on the ring could dramatically affect the
reaction, and a mixture of α-hydroxytropolone and 7-methoxytropolone resulted. Clean conversion to the
α-hydroxytropolones
OCH 3
O
O

107h and 107i, resulted
in the alternate DMAD

H 3C
R2

derived

species

from

the chloro and methoxy
cycloproducts in 87%
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107d, R 2=COMe, R 3=H (>95%)

106c, R 2=CO2 Et, R3 =H
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O
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165e, R2 =CO2 Et, R3 =CH 3 (77%)

107c/165c, (7:1),R2 =CO 2Et, R 3=H (39%)

Scheme 2.22. Substrates with ester and ether moieties outcomes in the BCl3 reaction.

and 85% respectively (Scheme 2.21). Also the cycloadduct that contained an ester, 106c, and methyl
ketone, 106d, showed a preference towards the α-hydroxytropolones, 107c and 107d, in 39% and >95%
yields respectively (Scheme 2.22). Compound 107c resulted in a lower yield due to possible hydrolysis
during the work up. The cycloproduct 106e with all three R groups fully substituted with electronically
different groups led exclusively to the 7-methoxytropolone 165e in 77% yield (Scheme 2.22).
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The phenyl ketone 106f resulted in a 1:1 mixture of α-hydroxytropolone 107f to 7-methoxytropolone 165f
in >95% yield (2.23). Further, the nitro phenyl 106g showed a 1:1 mixture (107g/165g) in 81% yield. The
phenyl
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an
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Scheme 2.23. Substrates that produced mixtures in the BCl3 reaction.

into the 7-methoxytropolone 165j and α-hydroxytropolone 107j via reversed phase column
chromatography conditions in acetonitrile and water spiked with 0.05% trifluoroacetic acid (TFA).
The product distribution between α-hydroxytropolone and 7-methoxytropolone was notable, so to
understand the preference a few experiments were explored. It was imagined that the 7methoxytropolones were intermediates in the ring expansion, so 7-methoxytropolone 165a and BCl3 were
allowed to react with one
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Scheme 2.24. a.) Mechanistic hypothesis for ring opening with BCl3 to generate α-hydroxytropolones.
b.) Mechanistic hypothesis for formation of methoxytropolones via BCl3 .

sodium chloride and
potassium chloride were
added to increase the

chloride concentration of the reaction mixture to promote the demethylation, but this only showed variable
and inconsistent results. It was hypothesized that the nature of the electronics on the ring may dominate
the reaction mechanism. It was deduced that if R3 was electron donating such as in 106e, the mechanism
proceeded by formation of a stable allylic carbocation at R1, 168, which then re-aromatized to the 7methoxytropolone 165 (b, Scheme 2.24). If R3 was electron withdrawing as in such compounds as 106a,
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the carbocation was destabilized at the allylic position (168) and a mechanism may have existed where
demethylation occurs before ring opening (164) (a, Scheme 2.24). When a proton was at the R3 position
such as in compounds 106c, 106d, 106f, and 106g, results varied. With compounds that contained an
ester or methyl group at R2, such as 106c and 106d, the inductive withdrawing effects of the R2 group
may have destabilized the carbocation of intermediate 168 and lead to a demethylation type mechanism
as in mechanism a in Scheme 2.24. If R2 contained a phenyl ketone (106f) or a 4-nitrophenyl (106g) a 1:1
mixture of α-hydroxytropolone to 7-

Cl

methoxytropolone resulted which insinuated a
dual mechanism (Scheme 2.25). The electron

R1

OCH 3
O
BCl2
O

R 2 R3
164
proposed pathway
due to EW effects
of R2

withdrawing (EW) effects of both of these
groups could have lead to a demethylation
followed by ring opening such as was seen in
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O
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1

H3 CO
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R

R2

R3

R2

167
if R 2=4-NO2Ph ( 106g)
or PhCO (106f )

R3

168
proposed pathway
due to phenyl
stabalization of R 2

Scheme 2.25. Phenyl groups at the R 2 position lead to a dual mechanism.

the case of methyl and ester moieties leading to intermediate 164 (Scheme 2.25). Alternatively, it may
have been possible that the phenyl group at R2 of 106f and 106g added a layer of stabilization to the
carbocation at R1 of 168 through space pi-cation interactions allowing for the ring opening mechanism to
also take place (Scheme 2.25). 82
As mentioned earlier, reverse phase column chromatography was a means of purification. Some
of the substrates displayed sensitivity as well as low yields after column purification. To receive exclusive
α-hydroxytropolone products, the mixtures of α-hydroxytropolones and 7-methoxytropolones could be
demethylated through a known demethylation process of methoxytropolones using hydrogen
bromide/acetic acid (HBr/AcOH), and these conditions were necessary for such substrates as the
nitrophenyl 165g (Scheme 2.26).45
OH

Under

demethylation

α-hydroxytropolone

107g

was

produced in 80% yield without further

OH

O

conditions

O
AcOH/HBr

H 3CO
Me

NO2

HO

90°C, 3 hrs

165g
Scheme 2.26. Demethylation with acetic acid and HBr.

purification. This not only allowed us to
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Me
107g (80%)

NO2

access 107g which was not compatible with the column conditions but solidified conditions to gain pure
α-hydroxytropolones in high yields with only one step. Some substrate mixtures such that gained from the
phenyl oxabicyclo 106b could not be separated into identifiable products 107b/165b by either method.
These studies showed the formation of α-hydroxytropolones through an acid catalyzed ring
opening with BCl3, but the unpredictable nature of this reaction called for an alternative method with
foreseeable results especially for the rapid production of α-hydroxytropolones for SAR studies.
2.3.2

Formation

of

7-Methoxytropolones

and

Furans

from

8-Oxabicyclo-[3.2.1]

octadienones via a Triflic Acid (TfOH) Mediated Process80
The inability to obtain a clean phenyl substituted 7-methoxytropolone and/or α- hydroxytropolone
from 106b motivated the development of other ring opening strategies. During these studies Brønsted
acids were explored such as trifluoroacetic acid, toluenesulfonic acid, hydrochloric acid, sulfuric acid, and
triflic acid. Trifluoroacetic acid, toluenesulfonic acid, and hydrochloric acid failed to produce ring opened
products, but sulfuric acid and triflic acid produced the 7-methoxytropolone 165b within a half an hour at
room temperature. Working with 106b it was as found that 0.5 equivalents of triflic acid formed the clean
7-methoxytropolone 165b in >95% yield (Scheme 2.27).

This was a thrilling result as further purification was not needed and as it was displayed through previous
purification procedures developed through the BCl3 reaction, a simple HBr/AcOH demethylation could
lead to our desired α-hydroxytropolones for SAR studies. Next, the 4-nitrophenyl species 106g was tried
under the new triflic acid conditions, but it was found that 0.5 equivalents did not yield the desired
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7- methoxytropolone. Doing a quick screen we found that 4 equivalents of triflic acid were optimal and the
4-nitrophenyl substituted methoxytropolone 165g was obtained in 95% yield (Scheme 2.27). Not only did
this new method convert the complex mixture of the phenyl cycloproduct to a clean 7-methoxytropolone, it
offered a clean conversion to single product in high yield. For example, the 4-nitrophenyl gave a 1:1
mixture of 7-methoxytropolone to hydroxytropolone under the BCl3 conditions, but this triflic acid process
allowed for the generation of a singular predictable product in 95% yield.
With these results in hand substrates that were studied under the BCl3 conditions were subjected
to the triflic acid conditions. As was initially found with the nitrophenyl, the other cycloadducts that gave
mixtures in the BCl3 reaction such as 106c and 106f went cleanly to 7-methoxytropolones, 165c and 165f
in 89% and >95% yields respectively (Scheme 2.28).

Cycloadduct 106c mainly favored the α-hydroxytropolone 107c in the BCl3 conditions, but the yield was
very low. This process offered access to the methoxytropolone and the yield was greatly increased from
39% to 89% of recovered compound. The cycloproduct 106e produced 7-methoxytropolone 165e in
>95% yield; although this substrate was achieved in the BCl3 reaction, it resulted in a lower yield at 77%
(Scheme 2.28).
Since α-hydroxytropolones tend to be sensitive to certain reaction conditions, especially due to
their binding ability to metals, they could possibly interfere with the ability of the cross coupling catalysts.
On the other hand, it has been shown through Banwell’s work that methoxytropolones can be
manipulated through cross coupling reactions.57 The triflic acid sequence allowed for the formation of
exclusive methoxytropolones. Gratifyingly, 7-methoxytropolones 165k and 165l were gained from
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oxabicyclic compound 106k and 106l through the triflic mediated method in 92% and 95% yields
respectively (Scheme 2.29).
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Scheme 2.29. Use of halogenated methoxytropolones to incorporate ring diversity.

With these substrates in hand, cross coupling methods were attempted. It was found that a Stille coupling
in the presence of tetrakis(triphenylphosphine) palladium (0) (Pd(PPh3)4) produced the coupled product
165m in 44-55% yield. This product was converted to α- hydroxytropolone 107m via HBr/AcOH in 95%
yield. The cross coupling was ineffective on chloro appended 7-methoxytropolone 165l. This substrate
was able to react with nucleophiles such as sodium acetate and sodium azide. The azide was then
converted to the triazole containing 165o in 50% yield after click conditions.83
Though most substrates converted to 7-methoxytropolones, surprisingly, cycloadduct, 106a,
which went cleanly to α-hydroxytropolones 107a in the BCl3 reaction, was converted to furan 170a with
the triflic acid conditions (a, Scheme 2.30). The pyromeconic acid derived cycloproduct 106j that gave a
complex mixture in the BCl3 reaction went to the furan 170j. It was hypothesized that that the mechanism
in which these substrates converted to furans was a type of cycloreversion following a similar
fragmentation path as the work done by Mann and co-workers who worked with similar oxabicyclic
compounds as possible access points to tropolones (b, Scheme 2.30).84

53

As in the BCl3 conditions, when the 7-methoxytropolone was favored, an intermediate carbocation at the
carbon connected to R1 was formed. It was believed that possibly the two electron withdrawing methyl
esters destabilize this allylic carbocation, allowing for an alternative carbocation to form at the methoxy
group as shown in structure 169 (a, Scheme 2.30). Similar to Mann’s mechanism with intermediate 173,
the carbocation formed at the methoxy group allowed for the fragmentation of the oxabicyclic compound
into the furan 174 (b, Scheme 2.30).
Finally, it is well known that the methoxytropolones exist in tautomeric forms, 3-methoxy and 7
methoxy tropolone (Figure 2.1). In literature it is often expressed as the 3-methoxytropolone tautomeric
form, but it was found through HMBC (Heteronuclear Multiple Bond Correlation)/HSQC (Heteronuclear
Single Quantum Coherence) NMR data that in this research it exists in the 7-methoxytropolone form

7
H3 C

1

O
2 OH

6
5
4

Br
3-methoxytropolone

3 OCH3

H 3 CO
2 1 O
3
7
4
OH
H 3C
6
5

(Figure 4.2, Chapter 4.4, Section 4.4.3). The isolated
bromophenyl methoxytropolone (165k) was used to
identify the connections (Figure 2.1). HSQC measures
the direct connections of a specific carbon to specific

165k

Br
7-methoxytropolone

Figure 2.1. 3-methoxytropolone vs. 7-methoxytropolone.

proton, and HMBC measures the connections of a
carbon and proton separated by two or three bonds,

and sometimes further depending on the sensitivity. The HSQC data showed that the proton (H6) was
connected to the aryl carbon (C6) and it was identified in our studies that the chemical shift of this proton
(proton next the hydroxyl group) was 7.32 ppm. C3 and H3 were identified as being associated. The
54

proton H3, next to the methoxy group could be assigned a chemical shift upfiled at 7.14 ppm that was
confirmed with HSQC data. This data suggested a 7-methoxytropolone structure.
The HMBC data revealed further correlations which lead to the deduction of the 7methoxytropolone structure. For example proton H3 showed through space connections to C1 (carbon at
the carbonyl) and C2 (carbon at the methoxy group) (see 7-methoxytropolone structure in figure 2.1).
Additionally, proton H6 displayed through space connections to C1 and C7 (carbon attached to the
hydroxyl group). These relationships revealed a structure such as that of 7-methoxytropolone. If the 3methoxytropolone was the product the carbonyl carbon (C1) would have only one through space
relationship with a proton (H7) (see 3-methoxytropolone structure in figure 2.1). In addition proton (H4)
would correlate through space to both the hydroxyl carbon (C2) and methoxy carbon (C3) (3methoxytropolone structure in figure 2.1).
2.3.3. Conclusion, Limitations, and Future Challenges
In conclusion two acid catalyzed ring openings were discovered that could convert oxabicylic
compounds

achieved

through

an

oxidopyrylium

cycloaddition

to

α-hydroxytropolone

and

7-

methoxytropolone products. Each method was a necessary invention as substrate diversity created
product variability in both cases. For example mixtures of α-hydroxytropolones and 7-methoxytropolones
were found under the BCl3 conditions for some substrates, yet the triflic acid sequence led to pure 7methoxytropolone products. However other substrates that cleanly converted to α-hydroxytropolones in
the BCl3 conditions were transformed into furans under the triflic acid conditions. The ability to have
alterative processes to obtain the desired α-hydroxytropolone products was a key achievement in this
medicinal chemistry driven synthesis. While successful, problems with the purification methods resulted.
The HBr/AcOH conditions were too harsh for some sensitive functionality that was introduced into the
ring, while column conditions were incompatible in other cases. The discovery of alternative ring opening
methods and purification techniques are future challenges of this work.
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2.4: Alcohol Exchange: New Findings in the Oxidopyrylium Cycloaddition
2.4.1 Initial Discoveries
While the ring opening procedures were successful for the completion of most of the targeted αhydroxytropolones, problems occurred during the incorporation of certain functionalities. For example,
after many futile synthetic attempts, a biotintilated moiety could not be functionalized on the 7methoxytropolone or α-hydroxytropolone structure. Through the triflic acid conditions the pure 7methoxytroponoe was achieved but the demethylation conditions cleaved the biotin functionality. In the
BCl3 conditions a mixture of α-hydroxytropolone and 7-methoxytropolone was obtained but column
purification
OCH3
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H3 C

O
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Br

OCH 3
O
O

H

OCH2 CH3
O
O

H 3C

(i-Pr)2NPh
µwave, 100°C, CHCl3

105a

H 3C
106k

176k

Br

Br

Scheme 2.31. Initial discovery of ethyl incorporated cycloproducts.

only

led

to

decomposition. Another effort
was undertaken that involved
assembling the substrate via
our

newly

invented

cross

coupling conditions. The first step was to create a substantial amount of the bromocycloproduct (106k) to
complete these studies. Although this reaction was run multiple times previously, surprisingly, after
scaling the reaction up, it was found that the oxidopyrylium cycloaddition yielded two compounds. One,
which happened to be the desired product 106k, in addition to another product which was identified as
176k (Scheme 2.31). It appeared that an ethyl group replaced the methyl group in the cycloproduct. No
ethanol was used in the reaction, but it was suspected that possibly the reagent grade chloroform used in
this reaction may have been stabilized with ethanol, and during the cycloaddition this ethanol got
incorporated into the oxidopyrylium species. Our previous studies were done in deuterated chloroform, so
the product was never identified. This serendipitous discovery not only uncovered new findings in the
oxidopyrylium cycloaddition, but offered a possible new alternative for our α-hydroxytropolone synthesis
that could possibly circumvent the challenges.
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Scheme 2.32. Proposed synthetic use of alcohol exchange for formation of α-hydroxytropolones.

substituted in the place of

ethanol, 177 (Scheme 2.32). The bicyclic intermediates formed could then be submitted to protecting
group removal conditions that would hopefully open the ring and form our desired α-hydroxytropolones
(107) and lead to milder conditions to address sensitive functionality (Scheme 2.32).
The research quickly turned to explore conditions that would favor the ethanol incorporated
cycloproduct. Using the previous optimized conditions with the phenyl acetylene as the alkyne, the first
experiment ran was the reaction in the presence of varying known amounts of ethanol. Deuterated
chloroform was used because it helped in monitoring the reaction, and allowed for complete control over
ethanol concentration. Testing
Table 2.2. Effect of varying equivalents of ethanol in exchange.

of a typical concentration in

OCH3
OH

ethanol stabilized chloroform of
1% of ethanol in deuterated
chloroform (0.33 equivalents) as

H3 C

O -OTf

and 10 molar equivalents of
ethanol were explored (Table
2.2). A balance between yield
substantial

CDCl3 µwave 30m
100°C

H 3C

105a

well as increases of 1, 2.5, 5,

and

OCH 3
O
O

H
Ph
CH3 CH 2 OH, (i-Pr) 2NPh

H 3C
106b

% yield (106b:176b)

176b

Eq. of EtOH

62

(1:0.19)

0.33

65

(1:0.38)

1

62

(1:0.96)

2.5

64

(0.83:1)

5

63

(0.63:1)

10

ethanol

OCH2 CH3
O
O

incorporation was sought. As
suspected, as the equivalents of ethanol increased, the formation of the ethanol cycloproduct 176b was
favored; 10 equivalents showed a ratio of nearly 1.6 to 1 of ethyl to methyl product. Importantly, the yields
stayed consistent within the mid 60% range for all the amounts tried which was promising in regards to
the viability of the reaction. Since increased amounts of ethanol showed better conversion, ethanol was
tried as the solvent, but this led to decomposition.
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2.4.2 Optimization and Substrate Scope
After these initial findings, it was hypothesized that incorporation of the alcohol could be taking
place before cycloaddition. To test this theory, the reaction was allowed to stir with the deuterated
chloroform, the salt, base, and ethanol at room temperature which was termed “equilibrating” conditions
(Table 2.3).

Table 2.3. Optimization of alcohol exchange with ethanol.

H 3C

OCH 3
OH

1. CH 3CH2 OH, (i-Pr)2 NPh
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OCH 2 CH 3
O
O
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phenyl acetylene was added and
the oxidopyrylium cycloaddition

176b

addition

was

microwave
% yield (106b:176b)

Eq. of EtOH

time

After one week,

subjected

irradiation.

to
The

temp

greatest incorporation was seen
61

0.65:1

2.5

1 week

r.t.

64

0.26:1

5

1 week

r.t.

55

0.25:1

10

1 week

r.t.

reactions with a ratio of 4:1 of

64

0.85:1

5

12 hours

r.t.

ethyl to methyl, by far exceeding

63

0.71:1

5

1 hour

60°C

63

0.48:1

5

2 hours

60°C

62

0.37:1

5

4 hours

60°C

58

0.46:1

5

1 hour

80°C

the yield did not decrease. This

29

0.06:1

5

4 hours

80°C

experiment clearly showed that a

41

0.28:1

5

1 hour

90°C

with the 5 and 10 equivalent

the

amounts

when

all

the

reactants were run together, and

substantial

amount

of

incorporation was taking place before the cycloaddition was initiated. Although it seemed the reaction
was optimized greatly, a one week reaction was too long for assembling molecules for medicinal
chemistry studies. The next step was to convert a one week reaction into a day or few hours, and it was
thought this could be done with heat. With the equilibrating conditions and equivalents of ethanol
established a set of experiments that utilized heating to speed up the reaction was undertaken (Table
2.3). The 5 equivalents of ethanol were chosen because it gave a similar ratio to the 10 equivalents and
yield was preserved. It involved the use of lesser reagent and this could be important for scare or pricey
alcohols. It was found that at lower temperatures (60°C) and longer reaction times, 4 hours, a 3:1 ratio of
ethyl to methyl product was found and the yield was preserved. At higher temperatures, longer times led
to a better ratio, but the yield decreased. For example at 80°C, at the 4 hour time point almost all the
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product was the ethyl incorporated 176b, but the yield was only 29%.

At shorter times but higher

temperatures, 1 hour at 80°C, the ratio decreased to about 2:1, but the yield was increased to 58%. At a
slightly higher temperature, 90°C at 1 hour, the ratio was in the same range as the one week reaction at
about 4:1, but the yield again decreased. Finding a balance between a practical yield, and respectable
ratio in partiality of the ethyl product was the challenge, but moving forward, the 60°C at 4 hours fulfilled
that criterion.
Additionally, a quick study was done to verify that the majority of the incorporation was indeed
taking place before the cycloaddition reaction and if any further modification could be found. At the newly
found 60°C temperature point the reaction between the salt and alcohol was monitored at various time
points from zero to 8 hours, with aliquots taken every 2 hours and the reaction was analyzed by 1H NMR
spectroscopy (Figure 2.2).

Figure 2.2. 1H NMR data monitoring conversion of the methyl ether dimer to the ethyl ether dimer
As discussed in our earlier studies, we were actually monitoring the conversion to the dimer (substrates
163 and 178). It was clearly seen that at time zero there was only one peak that represents a proton (A)
and methyl group (B) on the methoxy dimer (163) (Figure 2.2). As time increased another peak emerged
more upfield that represented the same proton (D) and methyl group (E) but on the ethyl dimer (178).
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Further validation was seen with the disappearance of the methoxy groups (C) at the zero time point
replaced by a methanol peak at the 8 hour time point, which was the byproduct of the exchange. This
data

supported
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Scheme 2.33. Mechanism of alcohol exchange reaction.

incorporation was taking place at this “equilibrating” step. This could lead to a mechanism were the
ethanol adds in at the carbon where the methoxy group is attached as in 179 (Scheme 2.33) redistributing
electrons on the positively charged cyclic oxygen. Then the methoxy group extracts a proton (180) that
then generates a positive charge on the oxygen allowing the cyclic oxygen to be positively by
redistribution of electrons (181) and loss of methanol to form the oxidopyrylium species 182.
The reaction was further adapted for medicinal chemistry studies. As discussed, the initial
optimized conditions required an equilibration with the alcohol at 4 hours at 60°C. Due to the long reaction
time, the microwave reactor became an impracticable source of heating. Since our 1H NMR experiments
showed that in a sealed tube, the reaction could be achieved with the same results, conditions were
adapted accordingly. For our medicinal chemistry studies this would provide the ability to synthesize
multiple substrates at once, as well as provide a more universal oxidopyrylium cycloaddition especially for
those who may want to perform it but have no access to a microwave reactor. With the reaction
conditions, a two step sequence that involved an equilibation with the alcohol at 60°C then heating up to
100°C for the cycloaddition was followed. Various time points were reviewed at the 60°C equilibration
point of the ethanol sequence to compare results. At the 2 hour time point, the reaction gave the same
ratio (2:1) as in the microwave conditions, and the yield was in a similar range (56% yield), the reaction
was ran twice to verify (Table 2.4). At the 4 hour optimized time point, the ratio of ethyl (176b) to methyl
product (106b) increased from 3:1 to 5:1, which was promising, but the yield decreased from the 60%
range to 40% range. A suitable amount of ethyl product (34-41%) was gained at both time points.
Pushing the reaction further, an overnight reaction was run and full conversion to the ethyl product was
established, and as previously seen, as the ratio increased the yield decreased to 14%.
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Next, substrate scope studies

Table 2.4. Exchange with diff erent alcohols.
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ROH, (i-Pr)2 NPh
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O
H 3C

alcohols
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2.4).

First
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of methyl (106b) to ethyl (183b)

31

8

183b
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Isopropyl
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0
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183b
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Isopropyl
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16
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184b

41

Benzyl

30 minutes

5

11

184b

16
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2 hours

isopropyl was increased with a

19

27

184b

46

Benzyl

12 hours**

4:1 ratio of methyl to ethyl, but

34

22

185b

56

Allyl

30 minutes

5

9

185b

14

Allyl

2 hours

31

9

185b

40

Allyl

12 hours**

*Second run
**Prestir done at room temperature

compared with ethanol. At the 2

was 10:1 favoring the methyl; at
4 hours the incorporation of the

yield declined from 48% to 39%.
Again

an

overnight

reaction

produced full conversion to the
isopropyl product. The benzyl

and allyl alcohol series proved to have a different profile. After only 30 minutes at 60°C the conversion
ratio of benzyl (184b) to methyl (106b) was 1.5:1 with a yield of 41%. As time increased to 2 hours, the
ratio did not increase much (approximately 2:1) and the yield decreased from 41% to 16%. Milder
conditions were then tried, 12 hours at room temperature, which gave similar results to the half hour
reaction with a yield to 46%, and the same ratio of benzyl to methyl at about 1.5:1. In the case of the allyl
alcohol, the 2 hr time point at 60°C showed a lower yield and increased ratio of the allyl cycloproduct
(185b) at 2:1 to the methyl. At 30 minutes the methyl was favored at a ratio of about 1.5:1 with a decent
overall yield of 56%. Overnight conditions at room temperature did not increase the allyl ratio. It was
obvious that all alcohols may not follow the general optimized conditions as set by the ethanol series
which may be due to the steric and electronic difference between the alcohols. For example, when 4methoxybenzyl alcohol and 2-(trimethylsilyl) alcohol were used there was no conversion to their
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respective alcohol products; the methyl cycloproduct was isolated from both in approximately 30% yield.
This may have been due to the more polarizing electronic nature of these substrates as compared to the
other alcohols used. The 2-trimethylsilyl may come on and off more easily due to its electronically
deficient nature, and the electron donating nature of the paramethoxybenzyl may revert the substrate
back to deoxykojic acid.
Not only was variability seen with different alcohols, if the alkyne was exchanged there were also
different results. For example, the alkyne ethyl propiolate was substituted in place of phenyl acetylene
under the optimized conditions which entailed an equilibration at 60°C for 4 hours, then cycloaddition
reaction at 100°C for 15 minutes. The total yield of the reaction was 77% and there appeared to be a 1:1
ratio between the amounts of ethyl to methyl product. The yield stayed in the upper range, but the ratio of
ethyl product decreased.
2.4.3 Conclusion, Limitations, and Future Challenges
This preliminary work enhanced our knowledge on the oxidopyrylium cycloaddition, as well as
opened up the way for alternative ring opening procedures. This reaction and the ability to utilize
protecting group removal techniques to yield α-hydroxytropolones will continue to be explored within the
Murelli laboratory. Additionally, alternative alkynes need to be explored to fully understand the conversion
issues, so this process can keep in line with our goal of introducing diversity through the alkyne
counterpart. Also, varying conditions with different alcohols and the ability of some alcohols to exchange
while others do not is a limitation of the current conditions.
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2.5 Conclusion to Synthetic Route and Chemistry
This research not only displayed a key intermolecular β-hydroxy-γ-pyrone oxidopyrylium
cycloaddition reaction with a wide range of alkyne dipolarophiles, but additional important information was
gained about this scarcely studied reaction. It was found that a dimer formed from the oxidopyrylium salt
was a key intermediate, and that a side product, deoxykojic acid, was produced due to the use of less
bulky bases. Additionally, the oxidopyrylium species displayed an exchange mechanism with various
alcohols which outlined the reactive nature of various places on the ring of the oxidopyrylium species.
These discoveries not only produced intermediates for two alternative acid catalyzed ring openings to
yield α-hydroxytropolones and 7-methoxytropolones, but opened up the possibility of alternative ring
opening procedures. With this research the immediate synthetic goal was met, a medicinal chemistry
driven synthesis of α-hydroxytropolones, each with distinct functionality. Even though limitations do exist
such as harsh or incompatible purification techniques, mixtures of products at the acid catalyzed ring
opening stage, and the inability to incorporate aliphatic appendages, these initial synthetic endeavors
lead to the ability to begin medicinal chemistry studies as was envisioned at the start.
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CHAPTER 3: Preliminary Structure-Function Studies of Synthetic α-Hydroxytropolones
3.1 Introduction
The chemistry developed in the Murelli laboratories and the basis of this thesis served as the
platform for the synthesis of compounds for SAR studies. Our target molecule was the core scaffold of a
α-hydroxytropolone, a potential small molecule therapeutic whose bioactivity was limited by its
cytotoxicity. The goal of this research was to enhance selectivity of these molecules for their given
therapeutic target, hopefully circumventing this cytotoxicity while also increasing potency. First a simple
and easy pathway to synthesize the starting material, a triflate salt was achieved as the general starting
material (105) (Scheme 3.1).

Complexity was introduced through a key oxidopyrylium cycloaddition that was optimized to a quick, high
yielding reaction. The efficiency of the reaction allowed for the attainment of an array of oxabicylic
compounds (106) with diverse substitution patterns, and most could be generated in only a few hours.78
Once selectivity was established the core scaffold was sought, and two acid derived sequences led to the
ring opened 7-membered heptatriene ring (165/107).78,80 Further modification could be introduced at a
late stage cross coupling reaction on the 7-methoxytropolone core.80 Finally purification methods allowed
for discrete retrieval of the diverse α-hydroxytropolones under demethylation or reverse phase column
chromatography conditions. The second goal of this research was to test the various synthetic αhydroxytropolones obtained through the oxidopyrylium/ring opening synthetic sequence and
subject them to various medicinal chemistry studies to find how therapeutic activity was
influenced by structure.
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3.2 Aminoglycoside-2’’-O-nucleotidyltransferase-[ANT(2’’)-Ia]
3.2.1 Overview of Aminoglycosides and Resistance
Aminoglycosides are a form of antibiotics isolated from bacterial fermentation; one of the first
discovered was streptomycin in 1944, and it was found to have inhibitory activity against M.
tuberculosis.85 After years of use for bacterial and tuberculosis infections, streptomycin displayed
inactivity and was replaced by other antituberculosis drugs such as isoniazid, rifampicin, and
ethambutol.86 These drugs too became resistant, so renewed interest in streptomycin for drug resistant
M. tuberculosis strains became apparent. In addition to streptomycin other aminoglycoside based
antibiotics were isolated from bacterial sources such as neomycin, gentamicin and tobramycin.87
Aminoglycosides’ antibacterial properties work by disrupting gram negative bacterial protein synthesis,
but bacteria have developed several mechanisms of resistance including enzymes that modify these
aminoglycosides, reducing their antibiotic ability.88 The three important enzymes that impart this
resistance are O-adenylyltransferases (adenyltransferase, nucleotidyltransferase, ANT), Nacetyltransferases (AAC), and O-phosphotransferases (APH).27 In combination with resistance the clinical
use of aminoglycosides have some issues including poor oral absorption and toxicity at higher
concentrations and increased number of doses where the molecules were found to collect in the renal
tubule and cause nephrotoxicity in addition to ototoxicity.86,87 Combination therapies that combine cell
wall disrupting β-lactam antibiotics with gentamicin have shown to increase potency of the
aminoglycoside, while relieving the dosage requirements and circumventing some resistance.86
Unfortunately, β-lactams have their own issues with resistance with modifying enzymes such as Ser-βlactamases and Zn2+ containing dimetallic enzyme metallo-β-lactamases.89
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3.2.2 Overview of ANT-(2”) and its Inhibitors
Aminoglycoside-O-nucleotidyltransferases are enzymes that catalyze adenylation. Adenylation is
the process in which a protein or biological molecule (in this case an aminoglycoside antibiotic) containing
a functional group such as amino, hydroxyl, or carboxylate group reacts with one phosphate group of ATP
(adenosine triphosphate).90 In particular, a clinically prevalent ANT enzyme ANT(2’’)-Ia is one of the few
aminocglycoside modifying enzymes to modify a hydroxyl group.91 The unique mechanism is catalyzed by
two magnesium ions
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residue in the enzyme and reacts with one of the phosphate groups in ATP (Figure 3.1).91 Once
gentamicin is bound to ATP, the remaining two phosphate groups are induced to leave as a
pyrophosphate. ATP becomes AMP (adenosine monophosphate) and takes the place of C2” alcohol on
gentamicin’s structure hence rendering the antibiotic inactive.
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ANT(2’’)-Ia is particularly important because it is one the most clinically prevalent modifying enzymes.91,92
Although inhibitors based on modifying or
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and tobramycin. The 2-DOS core structure contains a 1,3 diamine motif (outlined in red) which the
synthesized non-carbohydrate molecules mimic (Figure 3.2).93 Serpersu and co-workers synthesized 45
different 1,3-diamine based compounds and found compounds G,H and H, I to be the best inhibitors of
ANT(2”) (Figure 3.2).93 Compound G,H had 22% inhibition at a 0.05 mM concentration and was
competitive with the aminoglycoside with a Ki of 540 ± 32 µM. Compound H,I gave 42% inhibition at a
0.05 mM concentration and was competitive with ATP with a Ki of 125 ± 24 µM. As previously discussed,
α-hydroxytropolones are another important inhibitor of ANT(2’’) where β-thujaplicinol and αhydroxytropolone displayed inhibition in the upper 70% range of ANT(2’’) at 55 µM and 73 µM
concentrations, respectively. In addition, α-hydroxytropolone displayed a competitive mechanism with
ATP with a Ki value of 10 µM. These two classes of compounds are the only known non-carbohydrate
based inhibitors to date to selectively inhibit ANT(2”).
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3.2.3 ANT(2”)-Ia Enzymatic Inhibition and Rescue of Aminoglycoside Antibiotics by
Synthetic α-Hydroxytropolones14,94
In collaboration with the Wright group at McMaster University, new α-hydroxytropolones
synthesized by the methods discussed were tested for their ability to inhibit the enzyme and rescue
antibiotic activity. The bacterial strain Escherichia coli BL21 (λDE3) where the ANT(2”)-Ia enzyme is over
expressed was used. The enzyme was extracted and purified and applied to a 96 well system and its
activity was monitored by the formation of the byproduct pyrophosphate. Serial dilutions of αhydroxytropolones were added to the system and their inhibitory activity for the enzyme was measured in
IC50 values as shown in Table 3.1. The natural product β-thujaplicinol had the best inhibition activity at 6.6
µM.
Table 3.1. ANT(2'')-Ia Inhibition by α-hydroxytropolones.
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the fact that β-thujaplicinol was the only monosubstituted substrate, again bringing in the notion that less
sterically demanding functionality may be better for this enzyme. Ki values were determined for those
substrates that showed inhibition, and these Ki values indicated competitive inhibition with ATP and
mixed inhibition with the aminoglycoside. This data proposed that the α-hydroxytropolones could usurp
the place of ATP at the enzymatic site or bind near the binding pocket of ATP.
Furthermore, a study was run to gauge the ability of α-hydroxytropolones to rescue antibiotic
activity in the bacteria cells. A gentamicin resistant strain of E. coli BW25113 which also contained the
ANT(2’’)-Ia enzyme was produced. Gentamicin resistance was increased to MIC of 64 µg/mL vs. 0.25
µg/mL in the wild type. For these studies, a negative control was constructed with the strain of an E.coli
that contained an enzyme that was resistant to aminoglycoside antibiotics and was not inhibited by αhydroxytropolones called aminoglycoside phosphotransferase termed APH[2’’]-Id. The synergetic value
of gentamicin working in concert with the α-hydroxytropolone was measured by calculating the FIC index
(FICI) and graphically outlined in a checkerboard analysis (Figure 3.3). A FICI value less than 0.5 implied
a synergetic relationship while values between 0.5 and 4 showed no synergetic relationship. Also for a
qualitative assessment a triangular shape of checkerboard graphs indicated a synergetic relationship.
The compounds that showed positive inhibition values were tested for their ability to rescue antibiotic
activity in these cellular assays, so β-thujaplicinol, and compounds 107d and 107g were evaluated. First,
β-thujaplicinol showed a FICI value of 0.375 which indicates a synergic value. For the ANT(2”)-Ia deficient
strain, APH(2’’)-Id, there was no synergetic relationship with a FICI value of 3. This evidence supported a
mechanism were the α-hydroxytropolone inhibits the ANT(2”)-Ia enzyme and not ATP.
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Figure 3.3. Checkerboard analysis and FICI values for α-hydroxytropolones.

Compound 107d showed a synergetic value of 0.187 and while 107g did not with a value of 0.5. Other
data gained through this analysis showed that at concentrations of 12 µM of β-thujaplicinol and 107d, the
MIC of gentamicin was 8 µg/mL and 32 µg/mL, respectively. This mimicked the inhibitory behavior of the
two substrates, demonstrating that β-thujaplicinol was the more potent of the two. Surprisingly at 50 µM
concentrations of both substrates no healthy bacteria cells remained with β-thujaplicinol but with
compound 107d a nice amount of 80% of cells remained alive. At 50 µM concentrations of 107d,
minimum amounts of gentamicin were needed (2 µg/mL) to inhibit bacterial cell growth. From these
results it was inferred that the α-hydroxytropolone was not killing the cells, but that the cell death was
caused by the aminoglycoside. It was found that at the same concentration β-thujaplicinol was toxic.
These α-hydroxytropolones may not be useful therapeutically as of yet, but for the synthetic compound,
107d there may be opportunity to use it in cellular assays to study the bacterial stain and ANT(2’’)-Ia
activity were aminoglycoside activity is problematic. This study not only built on and supported the
positive inhibition qualities of α-hydroxytropolones with respect to the ANT(2’’)-Ia enzyme, but offered a
more in-depth analysis with a cellular assay that could reveal more about the reaction within the cells and
guide future SAR studies.
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3.3 The RT RNase H Metalloenzyme Active Site
3.3.1 Background on RNase H
Reverse transcriptase is an enzyme present in many viruses that include the Human
Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), and the Xenotropic Murine Leukemia-Virus
related virus (XMRV), and Herpes Simplex (HSV).17, 34, 35, 39, 41 The role of reverse transcriptase is that it
converts single stranded RNA (Ribonucleic acid) into double stranded DNA (Deoxyribonucleic acid). The
enzymatic sites vary between the viruses: often the enzyme has two active sites that impart its activity
called DNA polymerase and Ribonuclease H (RNase H) which can be fairly far apart. For example, in HIV
the active sites are 40 Å distance apart and exist on alternative ends of the enzyme unit.95,96 Current HIV
and HBV drugs target the polymerase site. No current drugs on the market target the RNase H site and
therefore pharmacophores that target this site would be of great value. The RNase H active site includes
amino acid residues that loosely bind to two metal centers, thought to be Mg2+ or Mn2+.96 Once the metal
centers are anchored into the RNase H site, they stabilize the 5’-scissile phosphate of RNA which actives
water for hydrolysis, cleaving the RNA primer to complete the DNA synthesis.96,97 Viruses without RNase
H are non-infectious therefore it is essential for replication.98 Inhibitors work in one of two ways; as active
site inhibitors whereby they usurp the position of the scissile phosphate at the dimetallic center, or
allosteric inhibitors that inhibit by binding to a pocket near the RNase H active site.99
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3.3.2 Active Site Inhibitors of RNase H
There are six important pharmacophores of active site HIV RT RNase H inhibitors: diketo acids,
N-hydroxy naphthyridinones, N-hydroxyimides pyrimidinol carboxylic acids, pyrido-pyrimidinones, and αhydroxytropolones (Figure 3.4).96 These structures all have similar components such as hydroxyl groups
and carbonyls that are attracted to this dinulcelar metalloenzyme.
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Initial work on the diketo acid functional group produced compound, 4-[5-(Benzoylamino)thien-2-yl]-2,4dioxobutanoic acid (BTDBA) which was found to be an RNase H active site inhibitor in the presence of
metal cations with an IC50 value of 3.2 µM, but showed no activity in a HIV cell based assay.100 More
recently work done with the diketo complex found an inhibitor 186 with similar inhibition activity, but this
compound showed viral replication inhibition at an EC50 value of 17 µM and a CC50 of >50 µM, which
produced a Therapeutic Index (TI) (CC50/EC50) of >2.9.101 Further derivation found that with replacement
of an ethyl group at the methyl ketone moiety and carboxylic acid proton of 186 produced a compound
with lower inhibition at an IC50 value of 26 µM. Although inhibition activity of the enzyme was lowered,
they found increased inhibition activity in the antiviral assay with an EC50 of 3.7 µM, CC50 of >50 µM, and
a TI of >13.8. Modeling studies with diketo acids at the RNase H active site showed that the carbonyl
groups interact at the Mg2+ metal centers and that there are possible lipophilic interactions between the
para-fluoro benzyl and the piperazine moieties with residues in the enzymatic pocket.101 The N-hydroxy
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naphthyridinones are another class of active site RNase H inhibitors. A crystal structure with a substrate
from this class found that the hydroxyl group of the N-hydroxy naphthyridinone interacts with the metal
cation centers of the active site.102 Compound 188 was developed as a mimic of a less substituted
species. Due to the crystal structure data, the group believed substitution at the 4-position of the Nhydroxy naphthyridinone could increase residue interactions.102b The inclusion of the lipophilic side chain
in compound 188 in place of an ethyl ester at the 4-position, increased potency from 0.11 µM to 0.045
µM.102 Compound 188 even had good anti viral activity with an EC50 value of 0.2 µM, but it was found to
be too cytotoxic (CC50=3.3 µM).102b, 96 The N-hydroxyimide pharmacophore found in molecule 187
showed via a crystal structure to interact with the metal cations via the three contiguous oxygens found in
the core N-hydroxyimide structure.103 Initial SAR studies with this pharmacophore showed little antiviral
activity, cytotoxicity, and the need of the three contiguous oxygens for inhibition. Compound 187 was one
of the more potent inhibitors discovered with an IC50 of 0.06 µM, and an EC50 of 13.4 µM.104 Another core
active site moiety are pyrimidinol carboxylic acids. A crystal structure with this moiety in the active site
found that the hydroxyl groups on the carboxylic acid and alcohols bind to the two metal centers of the
enzyme through a three pronged approach such as N-hydroxyimides and α-hydroxytropolones.105
Compound 190 was designed from this class and showed one of the best results with an IC50 of 0.17 µM
for RNase H but no antiviral activity was established.106 In addition, 190 showed lower inhibition for
Human RNase H with an IC50 value of 48 µM, and all substrates synthesized showed similar selectivity for
RNase H. Researchers at GlaxoSmithKline discovered a new class of inhibitors termed pyridopyrimidinones which have shown promise with a number of substrates synthesized from this class
showing IC50 values for RNase H inhibitory activity ≤ 0.500 µM.107 One compound, 189, had an inhibition
value (IC50) of 0.032 µM and antiviral activity (IC50) of 0.10 µM. It was found to be cytotoxic with a CC50
value of 2.5 µM, which was probably due to its good cell permeability at 172 nm/s. They found that strong
cell permeability correlated to a good ratio of antiviral activity to inhibitory activity, but compounds that fell
under these criteria tended to be more cytotoxic. The mechanism of action of these compounds is not
yet known, yet the authors indicated that studies are forthcoming. Finally, as previously outlined,
α-hydroxytropolones are a final class of RNase H active site inhibitors. Like some of the previous
inhibitors, they were found via a crystal structure with the RNase H active site to inhibit the site at the two
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metal cations through the three contiguous oxygens on the core α-hydroxytropolone manifold.28 The best
known α-hydroxytropolone inhibitor to date is β-thujaplicinol (6) with an IC50 value of 0.2 µM, but this
substrate showed no antiviral activity and was cytotoxic (CC50=2.3 µM).17 Active site inhibitors serve as
important small molecule therapeutics for RNase H, and the ability to know how they bind via crystal
structures help provide a link to how the powerful pharmacophore give their potency and can gear future
activity studies of these important pharmacophores that have yet to be active drugs.
As HIV RNase H inhibitors are limited there are no known current RT RNase H inhibitors of HBV
Current drugs on the market for chronically ill HBV patients that target the RT polymerase site are the
inhibitors lamivudine, adefovir, entecavir, telbivudine.108

3.3.3 RNase H HIV and XMRV Data for Synthetic α-Hydroxytropolones
Previous SAR studies on the HIV RNase H active site did not reveal a compound with greater
inhibitory qualities than β-thujaplicinol or manicol, but did offer some promising leads on viral replication
inhibition and lowering cytotoxicity which exemplified a further need for continuing these studies.18 With
the synthetic strategies established in this research, and with multiple new synthetic α-hydroxytropolone,
preliminary work on this enzymatic site as well as XMRV RNase H site have been under way. SAR work
was established with the same group that did the manicol studies and led by Stuart Le Grice and John
Beutler at NIH/NCI (National Institutes of Health/National Cancer Institute). The first series of synthetic
substrates studies were those with the dimethyl ester moieties (Figure 3.5). While 107a had similar
inhibitory activity for both enzymatic targets to β-thujaplicinol, it was still cytotoxic with a CC50 value of 1.4
µM. There seemed to be a trend in these substrates that the bulkier the appendage got at the methyl
position, the lower the activity, but compound 107j that had no substitution at that position and showed
similar inhibition activity to the others (around 1 µM).
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The only difference was that 107j had the lowest cellular toxicity to all the substrates with a value of 21
µM. The next set of compounds were those with two places of substitution, and one being a short chained
ester or ketone (Figure 3.6). All these substrates showed similar inhibitory activity to β-thujaplicinol, but
they all seemed to be
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and esters, but the biphenyl 107m displayed the lowest activity profile with an IC50 value of 1.1 µM (Figure
3.7). It appeared that very bulky lipophilic appendages such as in 107m were unfavorable for HIV RNase
H. This compound tended to be less cytotoxic than the other substrates which could have something to
do with cell permeability. For all the substrates none were able to suppress viral replication, except for the
107d which produced an EC50 value of 0.13 µM. The XMRV RNase H site had similar inhibitory activity to
the
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Figure 3.7. HIV and XMRV RNase H, and cytotoxicity data for substrates with phenyl groups.

was four times more potent against XMRV (IC50=0.26 µM) than HIV RNase H (IC50=1 µM). Additionally,
compound 107g was five times more potent against XMRV (IC50=0.07 µM) as compared to HIV RNase H
(IC50=0.36 µM). Overall, these studies did not produce a stronger inhibitor, but exposed the usefulness of
the newly established synthetic strategies, the ability to produce more diversely substituted substrates,
and open the possibly of even more directed SAR studies.
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3.3.4 HBV RNase H Enzymatic Site Data for Synthetic α-Hydroxytropolones.109
Tavis and co-workers at St. Louis University School of Medicine developed an assay for HBV
RNase H inhibitors, and previously found that β-thujaplicinol had inhibitory activity against this enzyme.41
α-Hydroxytropolones constructed in the Murelli laboratory as well as manicol derivates from the Le Grice
group18 were tested in their assay. Recombinant HBV RNase H and Human RNase H1 were expressed
and purified from E.coli. RNase H activity was measured using an oligonucleotide directed RNA cleavage
assay and IC50 values were extracted. HBV replication and cell cytotoxicity were measured in EC50 and
CC50 values respectively, using HepDES19 cells. From these values therapeutic index (TI) was extracted
which was simply calculated from CC50/EC50. In this study 51 tropolone based compounds were
screened, 36 were α-hydroxytropolones; α-hydroxytropolones made in relation to research discussed in
this thesis and their results are listed in Table 3.2, and happened to be the most active compounds in the
study. Synthesized α-hydroxytropolones 107f, with the phenyl ketone moiety, and 107m, with the
biphenyl, are not listed in the table as they had no detectable inhibition in any of the assays even the
qualitative study. Compounds 107i and 107c showed inhibition values around 60µM for HBV RnaseH,
and 20 µM for human RNaseH in the qualitative study but failed to produce positive values in the more
indepth screen. Initial qualitative screening results revealed that the α-hydroxytropolone moiety was
needed for inhibition of RNase H. For example, α-hydroxytropolone, β-thujaplicinol (6) inhibited the
enzyme yet its tropolone counterparts β-thujaplicin and γ-thujaplicin showed no activity toward the
enzyme. In the initial qualitative screening all the synthetic α-hydroxytropolones had some activity toward
both HBV genotype RNase H sites as well as Human RNase H, but only the ones that showed the best
inhibition profiles were processed for further screening. Both genotypes had about the same qualitative
inhibition values for each α-hydroxytropolone, which showed that there may not be a preference for a
specific viral strain’s RNase H site.
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The only one that showed a slight difference between the two was for 107h, where genotype D
was inhibited at about 40 µM and genotype C at 65 µM concentration. This data could insinuate some
minor effect of the genotype, but these values are only specific to one substrate to constitute an overall
effect. Also, the RNase H data revealed a possible correlation between substrate size and inhibition
ability. For instance, the parent α-hydroxytropolone (3) with no substitution revealed no inhibition, βthujaplicinol with one short isopropyl appendage showed the best inhibition with IC50 values of 5.9 µM and
2.3 µM, and long appendages such as the biphenyl and phenyl ketone showed no activity while the
nitrophenyl, 107g, had very little activity. This was also further validated with synthetic compounds 107a
and 107d which have short appendages such as the methyl esters and methyl ketone which displayed
IC50 values of approximately 29 µM and 34.9 µM/22.9 µM respectively. As substitution length increased,
as in the ethyl ester, 107c, by one methylene group, activity diminished. Also, manicol and its derivatives
that were tested in the study demonstrated decreased activity, which further supports a size limitation
effect. These trends may insinuate a smaller binding pocket for HBV RNase H as compared to HIV
RNase H, as manicol and its derivatives did have some inhibition effects in HIV RNase H studies.18
Inhibition activity against Human RNase H1 was also tested, and substrates that had activity
against HBV RNase H, tended to inhibit human RNase H1 too. Inhibition values differed between the two
enzymatic targets, which imply selectivity. β-thujaplicinol was 10 to 20 times more active against HBV
RNase H as compared to Human RNase H1 (5.9/2.3 µM vs. 58 µM), while synthetic substrates 107a was
10 times more active against HBV RNase H (29 µM vs. 47.8 µM). Structures like the methyl ketone
substituted 107d exhibited similar inhibition activity for both targets. On the other hand, nitrophenyl, 107g,
displayed a slight preference for the Human RNase H1 enzyme.
The substrates that showed RNase H inhibition were tested for their ability to inhibit viral
replication (accumulation of plus-polarity DNA strand) indicated as an EC50 value along with their
cytotoxicity (loss of mitochondrial function) indicated with a CC50 value. EC50 values tended to be lower
than IC50 values; values were under 3 µM for the substrates referred to in the table. The greatest
inhibition was seen with the methyl ketone, 107d with an EC50 value of 0.34 µM. Even though manicol
had little to no inhibition against HBV RNase H and Human RNase H1, it had an EC50 value of 9 µM.
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Cytotoxicity values were similar to their substrates subsequent IC50 values, except β-thujaplicinol
with a value of 25 µM compared with 5.9/2.3 µM RNase H inhibition profile. Due to the values, some
cytotoxicity could be attributed to Human RNase H1 inhibition, but does not explain all routes of toxicity.
For example, manicol had a CC50 value of 35 µM which was similar to both 107a and 107d cytotoxicity;
whereas manicol had no inhibition activity against Human RNase H1, both 107a and 107d did.
Therapeutic indexes were calculated from EC50 and CC50 values by dividing the CC50 by the EC50
values. The best value of 94 was found with synthetic substrate 107d, and lowest value of 14 from
substrate 107a. The natural compounds β-thujaplicinol and manicol tended to be lower with values of 25
and 3.8 respectively. A difference between IC50 (enzymatic assay) to EC50 values (cellular assay) could
reflect that the more complex cellular environment influences the inhibition of the compounds. Inhibition
values were lower with EC50 values which insinuates possible other cellular interactions, greater cellular
absorption of the compounds, and differences between the cellular and isolated RNase H enzyme (native
vs. recombinant). In conclusion, this study offered the first in-depth SAR study to analyze the ability of αhydroxytropolones to inhibit HBV RNase H. Synthetic substrates such as 107d with a therapeutic index of
94, showed that comprehensive structure studies could open up discovery for an antiviral drug candidate.
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3. 4 Conclusion
This research achieved a novel synthesis of poly-substituted α-hydroxytropolones. The goal of
these synthetic studies was to accomplish a synthesis that could be applicable to medical chemistry
studies, and it thus offered a simple synthesis, late stage introduction of substitution, and the ability to
diversify that substitution to produce a robust library of unique α-hydroxytropolones for SAR studies. The
synthetic process involved a key step that utilized an efficient intermolecular oxidopyrylium cycloaddition
reaction that offered late stage incorporation of diverse substitution on the α-hydroxytropolone core
structure and a simple one step acid catalyzed ring opening that attained the core scaffold in respectable
yields. The medicinal chemistry side of the research came full circle, as the synthetic compounds were
analyzed in various biological contexts for their ability to inhibit such enzymes as ANT(2”)-Ia, HBV RNase
H, and HIV RNase H. Through this chemistry a new research program was established, and new
discoveries were made, such as the exchange of alcohols in the oxidopyrylium cycloaddition. Hardships
were overcome by discovery of alternate ring opening strategies. With any chemistry there still exists a
need for new methods, such as a more predictable ring opening process, and the need to incorporate
even more diverse groups such as aliphatic groups into the α-hydroxytropolone structure. This research
paved the way for such discoveries and opened up the possibility for more medicinal chemistry studies on
other targets for the future.
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CHAPTER 4: Supporting Information
4.1 General Information
All starting materials and reagents were purchased from commercially available sources and
used without further purification, with exception of dichloromethane (CH2Cl2) and benzene, which was
purified on a solvent purification system prior to the reaction. 1H NMR shifts are measured using the
solvent residual peak as the internal standard (CHCl3 δ 7.26, D2O δ 4.79), and reported as follows:
chemical shift, multiplicity (s = singlet, bs = broad singlet, d = doublet, t = triplet, dd = doublet of doublet, q
= quartet, m = multiplet), coupling constant (Hz), integration.13C NMR shifts are measured using the
solvent residual peak as the internal standard (CDCl3 δ 77.20 or D2O), and reported as chemical shifts.
Infrared (IR) spectral bands are characterized as broad (br), strong (s), medium (m), and weak (w).
Microwave reactions were preformed via the Biotage Intiator 2.5. Purification via reverse phase column
chromatography was performed on the Biotage Isolera Prime, with Biotage SNAP 12g cartridges, in a
solvent system of acetonitrile (CH3CN) in water each solvent containing 0.05% trifluoroacetic acid (TFA).
4.2: Data for the Oxidopyrylium Cycloaddition
4.2.1 Synthesis of Oxidopyrylium Salts
O
OH
R

O

108b, R=Me
108c, R=CH2Cl
108e, R=CH2OMe

OCH3
OH

MeOTf

R

O

-OTf

105a, R=Me
105b, R=CH2Cl
105c, R=CH2OMe

Scheme 4.1.General Syntheic scheme for synthesis of oxidopyrylium salt.

OCH3
OH
Me

O

TfO

5-Hydroxy-4-methoxy-2-methylpyrylium (105a).
Procedure: To a solution of 108b79 (1.31 g, 10.3 mmol) in CH2Cl2 (5.25 ml) was added

methyl trifluoromethanesulfonate (MeOTf), (1.77 ml, 15.6 mmol). Reaction stirred at reflux for 4 hours,
cooled to room temperature, and then evaporated under reduced pressure to yield crude 105a as an
orange to red tinted oil. Crystallization from Ethyl Acetate (EtOAc) yielded pure 105a as an orange solid
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(1.0g, 33% yield). 1H NMR (400 MHz, D2O) δ 8.78 (s, 1H), 7.65 (s, 1H), 4.33 (s, 3H), 2.79 (s, 3H).

13

NMR (100 MHz, CDCl3) δ 176.52 (s), 170.34 (s), 148.59 (s), 143.72 (s), 107.80 (s), 59.94 (s), 20.91 (s).
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C

OCH3

2-(Chloromethyl)-5-hydroxy-4-methoxypyrylium (105b).

OH

Procedure: To a solution of 108c2 (500 mg, 3.1 mmol) in benzene (1.6 ml) was added

TfO

O
Cl

MeOTf, (1.03 ml, 9.3 mmol). The reaction was placed in the microwave reactor for 20

minutes at 80°C, and then evaporated under reduced pressure to yield crude 105b as an off white solid
(999 mg, >95% yield). Crystallization from Ethyl Acetate (EtOAc) yielded pure 105b as an off white solid
(156 mg, 16% yield). Since the 105b salt does not dissolve in chloroform, and decomposes in other
common deuterated solvents such as DMSO and D2O, verification of product was found by conversion
and analysis of the dimer. To do this, an aliquot of the salt was placed in approximately 10-20% solution
of Diethyl aniline (Et2NPh) in CDCl3. The presence of the dimer and disappearance of 105b was
monitored by 1H NMR.

Signature dimer peaks: 1H NMR (400 MHz, CDCl3) δ 5.95 (s, 1H), 5.13 (s, 1H), 4.98 (d, J = 2.6 Hz, 1H),
4.63 (d, J = 2.6 Hz, 1H), 4.11 (s, 2H), 4.05 (d, J = 11.8 Hz, 1H), 3.80 (d, J = 11.1 Hz, 1H), 3.66 (s, 3H),
3.50 (s, 3H). NMR cut to highlight the signature peaks, tend to be dwarfed on full NMR due to the strong
base peaks.
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d

5-Hydroxy-4-methoxy-2-(methoxymethyl)pyrylium (105c).
Procedure: To a solution of 108e1 (153 mg, 0.994 mmol) in CH2Cl2 (502 μL) was added

OCH 3
OH
O

TfO

MeOTf, (167 μL, 1.49 mmol). Reaction stirred at reflux for 3.5 hours, cooled to room
temperature, and then evaporated under reduced pressure to yield crude 105c as an

OMe

orange to red tinted oil

2

(282 mg, 87%). The oil was taken up in hot chloroform, to which was added

several drops of EtOAc while hot and solution became cloudy. Solution was placed on ice, and a white
solid crystallized out 105c (20 mg, 6%). Decomposes at temperatures from 230-235 °C. IR (thin film,
KBr) 3486 (br), 1634 (m), 1259 (s), 1174 (m), 1035 (s), 764 (w), 643 (w) cm-1.1H NMR (400 MHz, CDCl3)
δ 8.99 (s, 1H), 7.53 (s, 1H), 4.72 (s, 2H), 4.42 (s, 3H), 3.60 (s, 3H).

13

C NMR (100 MHz, CDCl3) δ 174.37

(s), 171.16 (s), 149.51 (s), 145.13 (s), 105.07 (s), 69.82 (s), 60.01 (s), 59.96 (s). HRMS (ESI+) m/z calc’d
for C8H11O4: 171.0652. Found: 171.0653.

1H

of 105c

1

Prepared from a solution of 108b in a 0.2 M solution of methanol (MeOH) and 5eq of Na0 and stirred at
room temperature over a 72 hour period.
2 Oil decomposes when stored neat in the freezer. Storage in CHCl prevents this.
3
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13C

of 105c

4.2.2 Formation and Isolation of the Dimer
(1R,2S,6S,7R)-6,9-dimethoxy-4,7-dimethyl-3,11O CH 3
OCH 3

H 3CO
O

O

CH 3

dioxatricyclo[5.3.1.12,6]dodeca-4,8-diene-10,12-dione (163). Procedure: To
a solution of 105a (69.8 mg, 0.240 mmol) in CHCl3 (1.2 ml) was added

O

triethylamine (29.1 mg, 0.288 mmol). After a short mixing time (~10 s) at room
temperature, the reaction mixture was washed with NH4Claq (6 x 2mL) to yield 163 (24.4 mg, 73% yield)
as a pale yellow solid. Decomposes at temperatures at 161°C. Rf= 0.29 in 30% ethyl acetate (EtOAc) in
hexanes. IR (thin film, KBr) 3078 (w), 2982 (w), 1744 (s), 1704 (s), 1663 (m), 1617 (m), 1454 (m) 1367
(m) , 1289 (m), 1249 (m), 1186 (s), 1162 (m), 1133 (m), 1094 (m), 991 (m), 870 (s) cm-1. 1H NMR (400
MHz, CDCl3) δ 5.94 (s, 1H), 4.79 (d, J = 2.7 Hz, 1H), 4.74 (s,1H), 4.47 (d, J = 2.7 Hz, 1H), 3.64 (s, 3H),
3.45 (s, 3H), 2.00 (s, 3H), 1.47 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 199.67 (s), 186.12 (s), 158.15 (s),
150.52 (s), 118.91 (s), 94.67 (s), 88.15 (s), 85.19 (s), 84.27 (s), 82.28 (s), 55.56 (s), 54.37 (s), 20.86 (s),
19.58 (s). HRMS (ESI+) m/z calc’d for C14H16O6Na+: 303.08391 Found: 303.08455.
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4.2.2 Oxidopyrylium Cycloaddition

General Procedure A: To a solution of salt 105a and alkyne (20 equivalents) in CH2Cl2 (0.2 M) was
added N,N-dimethylaniline (2 equivalents). The reaction stirred at room temperature and was monitored
periodically by 1H NMR until dimer 163 was completely consumed. Reaction mixture was then loaded
directly onto column for chromatography and purified.
General Procedure B: The procedure was optimized from that published by Wender and Mascarenas.1
To a solution of salts 105a-105c and alkyne (5-20 equivalents) in CHCl3 (0.5 M) was added N,Ndiethylaniline. The reaction mixture was subjected to microwave irradiation at 100°C and was monitored
periodically by 1H NMR until the dimer was completely consumed. Reaction mixture was then loaded
directly onto column for chromatography and purified.
General Procedure C: The procedure for the synthesis of 106a-106l was optimized from that published
by Wender and Mascareñas.68 To a solution of salts 105a-105c and alkyne (5-20 equivalents) in CHCl3
(0.5 M) was added N,N-diisopropylaniline (1.2 equivalents). The reaction mixture was subjected to
microwave irradiation at 100°C and was monitored periodically by 1H NMR until the dimer was completely
consumed. Reaction mixture was then loaded directly onto column for chromatography and purified.
OCH 3
O
O
H 3C
H3CO 2C

CO 2CH 3

Dimethyl 3-methoxy-1-methyl-4-oxo-8-oxabicyclo[3.2.1]octa-2,6-diene-6,7dicarboxylate (106a).
Procedure A: 105a (100 mg, 0.34 mmol) and dimethyl acetylenedicarboxylate

(DMAD) (832 µL, 6.8 mmol) in CH2Cl2 (1.7 mL) was added N,N-dimethylaniline (86 µL, 0.68 mmol). After
stirring at room temperature for 17 hours, reaction was purified by chromatography (silica gel, 18cm x
1.8cm, solvent gradient: 5% EtOAc in hexanes (100 mL); 10% EtOAc in hexanes (200 mL); 20% EtOAc
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in hexanes (200 mL)). Product fractions were concentrated to yield 106a as an orange solid (71 mg, 73%
yield).
Procedure C: 105a (110.4 mg, 0.381 mmol) and DMAD (939 μL, 7.62 mmol) in CHCl3 (762 µL) was
added N,N-diisopropylaniline (88 μL, 0.457 mmol). After microwave irradiation at 100°C for 5 minutes,
reaction was purified by chromatography (silica gel, 18cm x 1.8cm, solvent gradient: hexanes (50 mL);
10% EtOAc in hexanes (100 mL); 15% EtOAc in hexanes (100 mL); 20% EtOAc in hexanes (100 mL);
25% EtOAc in hexanes (200 mL)). Product fractions were concentrated to yield 106a as an orange solid
(96.8 mg, 90% yield).
Characterization of 106a: Melting Point (MP)= 94-97°C. Rf= 0.35 in 25%EtOAc in hexanes. IR (thin film,
KBr) 2956 (m), 1723 (s), 1653 (m), 1608 (s), 1437 (s), 1323 (s), 1286 (s), 1129 (s), 1073 (m), 1031 (m),
980 (w), 866 (m) cm-1. 1H NMR (400 MHz, CDCl3) δ 6.03 (s, 1H), 5.26 (s, 1H), 3.91 (s, 3H), 3.80 (s, 3H),
3.61 (s, 3H), 1.68 (s, 3H).

13

C NMR (100 MHz, CDCl3) δ 186.86 (s), 163.72 (s), 161.38 (s), 153.46 (s),

145.20 (s), 135.82 (s), 118.03 (s), 87.79 (s), 86.54 (s), 54.82 (s), 52.76 (s), 52.61 (s), 20.80 (s). HRMS
(ESI+) m/z calc’d for C13H14O7H+: 283.08123, Found: 283.08170.

1H

of 106a
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3-Methoxy-5-methyl-6-phenyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (106b).
Procedure A: 105a (100 mg, 0.34 mmol) and phenylacetylene (745 μL, 6.8 mmol) in
CH2Cl2 (1.7 mL) was added N,N-dimethylaniline (86 µL, 0.68 mmol). After stirring at room
temperature for 1 week, reaction was purified by chromatography (silica gel, 18cm x

1.8cm, solvent gradient: hexanes (50 mL); 10% EtOAc in hexanes (100 mL); 25% EtOAc in hexanes (100
mL). Product fractions were concentrated to yield 106b as an off white solid (29 mg, 35% yield).
Procedure A with microwave heating: 105a (38.7 mg, 0.133 mmol) and phenylacetylene (292 μL, 2.6
mmol) in CHCl3 (0.665 mL) was added N,N-dimethylaniline (34 µL, 0.26 mmol). After microwave
irradiation at 100°C for 45 minutes reaction was purified by chromatography (silica gel, 18cm x 1.8cm,
solvent gradient: hexanes (50 mL), 10% EtOAc in hexanes (100 mL); 20% EtOAc in hexanes (100 mL).
Product fractions were concentrated to yield 106b as an off white solid (15 mg, 47% yield).
Procedure B: 105a (15.8 mg, 0.053 mmol) and phenylacetylene (29 μL, 0.27 mmol) in CHCl3 (0.665 mL)
was added N,N-diethylaniline (10.3 μL, 0.064 mmol). After microwave irradiation at 100°C for 45 minutes
reaction was purified by chromatography (silica gel, 18cm x 1.8cm, solvent gradient: hexanes (50 mL),
10% EtOAc in hexanes (50 mL); 20% EtOAc in hexanes (75 mL). Product fractions were concentrated to
yield 106b as an off white solid (7 mg, 53% yield).
Procedure C3: 105a (102.8 mg, 0.354 mmol) and phenylacetylene (776 μL, 7.08 mmol) in CHCl3 (708 µl)
was added N,N-diisopropylaniline (83 μL, 0.425 mmol). After microwave irradiation at 100°C for 30
minutes, reaction was purified by chromatography (silica gel, 18cm x 1.8cm, solvent gradient): hexanes

3

5 eq of alkyne conditions were the same as stated but with the following amounts: 105a (97 mg, 0.334
mmol), phenylacetylene (183 μL, 1.67 mmol), diisopropylaniline (78 μL. 0.400 mmol), neat yielded 106b
(34 mg, 42%).
89

(50 mL); 10% EtOAc in hexanes (75 mL); 15% EtOAc in hexanes (200 mL); Product fractions were
concentrated to yield 106b as an off white solid (49 mg, 57% yield).
Characterization of 106b: MP= 76-84°C. Rf=0.56 in 26% EtOAc in hexanes. IR (thin film, KBr) 2977 (w),
2934 (w), 2836 (w), 1711 (s), 1606 (m), 1491 (w), 1446 (w), 1130 (m), 1058 (w), 864 (m), 755 (m), 977
(w), 697 (w), 661 (w) cm-1.1H NMR (400 MHz, CDCl3) δ 7.43 – 7.34 (m, 3H), 7.29 (dd, J = 5.1, 2.8 Hz,
2H), 6.28 (d, J = 2.4 Hz, 1H), 6.19 (s, 1H), 4.99 (d, J = 2.5 Hz, 1H), 3.60 (s, 3H), 1.68 (s, 3H).

13

C NMR

(100 MHz, CDCl3) δ 189.89 (s), 158.72 (s), 145.91 (s), 133.02 (s), 128.73 (s), 128.70 (s), 125.97 (s),
123.00 (s), 119.13 (s), 86.39 (s), 85.81 (s), 54.71 (s), 22.08 (s). HRMS (ESI+) m/z calc’d for
C15H14O3Na+: 265.0835. Found: 265.0836.
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Ethyl-3-methoxy-5-methyl-2-oxo-8-oxabicyclo[3.2.1]octa-3,6-diene-6-carboxylate
(106c).

EtO2 C

Procedure A: 105a (100 mg, 0.34 mmol) and ethyl propiolate (694 μL, 6.8 mmol) in CH2Cl2 (1.7 mL) was
added N,N-dimethylaniline (86 µL, 0.68 mmol). After stirring at room temperature for 21 hours, reaction
was purified by chromatography (silica gel, 18cm x 1.8cm, solvent gradient: hexanes (50 mL); 10% EtOAc
in hexanes (100 mL); 25% EtOAc in hexanes (200 mL). Product fractions were concentrated to yield
106c as an off white solid (35.6 mg, 44% yield).
Procedure B: 105a (18.7 mg, 0.065 mmol) and ethyl propiolate (131 μL, 1.29 mmol) in CH2Cl2 (362 µl)
was added N,N-diethylaniline (12 μL, 0.077 mmol). After microwave irradiation at 100°C for 45 minutes,
reaction was purified by chromatography (silica gel, 18cm x 1.8cm, solvent gradient: hexanes (50 mL);
10% EtOAc in hexanes (50 mL); 20% EtOAc in hexanes (75 mL); Product fractions were concentrated to
yield 106c as an off white solid (11 mg, 72% yield).
Procedure C: 105a (104 mg, 0.359 mmol) and ethyl propiolate (726 μL, 7.18 mmol) in CHCl3 (718 µl)
was added N,N-diisopropylaniline (84 μL, 0.431 mmol). After microwave irradiation at 100°C for 15
minutes, reaction was purified by chromatography (silica gel, 18cm x 1.8cm, solvent gradient: hexanes
(50 mL); 10% EtOAc in hexanes (100 mL); 15% EtOAc in hexanes (200 mL); Product fractions were
concentrated to yield 106c as an off white solid (75.5 mg, 88% yield).
Characterization of 106c: MP= 52-55°C. Rf= 0.38 in 25% EtOAc in hexanes. IR (thin film, KBr) 2982
(w), 2938 (w), 1711 (s), 1604 (m), 1452 (w), 1317 (m), 1128 (m), 1073 (m), 987 (w), 783 (w) cm-1. 1H
NMR (400 MHz, CDCl3) δ 7.08 (d, J = 2.5 Hz, 1H), 6.07 (s, 1H), 5.00 (d, J = 2.5 Hz, 1H), 4.24 (q, J = 7.2
Hz, 2H), 3.54 (s, 3H), 1.76 (s, 3H), 1.31 (t, J = 7.1 Hz, 3H).

13

C NMR (100 MHz, CDCl3) δ 189.41 (s),

163.46 (s), 150.25 (s), 145.64 (s), 139.18 (s), 119.99 (s), 86.51 (s), 86.13 (s), 61.80 (s), 55.30 (s), 21.96
(s), 14.78 (s). HRMS (ESI+) m/z calc’d for C12H14O5H+: 239.0914. Found: 239.09073.
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6-Acetyl-3-methoxy-5-methyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (106d).
Procedure A: 105a (50 mg, 0.172 mmol) and 3-butyn-2-one (270 µL, 3.4 mmol) in CH2Cl2

(862 μL) was added N,N-dimethylaniline (44 µL, 0.34 mmol). After stirring at room temperature for 70
hours, reaction was purified by chromatography (silica gel, 18cm x 1.8cm, solvent gradient: hexanes (50
mL); 10% EtOAc in hexanes (100 mL); 15% EtOAc in hexanes (200 mL).
concentrated to yield 106d as a white solid (15.8 mg, 44% yield).
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Product fractions were

Procedure B: 105a (17 mg, 0.057 mmol) and 3-butyn-2-one (92 μL, 1.17 mmol) in CH2Cl2 (293 µl) was
added N,N-diethylaniline (11 μL, 0.070 mmol). After microwave irradiation at 100°C for 45 minutes,
reaction was purified by chromatography (silica gel, 18cm x 1.8cm, solvent gradient: hexanes (50 mL);
10% EtOAc in hexanes (50 mL); 20% EtOAc in hexanes (75 mL+); Product fractions were concentrated
to yield 106d as an off white solid (8 mg, 67% yield).
Procedure C: 105a (102.4 mg, 0.353 mmol) and 3-butyn-2-one (540 μL, 7.06 mmol) in CHCl3 (706 µL)
was added N,N-diisopropylaniline (82 μL, 0.424 mmol). After microwave irradiation at 100°C for 15
minutes, reaction was purified by chromatography (silica gel, 18cm x 1.8cm, solvent gradient: hexanes
(50 mL); 10% EtOAc in hexanes (100 mL); 15% EtOAc in hexanes (200 mL). Product fractions were
concentrated to yield 106d as a white solid (71 mg, 97% yield).
Characterization of 106d: MP=146-150°C. Rf= 0.23 in 25% EtOAc in hexanes. IR (thin film, KBr) 3074
(s), 2931 (w), 1708 (s), 1663 (s), 1608 (s), 1441 (w), 1228 (m). 1129 (m). 1063 (m), 990 (w), 881 (w), 660
(w) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.07 (d, J=1.4 Hz. 1H), 6.08 (s, 1H), 5.03 (d, J = 1.4 Hz, 1H), 3.52
(s, 3H), 2.36 (s, 3H), 1.71 (s, 3H).

13

C NMR (100 MHz, CDCl3) δ 194.63 (s), 189.16 (s), 156.78 (s),

145.40 (s), 139.26 (s), 119.94 (s), 86.40 (s), 86.13 (s), 55.03 (s), 28.07 (s), 21.63 (s). HRMS (ESI+) m/z
calc’d for C11H12O4Na+: 231.06278. Found: 231.06338.
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Ethyl-3-methoxy-5,7-dimethyl-2-oxo-8-oxabicyclo[3.2.1]octa-3,6-diene-6carboxylate (106e).

EtO2C

CH 3

Procedure A: 105a (50 mg, 0.17 mmol) and ethyl but-2-ynoate (402 µL, 3.4 mmol) in CH2Cl2 (862 μL)
was added N,N-dimethylaniline (44 µL, 0.34 mmol). After stirring at room temperature for 70 hours, there
was no conversion to product 106e.
Procedure C: 106a (106.3 mg, 0.367 mmol) and ethyl but-2-ynoate (855 μL, 7.34 mmol) in CHCl3 (734
µL) was added N,N-diisopropylaniline (78 μL, 0.440 mmol). After microwave irradiation at 100°C for 60
minutes, reaction was purified by chromatography (silica gel, 18cm x 1.8cm, solvent gradient: hexanes
(50 mL); 2% EtOAc in hexanes (50 mL); 5% EtOAc in hexanes (200 mL); 10% EtOAc in hexanes (300
mL). Product fractions were concentrated to yield 106e as a white solid (29.3 mg, 32% yield).
Characterization of 106e: MP=64-66°C. Rf= 0.53 in 25% EtOAc in hexanes. IR (thin film, KBr) 2981
(w), 2937 (w), 1706 (s), 1606 (m), 1446 (w), 1328 (m), 1132 (m), 1083 (m), 1048 (m), 871 (w), 785 (w)
cm-1.

1

H NMR (400 MHz, CDCl3) δ 6.13 (s, 1H), 4.80 (s, 1H), 4.36 – 4.15 (m, 2H), 3.54 (s, 3H), 2.12 (s,

3H), 1.71 (s, 3H), 1.32 (t, J = 6.9 Hz, 3H).

13

C NMR (100 MHz, CDCl3) δ 190.23 (s), 164.58 (s), 152.19

(s), 145.66 (s), 141.22 (s), 121.66 (s), 91.06 (s), 87.45 (s), 61.36 (s), 55.25 (s), 22.45 (s), 14.86 (s), 13.33
(s). HRMS (ESI+) m/z calc’d for C13H16O5H+: 253.1071. Found: 253.1059.
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6-Benzoyl-3-methoxy-5-methyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (106f).
Procedure C: 105a (100 mg, 0.340 mmol) and benzyl acetylene (225 mg, 1.72 mmol)

PhOC

in CHCl3 (706 µL) was added N,N-diisopropylaniline (80 μL, 0.408 mmol). After microwave irradiation at
100°C for 10 minutes, reaction was purified by chromatography (silica gel, 26 cm x 2.6 cm, solvent
gradient: hexanes (50 mL); 2% EtOAc in hexanes (100 mL), 5% EtOAc in hexanes (100mL), 10% EtOAc
in hexanes (100 mL); 20%-25% EtOAc in hexanes (200 mL). Product fractions were concentrated to yield
106f as a light yellow solid (78 mg, 85% yield). In addition, the benzyl acetylene was re-isolated (125 mg,
70% yield (180 mg would be 100% theoretical yield of un-reacted product).
Characterization of 106f: MP= 93-95°C. Rf=0.50 in 30% EtOAc in hexanes. IR (thin film, KBr) 3068 (w),
2978 (w), 2936 (w), 1711 (s), 1643 (s), 1608 (s), 1448 (m), 1325 (s), 1227 (m), 1180 (m), 1126 (s), 1075
(m), 988 (m), 819 (m), 843 (m), 701 (m), 667 (m) , 654 (m) cm-1.1H NMR (400 MHz, CDCl3) δ 7.82 (d, J =
7.2 Hz, 2H), 7.59 (t, J = 7.4 Hz, 1H), 7.47 (dd, J =7.6, 7.6 Hz, 2H), 6.78 (d, J = 2.3 Hz, 1H), 6.26 (s, 1H),
5.15 (d, J = 2.5 Hz, 1H), 3.56 (s, 3H), 1.74 (s, 3H).

13

C NMR (100 MHz, CDCl3) δ 190.59 (s), 188.44 (s),

155.01 (s), 145.05 (s), 138.84 (s), 136.82 (s), 133.61 (s), 129.01 (s), 128.73 (s), 120.31 (s), 87.04 (s),
86.70 (s), 54.71 (s), 20.80 (s). HRMS (ESI+) m/z calc’d for C16H14O4H+: 271. 0965. Found: 271.0964.
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3-Methoxy-5-methyl-6-(4-nitrophenyl)-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one
(106g).
Procedure C: 105a (100 mg, 0.355 mmol) and 1-ethynyl-4-nitrobenzene (1.05 g, 7.10

mmol) in CHCl3 (2.80 ml)4 was added N,N-diisopropylaniline (83 μL, 0.426 mmol). After microwave
irradiation at 100°C for 30 minutes, reaction was purified by chromatography (silica gel, 26 cm x 2.6 cm
solvent gradient, dry loaded5): hexanes (50 mL); 10% EtOAc in hexanes (100 mL); 15% EtOAc in
hexanes (100 mL); 20% EtOAc in hexanes (100 mL); 25% EtOAc in hexanes (200 mL)). Product fractions
were concentrated to yield 106g as a yellow solid (65 mg, 64% yield).
Characterization of 106g: MP= 145-148°C. Rf=0.27 in 16% EtOAc in hexanes. IR (thin film, KBr) 3075
(w), 2935 (w), 1712 (s), 1604 (m), 1516 (s), 1453 (w), 1341 (s), 1129 (m), 1108 (w), 987 (w), 865 (w), 851
(m), 750 (m) cm-1.

1

H NMR (400 MHz, CDCl3) δ 8.24 (d, J=8.7 Hz, 2H), 7.44 (d, J=8.7, 2H), 6.51 (d, J =

2.5 Hz, 1H), 6.18 (s, 1H), 5.03 (d, J = 2.5 Hz, 1H), 3.61 (s, 3H), 1.67 (s, 3H).
4

13

C NMR (100 MHz, CDCl3)

Increased solvent amount due to reduced solubility in lower amounts of chloroform.
Took about ~500 mg of silica gel and placed into a round bottom with reaction mixture directly after
microwave irradiation. Evaporated off any excess solvent and dried under vacuum for ~ 30 minutes. Then
applied dried silica mixture directly onto column.
5
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δ 189.08 (s), 156.93 (s), 147.67 (s), 146.13 (s), 139.53 (s), 127.42 (s), 126.77 (s), 124.07 (s), 118.26 (s),
86.33 (s), 86.00 (s), 54.84 (s), 21.95 (s). HRMS (ESI+) m/z calc’d for C15H13NO5H+: 288.0866. Found:
288.0866.
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Dimethyl 1-(chloromethyl)-3-methoxy-4-oxo-8-oxabicyclo[3.2.1]
octa-2,6-diene-6,7-dicarboxylate (106h).
Procedure C: 105b (102.7 mg, 0.317 mmol) and DMAD (783 μL, 6.34 mmol) in

CHCl3 (634 µL) was added N,N-diisopropylaniline (74 μL, 0.380 mmol). After microwave irradiation at
100°C for 60 minutes, reaction was purified by chromatography (silica gel, 18cm x 1.8cm, solvent
gradient: hexanes (50 mL); 10% EtOAc in hexanes (100 mL); 15% EtOAc in hexanes (100 mL); 20%
EtOAc in hexanes (100 mL); 25% EtOAc in hexanes(100 mL)). Product fractions were concentrated to
yield 106h as a light yellow solid (76 mg, 76% yield). MP= 127-130°C. Rf= 0.33 in 40% in EtOAc in
hexanes. IR (thin film, KBr) 2956 (w), 1720 (s), 1649 (w), 1610 (s), 1437 (s), 1278 (s), 1219 (m), 1129
(s), 1079 (m), 985 (m), 797 (w), 727 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ 6.03 (s, 1H), 5.35 (s, 1H),
3.99 (dd, J = 12.3, 12.3 Hz, 2H), 3.88 (s, 3H), 3.81 (s, 3H), 3.61 (s, 3H).

13

C NMR (100 MHz, CDCl3) δ

185.98 (s), 162.87 (s), 161.01 (s), 148.90 (s), 146.05 (s), 138.27 (s), 113.71 (s), 90.08 (s), 86.92 (s),
55.06 (s), 53.00 (s), 52.81 (s), 44.10 (s). HRMS (ESI+) m/z calc’d for C13H13ClO7Na+: 339.02420. Found:
339.02506.
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Dimethyl 3-methoxy-1-(methoxymethyl)-4-oxo-8-oxabicyclo[3.2.1]
octa-2,6-diene-6,7-dicarboxylate (106i).
Procedure C: 105c (114.6 mg, 0.358 mmol) and DMAD (870 μL, 7.16 mmol) in

CHCl3 (716 µL) was added N,N-diisopropylaniline (84 μL, 0.430 mmol). After microwave irradiation at
100°C for 15 minutes, reaction was purified by chromatography (silica gel, 18cm x 1.8cm,

solvent

gradient: hexanes (50 mL); 10% EtOAc in hexanes (100 mL); 15% EtOAc in hexanes (100 mL); 20%
EtOAc in hexanes (100 mL); 25% EtOAc in hexanes (200 mL). Product fractions were concentrated to
yield 106i as a light yellow oil (68.3 mg, 58% yield). Rf= 0.22 in 26% EtOAc in hexanes. IR (thin film,
KBr) 2954 (w), 2841 (w), 1723 (s), 1610 (m), 1437 (m), 1263 (br/s), 1134 (m), 1110 (m), 1080 (w),
1029(w), 977 (w), 809 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ 6.03 (s, 1H), 5.31 (s, 1H), 3.87 (s, 3H), 3.81
(dd, J = 3.1, 3.1 Hz, 2H), 3.78 (s, 3H), 3.60 (s, 3H), 3.42 (s, 3H).

13

C NMR (100 MHz, CDCl3) δ 186.75

(s), 163.54 (s), 161.11 (s), 151.49 (s), 146.19 (s), 136.16 (s), 114.06 (s), 90.51 (s), 86.73 (s), 71.94 (s),
59.81 (s), 54.95 (s), 52.73 (s), 52.65 (s). HRMS (ESI+) m/z calc’d for C14H16O8H+: 313.0918. Found:
313.0922.
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Dimethyl 3-methoxy-4-oxo-8-oxabicyclo[3.2.1]octa-2,6-diene-6,7-dicarboxylate
(106j).
Procedure C: Triflate salt 105d6 (108 mg, 0.391 mmol), and dimethylacetylene

dicarboxylate (1.11 mg, 7.82 mmol) were dissolved in CHCl3 (780 μL). N,N-diisopropylaniline (91 μL, 0.47
mmol) was added to the reaction, the reaction vessel was sealed, and the reaction mixture was heated
under microwave irradiation to 150ºC for 5 min. The reaction mixture was then concentrated and purified
by chromatography (silica gel, 18 x 1.8cm, 50 ml of Hexanes, 75 ml 10% EtOAc in Hexanes, 100 ml 20%
EtOAc in Hexanes, 200 ml 30% EtOAc in Hexanes) to lead to 106j as a white solid (64 mg, 61% yield).
Characterization of 106j: MP = 113-116ºC. Rf = 0.15 in 25% EtOAc/Hexanes. IR (thin film, KBr) 688
(m), 794 (w), 1000 (b), 1129 (s), 1611 (s), 1654 (m), 1716 (b), 2838 (m), 2956 (s), 3019 (w) cm-1; 1H NMR
(400 MHz, CDCl3) δ 6.17 (d, J = 4.8 Hz, 1H), 5.46 (d, J = 4.8 Hz, 1H), 5.28 (s, 1H), 3.86 (s, 3H), 3.81 (s,
3H), 3.60 (s, 3H).

13

C NMR (100 MHz, CDCl3) δ 186.8, 162.7, 161.9, 149.5, 146.9, 138.5, 114.2, 88.9,

80.9, 55.2, 53.2, 53.1. HRMS (ESI+): calc’d for C12H13O7 (M+H): 269.0656; Found: 269.0652

13C

of 106j

6 Triflate salt 105d was prepared by mixing pyromeconic acid (500 mg, 4.46 mmol) and methyl triflate
(759 μL, 6.69 mmol) in CH2Cl2 (2.25 ml, 1.98 M) and heating under reflux for 3 hours. After 3 hours,
solvent was removed under reduced pressure, and recrystallized from CHCl3. Unlike other salts however,
105d decomposes over time (a few hours) as a solid, and thus it must be stored as a suspension in
chloroform to prevent decomposition.
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6-(4-Bromophenyl)-3-methoxy-5-methyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one
(106k).
Procedure C: Triflate salt 105a (100 mg, 0.34 mmol), and 1-ethynyl-4-bromobenzene

Br

(1.0 g, 6.9 mmol) were suspended in CHCl3 (2 mL). N,N-diisopropylaniline (81 μL, 0.41

mmol) was added to the reaction, the reaction vessel was sealed, and the reaction mixture was heated
under microwave irradiation to 100ºC for 30 min.

The reaction mixture was then concentrated and

purified by chromatography (silica gel, 18 x 1.8cm, 50 ml Hexanes, 200 ml 2% EtOAc in Hexanes, 100 ml
10% EtOAc in Hexanes, 200 ml 15% EtOAc in Hexanes) to lead to 106k as a light yellow solid (68 mg,
61% yield).
Characterization of 106k: MP = 192-200ºC. Rf = 0.17 in 16% EtOAc/Hexanes. IR (thin film, KBr) 525
(m), 714 (m), 1057 (w), 1132(m), 1606(s), 1708(s), 1905 (w), 2978(m) cm-1. 1H NMR (400 MHz, CDCl3) δ
7.49 (d, J = 8.5 Hz, 2H), 7.14 (d, J = 8.5 Hz, 2H), 6.29 (d, J = 2.5 Hz, 1H), 6.14 (s, 1H), 4.96 (d, J = 2.5
Hz, 1H), 3.58 (s, 3H), 1.64 (s, J = 3H).

13

C NMR (100 MHz, CDCl3) δ 105.6, 97.6, 94.7, 91.2, 90.0, 89.1,

88.9, 87.8, 79.7, 79.6, 71.8, 63.5. HRMS (ESI+): calc’d for C15H14BrO3 (M+H): 321.0121; Found:
321.0114
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5-(Chloromethyl)-3-methoxy-6-phenyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (106l).
Procedure C: Triflate salt 105b (200 mg, 0.616 mmol), and phenylacetylene (1.35 mL,
12.3 mmol) were dissolved in CHCl3 (3.08 mL). N,N-diisopropylaniline (240 µL, 1.23

mmol) was added to the reaction, the reaction vessel was sealed, and the reaction mixture was heated
under microwave irradiation to 100ºC for 4 h. The reaction mixture was then concentrated and purified by
chromatography (silica gel, 18 x 1.8 cm, 50 ml Hexanes, 200 ml 2% EtOAc in Hexanes, 100 ml 10%
EtOAc in Hexanes, 200 ml 15% EtOAc in Hexanes) to lead to 106l as a yellow solid (114 mg, 67% yield).
Characterization of 106l: MP = 41-65ºC. Rf = 0.14 in 20% EtOAc in Hexanes. IR (thin film, KBr)
656(w), 798(s), 1078(m), 1261(s), 1607(b), 1709(b) 1960(w), 2254(w), 2838(w), 2962(s) cm-1. 1H NMR
(400 MHz, CDCl3) δ 7.36 – 7.09 (m, 5H), 6.22 (d, J = 2.4 Hz, 1H), 6.11 (s, 1H), 4.98 (d, J = 2.4 Hz, 1H),
105

3.94 (d, J = 12.4 Hz, 1H), 3.77 (d, J = 12.4 Hz, 1H), 3.52 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 189.2,
156.3, 146.9, 132.7, 129.4, 129.2, 125.9, 124.9, 114.8, 88.7, 86.4, 55.2, 45.9. HRMS (ESI+): calc’d for
C15H13ClO3: 277.0553; Found: 277.0548.
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4.3 Data for the BCl3 Induced Ring Opening
H3 CO
O
OH

H3 C
H3CO 2C

CO2 CH3

Dimethyl 7-hydroxy-5-methoxy-3-methyl-6-oxocyclohepta-2,4,7-triene-1,2dicarboxylate (165a).
Procedure: To a solution of 106a (50 mg, 0.17 mmol) in CH2Cl2 (1.5 mL) at 0°C was

added boron tribromide in CH2Cl2 (102 µL of 1.0 M solution, 0.1 mmol). The reaction ran for 10 minutes,
and a second portion of boron tribromide solution was added (102 µL, 0.1 mmol). The reaction ran for an
additional 10 minutes, at which time the reaction mixture was quenched with a saturated aqueous
NaHCO3 solution (5 mL). The aqueous layer was extracted with CH2Cl2 (3 x 5 mL), and then acidified to
a pH of 7 by dropwise addition of a 2M HCl solution. The acidified solution was then extracted with
CH2Cl2 (5 x 5 mL), dried over Na2SO4, filtered and concentrated to yield 165a as a yellow oil (16 mg, 0.56
mmol, 33% yield). MP=129-134. IR (thin film, KBr) 3225 (br), 2953 (w), 2852 (w), 1738 (s), 1571 (m),
1437 (m), 1320 (w), 1263 (s), 1156 (m), 1068 (m), 939 (w), 763 (w) cm-1.
7.02 (s, 1H), 4.02 (s, 3H), 3.92 (s, 3H), 3.88 (s, 3H), 2.46 (s, 3H).

13

1

H NMR (400 MHz, CDCl3) δ

C NMR (100 MHz, CDCl3) δ 171.22

(s), 168.52 (s), 167.26 (s), 158.96 (s), 156.35 (s), 134.72 (s), 131.45 (s), 122.78 (s), 121.71 (s), 56.81 (s),
53.27 (s), 53.12 (s), 26.08 (s). HRMS (ESI+) m/z calc’d for C13H14O7Na+: 305.06317. Found: 305.06278.

1H
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Dimethyl 5,7-dihydroxy-3-methyl-6-oxocyclohepta-2,4,7-triene-1,2-dicarboxylate

O
H 3C
CH3 O2 C

OH
CO 2CH3

(107a).
Procedure: A solution of BCl3 (1.0 M in CH2Cl2) (588 μL, 0.588 mmol) was diluted

with CH2Cl2 (6.0 mL) and cooled to 0°C. In a separate round bottom flask, 106a (23.7 mg, 0.084 mmol)
was dissolved in CH2Cl2 (6.0 mL), was cooled to 0°C and was added to the BCl3 solution. After 10
minutes of stirring at 0°C, the reaction mixture was quenched with H2O (12.0 mL), stirred for 2 minutes at
0°C, and then warmed to room temperature where it continued to stir for 60 minutes. The organic layer
was isolated and the aqueous layer was extracted with CH2Cl2, (5 x 10mL). Combined organics were
dried over Na2SO4, filtered, and concentrated under reduced pressure to yield 107a as a yellow solid
(17.4 mg, 77%).7 MP= 159-161°C. IR (thin film, KBr) 3260 (br), 2957 (w), 1738 (s), 1543 (m), 1436 (w),
1256 (br/s), 1154 (m), 1065 (w), 1029 (w), 962 (w), 754 (w) cm-1.
1H), 3.94 (s, 3H), 3.89 (s, 3H), 2.46 (s, 3H).

13

1H

NMR (400 MHz, CDCl3) δ 7.48 (s,

C NMR (100 MHz, CDCl3) δ 169.27 (s), 168.41 (s), 166.90

7 Compound can be further purified via reverse phase column chromatography (C-18) with a gradient of
20-27% 16 column volumes (CV).
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(s), 158.40 (s), 154.56 (s), 138.42 (s), 132.18 (s), 125.28 (s), 124.48 (s), 53.40 (s), 53.20 (s), 25.74 (s).
HRMS (ESI+) m/z calc’d for C12H12O7Na+: 291.04752. Found: 291.04831.
1H

of 107a

13C

of 107a

109

X

Ethyl 4,6-dihydroxy-2-methyl-5-oxocyclohepta-1,3,6-trienecarboxylate (107c):

O
OH

H3C
EtO2 C

X=OH ( 107c):OMe (165c )

Ethyl 6-hydroxy-4-methoxy-2-methyl-5-oxocyclohepta-1,3,6-trienecarboxylate
(165c).
Procedure: A solution of BCl3 (1.0 M in CH2Cl2) (627 μL, 0.627 mmol) was diluted

with CH2Cl2 (6.4 mL) and cooled to 0°C. In a separate round bottom flask, 106c (21.3 mg, 0.089 mmol)
was dissolved in CH2Cl2 (6.4 mL), was cooled to 0°C and was added to the BCl3 solution. After 10
minutes of stirring at 0°C, the reaction mixture was quenched with H2O (12.8 mL), stirred for 2 minutes at
0°C, and then warmed to room temperature where it continued to stir for 30 minutes. The organic layer
was isolated and the aqueous layer was extracted with CH2Cl2, (3 x 10 mL) and EtOAc (2 x 10 mL).
Combined organics were dried over Na2SO4, filtered, and concentrated under reduced pressure. To the
resulting solid was added CHCl3 where a white solid precipitated out. The organic layer was decanted off
and concentrated under reduced pressure to yield a mixture of 107c:165c8 as a brownish green solid (7.9
mg, 39%).

13C

of 107d:165c

8 Compound can be purified via reverse phase column chromatography (C-18) with a gradient of 20-27%
for 1.9 CV (column volumes), 27-30% for 5 CV, 30-45% for 7 CV.
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HO

Ethyl 4,6-dihydroxy-2-methyl-5-oxocyclohepta-1,3,6-trienecarboxylate (107c).

O
OH

Procedure: To the mixture of 107c:165c (7.9 mg, 0.033 mmol) was added acetic acid

H 3C
EtO 2C

(192 μl) and 33% HBr in acetic acid (224 μl), and reaction was left to stir at 90°C for 3

hours. After 3 hours, reaction mixture was let to cool to room temperature. The reaction was quenched
with 7 pH phosphate buffer, and diluted with CH2Cl2. The organic layer was washed several times with
the phosphate buffer. The organic layer was dried over Na2SO4, and evaporated under reduced pressure
to yield a brown solid 107c (3.1 mg, 42% yield). Decomposes at temperatures above 80°C. IR (thin film,
KBr) 3260 (br), 2917 (w), 2849 (w), 1718 (s), 1500 (w), 1462 (w), 1217 (br/s), 1094 (m), 922 (w), 785 (w)
cm-1. 1H NMR (400 MHz, CDCl3) 1δ 7.68 (s, 1H), 7.45 (s, 1H), 4.37 (q, J = 7.1 Hz, 2H), 2.53 (s, 3H), 1.38
(t, J = 7.1 Hz, 3H).

13

C NMR (100 MHz, CDCl3) δ 168.72 (s), 168.65 (s), 159.04 (s), 156.74 (s), 140.73

(s), 132.94 (s), 124.35 (s), 120.54 (s), 62.28 (s), 25.67 (s), 14.33 (s).
C11H12O5H+: 225.07575. Found: 225.07611
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HRMS (ESI+) m/z calc’d for
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4-Acetyl-2,7-dihydroxy-5-methylcyclohepta-2,4,6-trienone (107d).

O
OH

H 3C
CH 3OC

Procedure: A solution of BCl3 (1.0 M in CH2Cl2) (673 μL, 0.673 mmol) was diluted with
CH2Cl2 (6.9 mL) and cooled to 0°C. In a separate round bottom flask, 106d (20.0 mg,

0.096 mmol) was dissolved in CH2Cl2 (6.9 mL), was cooled to 0°C and was added to the BCl3 solution.
After 10 minutes of stirring at 0°C, the reaction mixture was quenched with H2O (13.7 mL), stirred for 2
minutes at 0°C, and then warmed to room temperature where it continued to stir for 1 hour. The organic
layer was isolated and the aqueous layer was extracted with CH2Cl2, (5 x 10 mL). Combined organics
were dried over Na2SO4, filtered, and concentrated under reduced pressure to yield 107d as an orange
solid (19.6 mg, >95% yield). MP= 106-110°C. IR (thin film, KBr) 3240 (br), 2918 (w), 2852 (w), 1700
(s), 1536 (s), 1446 (w), 1283 (m), 1203 (s), 1134 (m), 1031 (w), 893 (w), 785 (w) cm-1.
MHz, CDCl3 δ 7.44 (s, 1H), 7.36 (s, 1H), 2.55 (s, 3H), 2.43 (s, 3H).

13

1

H NMR (400

C NMR (100 MHz, CDCl3 δ 204.08

(s), 168.56 (s), 159.03 (s), 157.48 (s), 141.72 (s), 137.77 (s), 125.04 (s), 118.06 (s), 30.92 (s), 24.80 (s).
HRMS (ESI+) m/z calc’d for C10H10O4H+: 195.06519. Found: 195.06531.
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MeO

Ethyl 6-hydroxy-4-methoxy-2,7-dimethyl-5-oxocyclohepta-1,3,6-trienecarboxylate
O
OH

H3 C
EtO2 C

CH3

(165e).
Procedure: A solution of BCl3 (1.0 M in CH2Cl2) (486 μL, 0.486 mmol) was diluted with

CH2Cl2 (5 mL) and cooled to 0°C. In a separate round bottom flask, 106e (17.5 mg, 0.069 mmol) was
dissolved in CH2Cl2 (5 mL), was cooled to 0°C and was added to the BCl3 solution. After 10 minutes of
stirring at 0°C, the reaction mixture was quenched with H2O (10 mL), stirred for 2 minutes at 0°C, and
then warmed to room temperature where it continued to stir for 1 hour. The organic layer was isolated
and the aqueous layer was extracted with CH2Cl2, (5 x 10 mL). Combined organics were dried over
Na2SO4, filtered, and concentrated under reduced pressure to yield 165e as a yellow solid (13.4 mg, 77%
yield). MP= 64-70°C. IR (thin film, KBr) 3381 (w), 2917 (w), 2848 (w), 1727 (s), 1551 (w), 1454 (w), 1317
(m), 1223 (s), 1146 (m), 1037 (m), 876 (w), 791 (w) cm-1.1H NMR (400 MHz, CDCll3) δ 6.95 (s, 1H), 4.40
(q, J = 7.1 Hz, 2H), 3.97 (s, 3H), 2.40 (s, 3H), 2.37 (s, 3H), 1.39 (t, J = 7.1 Hz, 3H).13C NMR (100 MHz,
CDCl3) δ 169.70 (s), 168.91 (s), 160.01 (s), 158.30 (s), 137.98 (s), 131.45 (s), 126.86 (s), 120.88 (s),
62.14 (s), 56.87 (s), 25.79 (s), 18.32 (s), 14.41 (s). HRMS (ESI+) m/z calc’d for C13H16O5Na+: 275.08899.
Found: 275.08788.

1H

of 165e
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13C

of 165e

4-Benzoyl-2,7-dihydroxy-5-methylcyclohepta-2,4,6-trienone (107f): 4-benzoylX

O

2-hydroxy-7-methoxy-5-methylcyclohepta-2,4,6-trienone (165f).
OH

H3C

Procedure: A solution of BCl3 (1.0 M in CH2Cl2) (503 μL, 0.503 mmol) was diluted

PhOC
X=OH (107f):OMe (165f)

with CH2Cl2 (5.2 mL) and cooled to 0°C. In a separate round bottom flask, 106f

(19.4 mg, 0.072 mmol) was dissolved in CH2Cl2 (5.2 mL), was cooled to 0°C and was added to the BCl3
solution. After 10 minutes of stirring at 0°C, the reaction mixture was quenched with H2O (10.3 mL),
stirred for 2 minutes at 0°C, and then warmed to room temperature where it continued to stir for 1 hour.
The organic layer was isolated and the aqueous layer was extracted with CH2Cl2, (5 x 10 mL). Combined
organics were dried over Na2SO4, filtered, and concentrated under reduced pressure to yield 107f:165f
as a yellow solid (19.6 mg, >95% yielded) in a 1:1 ratio. The mixture of compound 6i: 10i can be purified
for characterization via reverse phase column chromatography (C-18) with a gradient of 27-35% for 5
column volumes, and 35-65% for 8 column volumes, 165f collected on fractions 2-7; 107f was collected
on fractions 10-13.
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1H

of 107f:165f

HO

4-Benzoyl-2,7-dihydroxy-5-methylcyclohepta-2,4,6-trienone (107f).

O
OH

Procedure: To the mixture of 107f:165f (16.9 mg, 0.062 mmol) was added acetic acid

H 3C
PhOC

(364 μl) and 33% HBr in acetic acid (425 μl), and reaction was left to stir at 90°C for 3

hours. After 3 hours, reaction mixture was let to cool to room temperature. The reaction was quenched
with 7 pH phosphate buffer, and diluted with DCM. The organic layer was washed several times with the
phosphate buffer. The organic layer was dried over Na2SO4, and evaporated under reduced pressure to
yield a brown solid 6f (9.5 mg, 60% yield). Decomposed at temperatures from 45-50°C. IR (thin film,
KBr) 3279 (br), 2918 (w), 2849 (w), 1674 (s), 1595 (w), 1536 (m), 1448 (m), 1284 (m), 1231 (s), 1084 (m),
829 (w), 725 (w), 688 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.81 (d, J = 7.7 Hz, 2H), 7.64 (t, J = 7.3 Hz,
1H), 7.52 (s, 1H), 7.49 (dd, J = 7.7, 7.7 Hz, 2H), 7.32 (s, 1H), 2.32 (s, 3H).

13

C NMR (101 MHz, CDCl3) δ

197.09 (s), 168.38 (s), 158.69 (s), 156.94 (s), 139.71 (s), 138.08 (s), 135.58 (s), 134.36 (s), 130.10 (s),
129.03 (s), 124.31 (s), 118.83 (s), 24.48 (s). HRMS (ESI+) m/z calc’d for C15H12O4H+: 257.0808. Found:
257.0806.
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MeO

4-Benzoyl-2-hydroxy-7-methoxy-5-methylcyclohepta-2,4,6-trienone (165f).

O
OH

Characterization of 165f: MP= 143-145°C. IR (thin film, KBr) 3209 (br), 2918 (w), 2847

H 3C
PhOC

(w), 1673 (s), 1560 (s), 1448 (w), 1262 (s), 1241 (s), 1145 (m), 1087 (m), 828 (w), 725

(w), 688 (w) cm-1. 1H NMR (400 MHz, CDCll3) δ 7.81 (d, J = 8.1 Hz, 2H), 7.64 (t, J = 7.3 Hz, 1H), 7.49
(dd, J = 7.7, 7.7 Hz, 2H), 7.24 (s, 1H), 7.11 (s, 1H), 4.05 (s, 3H), 2.34 (s, 3H).13C NMR (100 MHz, CDCl3)
δ 197.18 (s), 170.53 (s), 159.26 (s), 158.90 (s), 139.39 (s), 135.52 (s), 134.75 (s), 134.37 (s), 130.09 (s),
129.03 (s), 122.00 (s), 116.76 (s), 56.54 (s), 24.83 (s). HRMS (ESI+) m/z calc’d for C16H14O4: 271.0965.
Found: 271.0957.
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13C

of 165f
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2,7-Dihydroxy-4-methyl-5-(4-nitrophenyl)cyclohepta-2,4,6-trienone (107g): 2X

hydroxy-7-methoxy-5-methyl-4-(4-nitrophenyl)cyclohepta-2,4,6-trienone

O
H 3C

OH

(165g).
Procedure: A solution of BCl3 (1.0 M in CH2Cl2) (728 μL, 0.728 mmol) was

O 2N
X=OH (107g):OMe (165g)

diluted with CH2Cl2 (7.4 mL) and cooled to 0°C. In a separate round bottom flask,

106g (29.8 mg, 0.104 mmol) was dissolved in CH2Cl2 (7.4 mL), was cooled to 0°C and was added to the
BCl3 solution. After 10 minutes of stirring at 0°C, the reaction mixture was quenched with H2O (15 mL),
stirred for 2 minutes at 0°C, and then warmed to room temperature where it continued to stir for 1 hour.
The organic layer was isolated and the aqueous layer was extracted with CH2Cl2, (5 x 10 mL). Combined
organics were dried over Na2SO4, filtered, and concentrated under reduced pressure to yield 107g:165g
as a yellow solid (23.3 mg, 81%) in a 1:1 mixture. Compound mixture 107g:165g9 was purified for
characterization via reverse phase column chromatography (C-18) with a gradient of 35-55% .Compound
165g was collected in fractions 2-4. A yellow solid was obtained.
1H
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Compound 107g decomposes on reverse phase column. Mixture 107g:165g was dissolved in
chloroform and applied to a dry load samplet, allow to dry under vacuum for an hour, then placed on
column.
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HO
O
OH

H 3C

2,7-Dihydroxy-4-methyl-5-(4-nitrophenyl)cyclohepta-2,4,6-trienone (107g).
Procedure: To the mixture of 107g:165g (23.3 mg, 0.081 mmol) was added acetic acid
(473 μl) and 33% HBr in acetic acid (552 μl), and reaction was left to stir at 90°C for 3
hours. After 3 hours, reaction mixture was let to cool to room temperature. The reaction

O2 N

was quenched with 7 pH phosphate buffer, and diluted with DCM. The organic layer was washed several
times with the phosphate buffer. The organic layer was dried over Na2SO4, and evaporated under
reduced pressure to yield a brown solid 107g (17.8 mg, 80% yield). Decomposes at temperatures
between 194-200°C. IR (thin film, KBr) 3229 (br), 2917 (w), 1595 (m), 1518 (s), 1344 (s), 1279 (m),
1260 (m), 1194 (m), 1092 (m), 855 (w), 702 (w) cm-1.1H NMR (400 MHz, CDCll3) δ 8.32 (d, J = 8.3 Hz,
2H), 7.57 (s, 1H), 7.44 (d, J = 8.3 Hz, 2H), 7.38 (s, 1H), 2.24 (s, 3H).13C NMR (100 MHz, CDCl3) δ 167.65
(s), 158.14 (s), 156.43 (s), 149.96 (s), 147.38 (s), 140.57 (s), 138.29 (s), 129.53 (s), 124.08 (s), 123.99
(s), 122.79 (s), 26.25 (s). HRMS (ESI+) m/z calc’d for C14H11NO5H+: 274.0710. Found: 274.0705.

1H

of 107g
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13C

of 107g

OMe

2-Hydroxy-7-methoxy-5-methyl-4-(4-nitrophenyl)cyclohepta-2,4,6-trienone (165g).
O

H 3C

OH

Characterization of 165g: MP= 210-214°C. IR (thin film, KBr) 3229 (br), 2917 (w),
2848 (w), 1558 (s), 1514 (s), 1480 (m), 1344 (s), 1265 (s), 1229 (s), 1133 (s), 855 (w),

O 2N

725 (w) cm-1. 1H NMR (400 MHz, CDCll3) δ 8.32 (d, J = 8.3 Hz, 2H), 7.44 (d, J = 8.3 Hz,

2H), 7.32 (s, 1H), 7.18 (s, 1H), 4.05 (s, 3H), 2.26 (s, 3H).13C NMR (100 MHz, CDCl3) δ 169.81 (s), 158.72
(s), 158.57 (s), 149.86 (s), 147.38 (s), 140.37 (s), 135.05 (s), 129.51 (s), 124.00 (s), 122.04 (s), 121.03
(s), 56.48 (s), 26.53 (s). HRMS (ESI+) m/z calc’d for C15H13NO5H+: 288.0866. Found: 288.0872.
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Figure 4.1. NOESY of 165g to confirm location of methoxy group.
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b

d
a H
CH 3

NO 2

Dimethyl 3-(chloromethyl)-5,7-dihydroxy-6-oxocyclohepta-2,4,7-triene-1,2-dicarboxylate (107h).
HO

Cl
H 3CO2C

Procedure: A solution of BCl3 (1.0 M in CH2Cl2) (1.26 mL, 1.26 mmol) was diluted with

O
OH

CH2Cl2 (6.0 mL) and cooled to 0°C. In a separate round bottom flask, 106h (26.5 mg,

CO2CH 3

0.084 mmol) was dissolved in CH2Cl2 (6.0 mL), was cooled to 0°C and was added to

the BCl3 solution. After 10 minutes of stirring at 0°C, the reaction mixture was quenched with H2O (12.0
mL), stirred for 2 minutes at 0°C, and then warmed to room temperature where it continued to stir for 30
minutes. The organic layer was isolated and the aqueous layer was extracted with CH2Cl2, (5 x 10 mL).
Combined organics were dried over Na2SO4, filtered, and concentrated under reduced pressure to yield
107h as a yellow solid (22 mg, 87%). Compound can be further purified via reverse phase column
chromatography (C-18) with a gradient of 20-27% over 16 CV (7.7 mg after purification). Decomposes at
temperatures 171-180°C. IR (thin film, KBr) 3261 (br), 2956 (w), 1737 (s), 1557 (m), 1436 (m), 1260
(br/s), 1153 (m), 989 (w), 668 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.63 (s, 1H), 4.59 (s, 2H), 3.94 (s,
3H), 3.92 (s, 3H).

13

C NMR (100 MHz, CDCl3) δ 170.79 (s), 168.17 (s), 167.28 (s), 159.48 (s), 156.78 (s),

137.55 (s), 133.51 (s), 125.94 (s), 124.11 (s), 54.40 (s), 54.27 (s), 48.03 (s). HRMS (ESI+) m/z calc’d for
C12H11O710: 267.0499. Found: 267.0502.

1H

of 107h

10

Molecular Formula minus Cl. Believe Cl cleavage is taking place in Mass Spectrometer. Showed
presence of Cl in 107b through positive Beilstein Test (presence of green flame) with control molecule
108c (showed positive test), and negative control molecule 107a (which showed negative test).
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Dimethyl 5,7-dihydroxy-3-(methoxymethyl)-6-oxocyclohepta-2,4,7-triene-1,2-

O
OH

H 3CO

170

CO 2CH3
CO2CH3

dicarboxylate (107i).
Procedure: A solution of BCl3 (1.0 M in CH2Cl2) (459 μL, 459 mmol) was diluted

with CH2Cl2 (4.7 mL) and cooled to 0°C. In a separate round bottom flask, 106i (20.5 mg, 0.066 mmol)
was dissolved in CH2Cl2 (4.7 mL), was cooled to 0°C and was added to the BCl3 solution. After 10
minutes of stirring at 0°C, the reaction mixture was quenched with H2O (9.4 mL), stirred for 2 minutes at
0°C, and then warmed to room temperature where it continued to stir for 1 hour. The organic layer was
isolated and the aqueous layer was extracted with CH2Cl2, (5 x 10 mL). Combined organics were dried
over Na2SO4, filtered, and concentrated under reduced pressure to yield 107i as a yellow oil (16.6 mg,
85%). IR (thin film, KBr) 3261 (br), 2953 (w), 1738 (s), 1548 (m), 1436 (m), 1343 (m), 1259 (s), 1148
(m), 1100 (m), 1061 (m), 890 (w), 734 (w), 668 (w) cm1. 1H NMR (400 MHz, CDCll3) δ 7.73 (s, 1H), 4.48
(s, 2H), 3.94 (s, 3H), 3.88 (s, 3H), 3.35 (s, 3H).

13

C NMR (100 MHz, CDCl3) δ 169.26 (s), 167.57 (s),

166.58 (s), 158.84 (s), 155.45 (s), 138.76 (s), 131.26 (s), 125.32 (s), 121.17 (s), 74.79 (s), 58.47 (s),
53.25 (s), 53.13 (s). HRMS (ESI+) m/z calc’d for C13H14O8H+: 299.0761. Found: 299.0757.
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Dimethyl 7-hydroxy-5-methoxy-6-oxocyclohepta-2,4,7-triene-1,2-dicarboxylate

X
O

(165j); Dimethyl 5,7-dihydroxy-6-oxocyclohepta-2,4,7-triene-1,2-dicarboxylate

OH
CO2 CH 3
H3 CO2 C
X=OH (107j ); OMe ( 165j)

(107j).

Procedure: A solution of BCl3 (1.0 M in CH2Cl2) (1.5 mL, 1.51 mmol) was diluted with CH2Cl2 (7.2 mL)
and cooled to 0°C. In a separate round bottom flask, 106j (27.3 mg, 0.101 mmol) was dissolved in
CH2Cl2 (7.2 mL), was cooled to 0°C and was added to the BCl3 solution. After 10 minutes of stirring at
0°C, the reaction mixture was quenched with H2O (15 mL), stirred for 2 minutes at 0°C, and then warmed
to room temperature where it continued to stir for 1 hour. The organic layer was isolated and the aqueous
layer was extracted with CH2Cl2, (5 x 10 mL). Combined organics were dried over Na2SO4, filtered, and
concentrated under reduced pressure to yield a yellow solid (23.4 mg, 92%) in a complex mixture.
Compound mixture was purified for characterization via reverse phase column chromatography (C-18)
with a gradient of 27-35%, then 35%-55% .Compound 165j was collected in fractions 5, fraction 6 was a
mixture, fraction 7,8 was 107j.

Dimethyl 5,7-dihydroxy-6-oxocyclohepta-2,4,7-triene-1,2-dicarboxylate (107j).
HO

O

Characterization of 107j: MP 140-146°C. IR (thin film, KBr) 3247 (br), 2961 (w),
OH

CH3 O2C

CO2CH3

1595 (m), 1716 (s), 1543 (m), 1424 (m), 1259 (m), 1179 (w), 1015 (m), 805 (w), 724

(w) cm-1. 1H NMR (400 MHz, CDCl3) δ 8.06 (d, J = 10.9 Hz, 1H), 7.50 (d, J = 11.0 Hz, 1H), 4.00 (s, J = 4.6
Hz, 3H), 3.92 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 170.49 (s), 166.65 (s), 166.05 (s), 160.93 (s), 155.51
(s), 132.16 (s), 128.13 (s), 126.56 (s), 118.66 (s), 53.50 (s), 53.09 (s). HRMS (ESI+) m/z calc’d for
C11H10O7H+: 255.0499. Found: 255.0489.
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4.4 Data for the Triflic Acid Induced Ring Opening
4.4.1 Formation and Substrate Scope of Methoxytropolones
H3 CO

2-Hydroxy-7-methoxy-5-methyl-4-phenylcyclohepta-2,4,6-trienone (165b).

O
OH

Procedure: 8-Oxabicyclo[3.2.1]octene 106b (10 mg, 0.041 mmol) was dissolved in

H 3C

CHCl3 (410 µL) and trifluoromethanesulfonic acid (15 µL, 0.165 mmol) was added to the
reaction. The reaction stirred for 30 min and was quenched with pH 7 phosphate buffer
(20 mL), extracted with CH2Cl2 (3 x 20 mL), dried over Na2SO4, filtered and concentrated to yield 165b as
a yellow solid (9.5 mg, 95% yield). MP = 159-175ºC. IR (thin film, KBr) 799 (s), 1095 (s), 1260 (s), 1451
(w), 1726 (b), 2923 (w), 2962 (m) cm-1; 1H NMR (400 MHz, CDCl3) δ 7.45 – 7.24 (m, 5H), 7.23 (s, 1H),
7.18 (s, 1H), 4.04 (s, 3H), 2.27 (s, 3H).

13

C NMR (100 MHz, CDCl3) δ 169.9, 158.9, 158.4, 143.9, 143.6,

135.4, 128.9, 128.6, 128.0, 122.7, 122.4, 56.8, 27.0. HRMS (ESI+): calc’d for C15H15O3 (M+H): 243.1016;
Found: 243.1019.

1H
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13C

H 3CO

of 165b

Ethyl 6-hydroxy-4-methoxy-2-methyl-5-oxocyclohepta-1,3,6-trienecarboxylate

O
OH

(165c).

H 3C
EtO2C

Procedure: 8-Oxabicyclo[3.2.1]octene 106c

(40 mg, 0.168 mmol) was dissolved in

CHCl3 (1.68 mL) and trifluoromethanesulfonic acid (59 µL, 0.672 mmol) was added to the reaction. The
reaction stirred for 30 min and was quenched with Phosphate buffer (1.6 M, pH = 7, 50 mL), extracted
with CH2Cl2 (3 x 50 mL), dried over Na2SO4, filtered and concentrated to yield 165c as an orange solid
(35.7 mg, 89% yield). MP = 99-106ºC. IR (thin film, KBr) 750 (s), 1056 (w), 1457 (s), 1561 (s), 1717 (s),
2927 (w), 3252 (b) cm-1; 1H NMR (400 MHz, CDCl3) δ 7.60 (s, 1H), 7.03 (s, 1H), 4.46 – 4.29 (q, J = 7.1
Hz, 2H), 4.02 (s, 3H), 2.56 (s, 3H), 1.39 (t, J = 7.1 Hz, 3H).

13

C NMR (100 MHz, CDCl3) δ 171.2, 168.9,

159.8, 137.4, 132.4, 121.9, 117.8, 62.3, 56.8, 26.2, 14.5. HRMS (ESI+): calc’d for C12H15O5 (M+H):
239.0914; Found: 239.0913.
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MeO

Ethyl 6-hydroxy-4-methoxy-2,7-dimethyl-5-oxocyclohepta-1,3,6-trienecarboxylate

O
OH

(165e).

H3 C
EtO2 C

CH3

Procedure: 8-Oxabicyclo[3.2.1]octene 106e (19 mg, 0.075 mmol) was dissolved in

CHCl3 (750 µL) and trifluoromethanesulfonic acid (26 µL, 0.3 mmol) was added to the reaction. The
reaction stirred for 30 min and was quenches with Phosphate Buffer (1.6 M, pH = 7, 30 mL), extracted
with CH2Cl2 (3 x 30 mL), dried over Na2SO4, filtered and concentrated to yield 165e as a red solid (18.5
mg, >95% yield). 1H NMR matched previously reported data.78 1H NMR (400 MHz, CDCl3) δ 6.97 (s, 1H),
4.45 (q, J = 7.1 Hz, 2H), 3.97 (s, 3H), 2.43 (s, 3H), 2.40 (s, 3H), 1.42 (t, J = 7.1 Hz, 3H).

1H

of 165e

H 3 CO

4-Benzoyl-2-hydroxy-7-methoxy-5-methylcyclohepta-2,4,6-trienone (165f).

O
OH

H 3C
PhOC

Procedure: 8-Oxabicyclo[3.2.1]octene 106f (20 mg, 0.074 mmol) was dissolved in
CDCl3 (0.74 mL) and trifluoromethanesulfonic acid (26.2 uL, 0.30 mmol) was added to

the reaction. The reaction stirred for 30 min and was quenched with Phosphate buffer (1.6 M, pH = 7, 25
mL), extracted with CH2Cl2 (3 x 25 mL), dried over Na2SO4, filtered and concentrated to yield 165f as a
dark yellow solid (19.7 mg, >95% yield). 1H NMR matched previously reported.78 1H NMR (400 MHz,
CDCl3) δ 7.82 (d, J = 7.4 Hz, 2H), 7.63 (t, J = 7.0 Hz, 1H), 7.49 (t, J = 7.3 Hz, 2H), 7.19 (d, J = 29.1 Hz,
1H), 7.10 (s, 1H), 4.30–3.69 (m, 3H), 2.33 (s, 3H).
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H3 CO

2-Hydroxy-7-methoxy-5-methyl-4-(4-nitrophenyl)cyclohepta-2,4,6-trienone (165g).

O
OH

H 3C

Procedure: 8-Oxabicyclo[3.2.1]octene 106g (29 mg, 0.10 mmol) was dissolved in
CHCl3 (1.0 mL) and trifluoromethanesulfonic acid (61 µL, 0.41 mmol) was added to the

O 2N

reaction. The reaction stirred for 30 min and was quenched with Phosphate Buffer (1.6

M, pH = 7, 20 mL), extracted with CH2Cl2 (3 x 20 mL), dried over Na2SO4, filtered and concentrated to
yield 165g as a fine, powdery yellow solid (30 mg, >95% yield). 1H NMR (400 MHz, CDCl3) δ 8.32 (d, J =
8.6 Hz, 2H), 7.45 (d, J = 8.6 Hz, 2H), 7.29 (s, 1H), 7.14 (s, 1H), 4.05 (s, 3H), 2.26 (s, 3H).
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H3 CO

H 3C

4-(4-Bromophenyl)-2-hydroxy-7-methoxy-5-methylcyclohepta-2,4,6-trienone

O
OH

(165k).
Procedure: 8-Oxabicyclo[3.2.1]octene 106k (70.1 mg, 0.22 mmol) was dissolved in

Br

CDCl3 (2.2 mL) and trifluoromethanesulfonic acid (77 μL, 0.87 mmol) was added to the

reaction. The reaction stirred for 30 min and was quenched with Phosphate Buffer (1.6 M, pH = 7, 50
mL), extracted with CH2Cl2 (3 x 50 mL), dried over Na2SO4, filtered and concentrated to yield 165k as a
yellow solid (70 mg, >95% yield). MP = 110-115ºC. IR (thin film, KBr) 815.4 (w), 1211.4 (s), 1264.2 (s),
1713.9 (w), 2939.4 (w), 3259.2 (b) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 8.3 Hz, 2H), 7.32 (s,
1H), 7.14 (s, 1H), 7.12 (d, J = 8.3 Hz, 2H), 4.02 (s, 3H), 2.25 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 170.1,
158.8, 158.5, 142.7, 141.8, 135.1, 132.1, 130.4, 122.4, 122.2, 121.7, 56.7, 26.9. HRMS (ESI+) calc’d for
C15H14BrO3 (M+H): 321.0120; Found: 321.0128.
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1H

of 165k

13C

of 165k

H 3 CO
Cl

4-(Chloromethyl)-7-hydroxy-2-methoxy-5-phenylcyclohepta-2,4,6-trienone (165l).

O
OH

Procedure:8-Oxabicyclo[3.2.1]octane 106l (37 mg, 0.13 mmol) was dissolved in CHCl3
(1.34 mL) and trifluoromethanesulfonic acid (47 μL, 0.54 mmol) was added to the
reaction. The reaction stirred for 20 min and was quenches with Phosphate Buffer (1.6

M, pH = 7, 5 mL), extracted with CH2Cl2 (3 x 5 mL), dried over Na2SO4, filtered and concentrated to yield
165l as a brownish solid (34 mg, 92% yield). MP = 159-167ºC. IR (thin film, KBr) 702 (s), 735 (m), 762
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(w), 1157 (w), 1261 (s), 1559 (b), 1713 (b), 2927 (b), 3247 (b) cm- 1. 1H NMR (400 MHz, CDCl3) δ 7.39 –
7.14 (m, 8H), 4.31 (s, 2H), 3.99 (s, 3H).

13

C NMR (100 MHz, CDCl3) δ 170.49, 159.48, 158.96, 144.55,

141.92, 134.06, 129.04, 128.72, 128.57, 122.05, 121.37, 56.97, 49.01. HRMS (ESI+): calc’d for
C15H13ClO3 (M+H): 277.0626; Found: 277.0627.
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13C

of 165l
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H 3CO
O
H3 C

OH

4-([1,1'-biphenyl]-4-yl)-2-hydroxy-7-methoxy-5-methylcyclohepta-2,4,6-trienone
(165m).
Procedure:6-(4-bromophenyl)-2-hydroxy-3-methoxy-5-methylcyclohepta-2,4,6-trien-1-

Ph

one 165k (28 mg, 0.087 mmol) was suspended in toluene (1.75 mL) and

trimethyl(phenyl)tin (47.6 uL) and tetrakis(triphenylphosphine)palladium(0) (10.02 mg, 0.26 mmol, 8.6 µM)
were added. The reaction was stirred vigorously for 4 days at reflux under argon. The solution was
cooled to room temperature and the solvent was removed under pressure. The resulting residue was
dissolved in CH2Cl2 (2 mL). The solution was then treated with aqueous NaOH (1 M, 25 mL), aqueous
NaF (Saturated, 25 mL) and stirred vigorously for 30 minutes. The solution was acidified with aqueous
HCl (2M, 25 mL) to a pH of 3. The solution was extracted with CH2Cl2 (3 x 25 mL), dried over Na2SO4,
filtered and concentrated to yield 165m as a light yellow solid (15 mg, 55% yield). MP = 190-200ºC. IR
(thin film, KBr) 1113 (s), 1132 (w), 1211 (s), 1554 (s), 1774 (w), 2933 (w), 2986 (w), 3018 (w), 3257 (s)
cm-1; 1H NMR (400 MHz, CDCl3) δ 7.70 – 7.21 (m, 11H), 4.04 (s, 3H), 2.35 (s, 3H).

13

C NMR (100 MHz,

CDCl3) δ 169.79, 158.77, 158.24, 143.03, 142.66, 140.69, 140.57, 135.29, 129.06, 128.97, 127.77,
127.40, 127.26, 122.54, 122.18, 56.61, 26.89.HRMS (ESI+): calc’d for C21H18O3 mass: 318.1251; Found:
318.1256.

1H

of 165m
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of 165m

OH

6-(p-Phenyl)phenyl-1,3-dihydroxy-5-methylcyclohepta-2,4,6-trien-1-one (107m).
O

H3 C
OH

Procedure: 165m (16.5 mg, 0.052 mmol) was dissolved in 33%HBr/Acetic Acid (0.52
mL). The reaction was heated to reflux for 3 h with constant stirring. The solution was

Ph

cooled to room temperature and extracted with CH2Cl2 (3 x 20 mL), dried over Na2SO4,

filtered and concentrated to yield 107m as a light yellow solid (16.1 mg, >95% yield). MP = 170-175ºC. IR
(thin film, KBr) 1525 (s), 2923 (w), 3246 (br), cm-1; 1H NMR (400 MHz, CDCl3) 1H NMR (400 MHz,
CDCl3) 1H NMR (400 MHz, CDCl3) δ 7.79 – 7.20 (m, 11H), 2.32 (s, 3H).

13

C NMR (100 MHz, CDCl3) δ

167.35, 158.12, 156.87, 143.80, 142.84, 140.92, 140.70, 139.41, 129.24, 129.13, 127.96, 127.58, 127.44,
126.51, 124.79, 26.86. HRMS (ESI+): calc’d for C20H16O3 mass: 304.1099; Found: 304.1105.

1H

of 107m
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H3CO

4-(Azidomethyl)-7-hydroxy-2-methoxy-5-phenylcyclohepta-2,4,6-trien-1-one

O
OH

N3

(165n).
Procedure: To a solution of chloromethoxytropolone 165l (62 mg, 0.22 mmol) in
acetonitrile (22 ml), was added sodium azide (285 mg, 4.39 mmol). The reaction was

stirred for 12 h at ambient temperature and atmosphere, and phosphate buffer (pH 6) was added. The
aqueous layer was extracted with CH2Cl2 and the combined organic layers were dried over Na2SO4,
filtered, and concentrated under reduced pressure to yield 165n as a brown solid (40mg, 64% yield). MP
= 115-119ºC. (KBr, thin film) 3228(s), 2102(s), 1524(s), 1463(s), 1228(s), 1128(s), 703(s) cm-1. 1H NMR
(400 MHz, CDCl3) δ 7.71 – 7.37 (m, 7H), 4.22 (s, 2H), 4.08 (s, 3H).

13

C NMR (100 MHz, CDCl3) δ

170.57, 159.18, 158.56, 143.64, 141.67, 131.40, 128.81, 128.42, 128.30, 121.13, 119.56, 56.54, 56.16.
HRMS (ESI+) m/z calc’d for C15H14N3O3 (M+H): 284.1030. Found: 284.1024.
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H 3CO
Ph

O

2-Hydroxy-7-methoxy-4-phenyl-5-((4-phenyl-1H-1,2,3-triazol-1- yl)
OH

N
N

N

methyl)cyclohepta-2,4,6-trien-1-one (165o).
Procedure: To a suspension of azidomethoxytropolone 165n (21 mg, 0.074 mmol)
in water (800 mL) and tert-butanol (800 mL) was added phenylacetylene (20 mL,

0.18 mmol), copper sulfate pentahydrate (2 mg, 0.008 mmol), and sodium ascorbate (3 mg, 0.015 mmol).
The reaction mixture was heated under microwave irradiation at 110ºC (controlled temperature) for 30
min. The t-BuOH/H2O was evaporated and the reaction was then re-suspended in NaCl (aq) (1 mL),
extracted with CH2Cl2 (3 x 1 mL), dried over
Na2SO4, filtered, and concentrated to yield 165o as a brown solid (14 mg, 50% yield). MP = 171-173ºC.
(KBr, thin film) 3221(s), 2939(s), 1568(s), 1467(s), 1229(s), 1121(s) cm-1. 1H NMR (400 MHz, CDCl3) δ
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7.75 (d, J = 7.5 Hz, 2H), 7.63 – 7.29 (m, 10H), 7.23 (s, 1H), 5.42 (s, 2H), 3.91 (s, 3H).

13

C NMR (100

MHz, CDCl3/CD3OD) δ 170.33, 159.35, 158.48, 147.62, 143.59, 141.20, 130.17, 129.42, 128.56, 128.40,
128.02, 128.00, 127.87, 125.16, 121.44, 120.40, 118.95, 55.62, 54.72. HRMS (ESI+) m/z calc’d for
C23H20N3O3 (M+H): 386.1499. Found: 386.1492.

1H

of 165o

13C

of 165o (CDCl3/CD3OD)
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H3 CO

4-Hydroxy-6-methoxy-5-oxo-2-phenylcyclohepta-1,3,6-trien-1-yl)methyl acetate

O
OH

AcO

(165p).
Procedure: To a solution of chloromethoxytropolone 165l (33 mg, 0.119 mmol) in
acetonitrile (11.9 ml) was added sodium acetate (195 mg, 2.38 mmol). The reaction

was stirred for 12 h ambient temperature and atmosphere, and phosphate buffer (pH 6) was added. The
aqueous layer was extracted with CH2Cl2, and the combined organic layers were dried over Na2SO4,
filtered, and concentrated under reduced pressure to yield 165p as a light yellow solid (20 mg, 56% yield).
MP = 159-161ºC. IR (thin film, KBr) 3243(s), 1743(s),1579(s), 1478(s), 1264(s), 1103(s), 704(m) cm-1.
1

H NMR (200 MHz, CDCl3) δ 7.72 –6.96 (m, 7H), 4.88 (s, 2H), 4.04 (s, 3H), 2.08 (s, 3H).

13

C NMR (50

MHz, CDCl3) δ170.70, 159.53, 158.55, 144.72, 141.82, 131.75, 128.74, 128.57, 128.39, 121.45,
120.33,67.72, 56.63, 21.16.

13

C NMR (50 MHz, CDCl3/CD3CN) δ 169.82, 169.73, 158.64,157.85, 143.49,

141.20, 131.33, 127.95, 127.86, 127.54, 120.40, 119.76, 66.76, 55.89,20.08. HRMS (ESI+) m/z calc’d for
C17H17O5 (M+H): 301.1071. Found: 301.1071.

1H

of 165p

142

13C

(CD3CN/CDCl3) of 165p

4.4.2 Formation and Substrate Scope of Furans

H3C

Dimethyl 2-methylfuran-3,4-dicarboxylate (170a)

O

Procedure: 8-Oxabicyclo[3.2.1]octene 106a (20 mg, 0.071 mmol) was dissolved in
H3 CO 2C

CO2CH 3

CHCl3 (0.71 mL) and trifluoromethanesulfonic acid (25 µL, 0.283 mmol) was added to

the reaction. The reaction stirred for 30 min and was quenched with triethylamine (50 µL), The reaction
mixture was then concentrated and purified by chromatography (silica gel, 18 x 1.8 cm, 50 ml Hexanes,
100 ml 5% EtOAc in Hexanes, 100 ml 10% EtOAc in Hexanes, 200 ml 20% EtOAc in Hexanes) to lead to
170a as a light yellow solid (10.9 mg, 78% yield). 1H NMR matched previously reported data.110 1H NMR
(400 MHz, CDCl3) δ 7.73 (s, 1H), 3.85 (s, 3H), 3.82 (s, 3H), 2.50 (s, 3H).
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Dimethyl furan-3,4-dicarboxylate (170j).

O

Procedure: 106j (20 mg, 268.22 mmol) was dissolved in CHCl3 (0.746 mL) and
H3 CO 2C

CO2CH 3

trifluoromethanesulfonic acid (.0263 mL, 0.289 mmol) was added to the reaction.
The reaction stirred for 30 min and was quenches with triethylamine (50 µL), The reaction mixture was
then concentrated and purified by chromatography (silica gel, 18 x 1.8 cm, 50 ml Hexanes, 100 ml 2%
EtOAc in Hexanes, 100 ml 5% EtOAc in Hexanes, 100 ml 8% EtOAc in Hexanes) to lead to 170j as a
light yellow solid (8.6 mg, 63% yield). 1H NMR matched that previously reported.111 1H NMR (400 MHz,
CDCl3) δ 7.94 (s, 2H), 3.86 (s, 6H).
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4.4.3. HMBC/HSQC of 165k
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Figure 4.2. HMBC and HSQC for 165k.
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4.5 Data for the Alcohol Exchange Reaction
OEt

3-Ethoxy-5-methyl-6-phenyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (176b).
O

Me

O

Procedure: 105a (50 mg, 0.172 mmol), N,N-diisopropylaniline (41 μL, 0.208 mmol, 1.2
eq), and CDCl3 (0.5 M, 344 μL) were added to a sealed tube reactor and stirred until no

solid was observed. Ethanol (50 μL, 0.860 mmol, 5 eq) was then added and the reaction was heated to
60ºC in silicon bath oil. After the appropriate times points, 2 hr, 4 hr, and 12 hr, the reaction was allowed
to cool to room temperature. Phenyl acetylene (373 µL, 3.44 mmol, 20 eq) was added to the reaction and
the seal tube was heated to 100ºC for 30 min. The reaction was then immediately purified by column
chromatography (silica gel, 6 inch height of silica gel, 18cm x 1.8cm, solvent gradient: hexanes (50 mL);
5% EtOAc in hexanes (100 mL); 10% EtOAc in hexanes (100 mL); 15% EtOAc in hexanes (150 mL)).
Product fractions were concentrated to yield 176b as yellowish oil and 106b as yellowish solid after 2 hr
(176b/106b = 17 mg: 8 mg, 56%), 4 hr (176b/106b = 15 mg: 3 mg, 41%), and 12 hr (176b only = 6 mg,
14%) time points.

Characterization of 176b: Rf = 0.21 in 15% EtOAc in hexanes. IR (thin film, KBr) 3057 (w), 2981 (w),
2936 (w), 1713 (s), 1603 (m), 1493 (w), 1446 (w), 1381(w), 1339 (w), 1130 (m), 1058 (w), 898 (w), 864
(w), 755 (m), 697 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.41 – 7.30 (m, 3H), 7.30 – 7.25 (m, 2H), 6.27
(d, J = 2.5 Hz, 1H), 6.18 (s, 1H), 4.98 (d, J = 2.5 Hz, 1H), 3.85 – 3.67 (m, 2H), 1.66 (s, 3H), 1.36 (t, J = 7.0
Hz, 3H).

13

C NMR (50 MHz, CDCl3) δ 190.36, 158.98, 145.41, 133.37, 129.02, 128.97, 126.25, 123.40,

119.91, 86.67, 86.19, 63.47, 22.39, 14.48. HRMS (ESI+) m/z calc’d for C16H17O3+: 257.1172. Found:
257.1173.
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3-Isopropoxy-5-methyl-6-phenyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (183b).
Procedure: 105a (50 mg, 0.172 mmol), N,N-diisopropylaniline (41 μL, 0.208 mmol, 1.2
eq), and CDCl3 (0.5 M, 344 μL) were added to a sealed tube reactor and stirred until no
solid was observed. Isopropyl alcohol (66 μL, 0.860 mmol, 5 eq) was then added and the reaction was
heated to 60ºC in silicon bath oil. After the appropriate times points, 2 hr, 4 hr, and 12 hr, the reaction was
allowed to cool to room temperature. Phenyl acetylene (373 µL, 3.44 mmol, 20 eq) was added to the
reaction and the seal tube was heated to 100ºC for 30 min. The reaction was then immediately purified by
column chromatography ( silica gel, 6 inch height of silica gel, 18cm x 1.8cm, solvent gradient: hexanes
(50 mL); 5% EtOAc in hexanes (100 mL); 8% EtOAc in hexanes (100 mL); 10% EtOAc in hexanes (100
mL); 15% EtOAc in hexanes (100 mL)). Product fractions concentrated to yield 183b as yellowish oil and
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106b as yellowish solid after 2 hr (183b/106b = 2 mg: 18 mg, 48%), 4 hr (183b/106b= 4 mg: 13 mg,
39%), and 12 hr (183b only = 5 mg, 10%) time points.

Characterization of 183b: Rf = 0.27 in 15% EtOAc in hexanes. IR (thin film, KBr) 3057 (w), 2979 (w),
2935 (w) 1710 (s), 1600 (m), 1493 (w), 1447 (w), 1384 (w), 1375 (w), 1263 (w), 1125 (m), 1058 (w), 865
(w), 754 (m), 697 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.42 – 7.31 (m, 3H), 7.30 – 7.25 (m, 2H), 6.28
(d, J = 2.4 Hz, 1H), 6.19 (s, 1H), 4.98 (d, J = 2.5 Hz, 1H), 4.24 (hept, J = 6.1 Hz, 1H), 1.66 (s, 3H), 1.32
(d, J = 6.1 Hz, 3H), 1.25 (d, J = 6.0 Hz, 3H). 13C NMR (50 MHz, CDCl3) δ 190.93, 159.00, 143.96, 133.49,
129.05, 128.94, 126.27, 123.58, 121.33, 86.67, 86.33, 70.12, 22.40, 21.68. HRMS (ESI+) m/z calc’d for
C17H19O3+: 271.1329. Found: 271.1331.
1H

of 183b

13C

of 183b
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OBn

3-(Benzyloxy)-5-methyl-6-phenyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (184b).
O

Me

O

Procedure: 105a (50 mg, 0.172 mmol), N,N-diisopropylaniline (41 μL, 0.208 mmol,
1.2 eq), and CDCl3 (0.5 M, 344 μL) were added to a sealed tube reactor and stirred

until no solid was observed. Benzyl alcohol (89 μL, 0.860 mmol, 5 eq) was then added and the reaction
was heated to 60ºC or left at room temperature in silicon bath oil. After the appropriate times points, 30
min and 2 hr at 60ºC and 12 hr at room temperature, phenyl acetylene (373 µL, 3.44 mmol, 20 eq) was
added to the reaction and the seal tube was heated to 100ºC for 30 min. The reaction was then
immediately purified by column chromatography (silica gel, 6 inch height of silica gel, 18cm x 1.8cm,
solvent gradient: hexanes (50 mL); 2% EtOAc in hexanes (100 mL); 5% EtOAc in hexanes (100 mL); 7%
EtOAc in hexanes (200 mL); 10% EtOAc in hexanes (100 mL)). Product fractions concentrated to yield
184b as white solid and 106b as yellowish solid after 30 min (184b/106b = 14 mg: 7 mg, 41%), 2 hr
(184b/106b = 6 mg: 2 mg, 16%), and 12 hr (184b/106b= 8 mg: 15 mg, 46%) time points.

Characterization of 184b: Melting Point (MP) = 112-114ºC. Rf = 0.24 in 15% EtOAc in hexanes. IR (thin
film, KBr) 3061 (w), 3033 (w), 2979 (w), 2933 (w), 1709 (s), 1604 (m), 1491 (w), 1454 (w), 1339 (w),
1263 (w), 1125 (m), 1058 (w), 866 (w), 754 (m), 697 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.27
(m, 8H), 7.18 – 7.12 (m, 2H), 6.27 (d, J = 2.4 Hz, 1H), 6.24 (s, 1H), 5.01 (d, J = 2.5 Hz, 1H), 4.92 (d, J =
12.0 Hz, 1H), 4.79 (d, J = 12.0 Hz, 1H), 1.62 (s, 3H).

13

C NMR (50 MHz, CDCl3) δ 190.14, 159.06,

144.85, 135.81, 133.33, 128.96, 128.91, 128.47, 127.73, 126.21, 123.37, 121.77, 86.70, 86.31, 69.86,
22.24. HRMS (ESI+) m/z calc’d for C21H19O3+: 319.1329. Found: 319.1329.
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3-(Allyloxy)-5-methyl-6-phenyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (185b)
Procedure: 105a (50 mg, 0.172 mmol), N,N-diisopropylaniline (41 μL, 0.208 mmol,
1.2 eq), and CDCl3 (0.5 M, 344 μL) were added to a sealed tube reactor and stirred
until no solid was observed. Allyl alcohol (59 μL, 0.860 mmol, 5 eq) was then added and the reaction was
heated to 60ºC or left at room temperature in silicon bath oil. After the appropriate times points, 30 min
and 2 hr at 60ºC and 12 hr at room temperature, phenyl acetylene (373 µL, 3.44 mmol, 20 eq) was added
to the reaction and the seal tube was heated to 100ºC for 30 min. The reaction was then immediately
purified by column chromatography (silica gel, 6 inch height of silica gel, 18cm x 1.8cm, solvent gradient:
hexanes (50 mL); 2% EtOAc in hexanes (100 mL); 5% EtOAc in hexanes (100 mL); 7% EtOAc in
hexanes (150 mL); 10% EtOAc in hexanes (50 mL); 15% EtOAc in hexanes (100 mL)). Product fractions
150

concentrated to yield 185b as yellowish oil and 106b as yellowish solid after 30 min (185b/106b = 10 mg:
14 mg, 56%), 2 hr (185b/106b = 4 mg: 2 mg, 14%), and 12 hr (185b/106b = 4 mg: 13 mg, 40%) time
points.

Characterization of 185b: Rf = 0.24 in 15% EtOAc in hexanes. IR (thin film, KBr) 3081 (w), 3057 (w),
2981 (w), 2935 (w), 1710(s), 1603 (m), 1491 (w), 1447 (w), 1338 (w), 1264 (w), 1125 (m), 1058 (w), 865
(w), 755 (m), 697 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.41 – 7.32 (m, 3H), 7.29 – 7.24 (m, 2H), 6.28
(d, J = 2.5 Hz, 1H), 6.21 (s, 1H), 5.96 (ddt, J = 17.2, 10.9, 5.5 Hz, 1H), 5.35 (dq, J = 17.3, 1.5 Hz, 1H),
5.27 (dq, J = 10.5, 1.3 Hz, 1H), 4.99 (d, J = 2.5 Hz, 1H), 4.34 (ddt, J = 12.6, 5.4, 1.4 Hz, 1H), 4.26 (ddt, J
= 12.7, 5.6, 1.3 Hz, 1H), 1.66 (s, 1H).13C NMR (100 MHz, CDCl3) δ 190.16, 159.02, 144.90, 133.40,
132.33, 129.04, 129.00, 126.31, 123.46, 121.02, 118.93, 86.70, 86.27, 68.81, 22.35. HRMS (ESI+) m/z
calc’d for C17H16O3Na+: 291.0992. Found: 291.0997.
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